2014N194466_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 200722
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: Follow-Up Study  to Assess L ong-Term Safety  and Outcomes in 
Infants and Children Born to Mothers Participating in Retosiban 
Treatment Studies
Compound Number: GSK221149
Development Phase: III
Study Name: ARIOS
Effective Date: 01-NOV-2018
Protocol Amendment Number:  02
Authors(GSK):   
Authors (PPD) :   
Copyright 201
8 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorized cop ying or use of this information is prohibited. 2019N413355_00
PPD
PPD
PPD
PPD
2014N194466_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 200722
2Revision Chronolog y
GlaxoSmithKline
Document NumberDate Version
2014N194466_00 2014-MAY-14 Original
2014N194466_01 2015-AUG-17 Amendment No. 1
The following changes are reflected in Protocol Amendment No. 1:
Extend the study  duration from 24 months to 5 y ears to identif y any potential 
neurodevelopmental and behavioral disorders through annual assessments at 
years 3, 4, and 5, specifically  autism and attention deficit hy peractivity  disorder.
Add an assessment using a modified version of the CHI questionnaire at 3, 4, 
and 5 years of the child’s chronological age to collect data to identify  any 
potential neurodevelopmental and behavioral disorders.
Add an additional assessment of the M -CHAT-R/F at 18 months (corrected age) 
per American Academ y of Pediatrics guidelines
Reviseto indicate that the M -CHAT-R/F (assessed at 18 and 24 months) and the 
CBCL/1.5-5 (assessed at 24 months) are mandatory for all infants, regardless of 
ASQ-3 results, per American Academ y of Pediatrics guidelines
Remove as a neurodevelopment endpoint the p roportion of infants referred for 
an additional behavior assessment using the M -CHAT-R/F and CBCL /1.5-5
Clarify that any infant serious adverse events ( SAEs)and/or AEs of special 
interest that were unresolved at the end of the Phase III treatment studies and 
any new SAEs reported during this study  should be followed to stabilization or 
resolution in those children participating in the follow- up study.
Revise the subgroups that may  be included in the safety analyses to reflect study  
design of Phase III SPTL Study 200719 (NEWBORN -1)
Clarify unblinding text to indicate that there is no requirement for the 
investigator to discuss unblinding with the PPD medical monitor in order to 
rapidly unblind a child’s treatment assignment, if needed
Incorporate other admin istrative changes
2014N194466_02 2018-NOV-01 Amendment No. 2
The following changes are reflected in Protocol Amendment No. 2 :
Reduction of study  duration from 5 y ears to 24 months due to :
‒Termination of the retosiban development program, such that there will be no 
further in utero exposure to retosiban, and hence safet y data from this ongoing 
study will not inform the potential risk for future use of retosiban. 
‒Lowrecruitment for interventional studies 200719 (NEWBORN -1) and  2019N413355_00
2014N194466_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 200722
3GlaxoSmithKline
Document NumberDate Version
200721 (ZINN) . Hence,the number of infants exposed to retosiban in utero 
and included in the current (200722) study is small.
‒The independent d ata monitoring c ommittee (IDMC)recommendation that the 
neonatal follow -up be limited to 2 4monthsof age given no safety issues
detected in their unblinded review of available 200722 data and also that 
statistical analy sis at a 5-year timepoint would not provide an y meaningful 
resultsdue to the small number of enrolled subjects.
Reclassification of all resource utilization endpoints as exploratory  endpoints 
due to the reduced sample size
Correction of an error in the mean BSID -III score for the cognitive impairment, 
fine motor and gross motor scales to <4 to reflect that these are not composite 
scores
Incorporation of other administrative cha nges 2019N413355_00
 2019N413355_00
PPD
PPD
2014N194466_02 CONFIDENTIA L
200722
5SPONSOR INFORMA TION PAGE
Clinical Study Identifier: 200722(ARIOS)
Sponsor Legal Registered Address:
GlaxoSmithKline Res earch & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Sponsor Contact Address
GlaxoSmithKline Research & Development Limited
Five Moore Drive 
P.O. 13398
Research Triangle Park, NC 27709- 3398, USA
Telephone: 
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline affiliate 
company (or designee). Where applicable, the details of the Sponsor and contact person 
will be provided to the relevant regulatory  authority  as part of the clinical trial
submission.
Sponsor Medical Monitors and Serious Adverse Events (SAEs) Contact Information
Issue North America 
ContractLatin America Contact Europe/Asia Contact
Safety Questions  MD, 
MPH
Associate Medical Director, 
Medical Affairs and 
Pharmacovigilance
PPD
Denver, CO, USA MD
Medical Director, Medical 
Affairs and 
Pharmacovigilance
PPD
Buenos Aires, BrazilEurope : , MD
Associate Medical Director, 
Medical Affairs and 
Pharmacovigilance
PPD
Sofia, Bulgaria
Asia:  MD
Associate Medical Director, 
Medical Affairs and 
Pharmacovigilance
PPD
Kuala Lumpur, Malaysia
SAE Reporting 24-Hour Safety Hotline:
Safety Fax:24-Hour Safety Hotline:
Safety Fax:  24-Hour Safety Hotline:
Safety Fax: 2019N413355_00
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
2014N194466_02 CONFIDENTIA L
200722
6Regulatory Agency Identifying Number(s):
IND Number: 73287
EudraCT Number: 2014 -000499-24 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
7RCC-PI PROTOCOL AGREEMENT PA GE
For protocol 200722 (ARIOS)
Iconfirm agreement to conduct the study  in compliance with the protocol, as amended by  
this protocol amendment.
I acknowledge that I am responsible for overall study  conduct. I agree to personall y 
conduct or supervise the described stud y.
I agree to ensure that all associates, colleagues and employees assisting in the conduct of 
the study are informed about their obligations. Mechanisms are in place to ensure that 
RCC staff receives the appropriate information throughout the stud y. 
RCC-PI Name:
RCC-PI Address:
RCC-PI Phone Number:
RCC-PI Signature Date 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
8TABLE OF CONTENTS
PAGE
LIST OF ABBREVIATION S AND DEFINITIONS ........................................................... 11
PROTOCOL SUMMARY ............................................................................................... 13
1.INTRODUCTION .................................................................................................... 19
1.1. Background ................................................................................................ 19
1.1.1. Previous Human Experience........................................................ 20
1.2. Rationale .................................................................................................... 21
1.3. Benefit:Risk Assessment ............................................................................ 21
1.3.1. Risk Assessment ......................................................................... 22
1.3.2. Benefit Assessment ..................................................................... 24
1.3.3. Overall Benefit:Risk Conclusion ................................................... 25
2.OBJECTIVES ......................................................................................................... 26
3.INVESTI GATIONAL PLAN ..................................................................................... 28
3.1. Study Design .............................................................................................. 28
3.2. Discussion of Design .................................................................................. 32
4.SUBJECT SELECTION AN D WITHDRAW AL CRITERI A....................................... 32
4.1. Number of Subjec ts .................................................................................... 32
4.2. Inclusion Criteria ......................................................................................... 33
4.3. Exclusion Criteria ........................................................................................ 33
4.4. Withdrawal Criteria ..................................................................................... 33
5. STUDY TREATMENTS .......................................................................................... 33
5.1. Investigational Product and Other Study Treatment .................................... 33
5.2. Treatment Assignment ................................................................................ 34
5.3. Blinding ....................................................................................................... 34
5.4. Product Accountability ................................................................................ 35
5.5. Treatment Compliance................................................................................ 35
5.6. Concomitant Medications and Nondrug Therapies ...................................... 35
5.7. Treatment After the End of the Study .......................................................... 35
5.8. Treatment of Study Treatment Overdose .................................................... 35
6.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 35
6.1. Critical Baseline Assessments .................................................................... 39
6.2. Safety ......................................................................................................... 39
6.2.1. Morbidity and Mortality E ndpoints ................................................ 39
6.2.1.1. Parent/Legal Guardian- Completed Child Health 
Inventory .................................................................... 39
6.2.1.1.1. Confirmation of Parent -Reported 
Data ........................................................ 40
6.2.2. Chronic Medical Conditions ......................................................... 42
6.2.2.1. Respiratory Conditions ............................................... 42
6.2.2.2. Neurological Conditions .............................................. 42
6.2.2.3. Sensory Conditions .................................................... 43
6.2.2.4. Gastrointestinal Conditi ons......................................... 43 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
96.2.2.5. Cardiovascular Conditions .......................................... 43
6.2.2.6. Renal Conditions ........................................................ 44
6.2.2.7. Growth Parameters .................................................... 44
6.2.3. Congenital Anomalies .................................................................. 44
6.2.4. Infant and Child Deaths ............................................................... 45
6.2.5. Parent/Legal Guardian- Completed ASQ -3, M-CHAT -R/F, 
and CBCL/1.5 –5 and Possible Referral to a Specialist ................. 45
6.2.5.1. The ASQ -3 Score Interpretation and Possible 
Specialist Referral Recommendations ........................ 46
6.2.5.2. Neurodevelopment ..................................................... 49
6.2.6. Overall Measure of Neurodevelopmental Impairment .................. 49
6.2.7 .Adverse Events ............................................................................ 50
6.2.7.1. Definition of an AE ...................................................... 50
6.2.7.2. Definition of an SAE ................................................... 51
6.2.8. Laboratory and Other Safety Assessment Abnormalities 
Reported as SAEs ....................................................................... 52
6.2.9. Cardiovascular Events ................................................................ .52
6.2.10. Death Events ............................................................................... 52
6.2.11. Time Period and Frequency of Detecting SAEs ........................... 53
6.2.12. Method of Detectin g SAEs ........................................................... 53
6.2.13. Follow -up of SAEs ....................................................................... 53
6.2.14. Prompt Reporting of SAEs and Other Events to GSK/PPD .......... 53
6.2.14.1. Regulatory Reporting Requirements for SAEs ............ 54
6.2.15. Other Safety Outcomes ............................................................... 55
6.2.15.1. Laboratory Assessments ............................................ 55
6.2.15.2. Ad Hoc Maternal Reports ........................................... 55
6.3. Health Outcomes ........................................................................................ 55
6.3.1. Parent/Legal Guardian- Completed Productivity 
Questionnaire .............................................................................. 56
7.DATA MANAGEMENT ........................................................................................... 56
7.1. Data Handling Conventions ........................................................................ 56
7.1.1. Attempts to Obtai n the Follow -Up Information .............................. 56
7.1.2. Loss to Follow -Up........................................................................ 57
7.2. Validation Procedures ................................................................................. 57
7.2.1. Follow -Up Process for Clarification of Information ........................ 57
8.DATA ANALYSIS AND ST ATISTICAL CONSIDERAT IONS ................................... 57
8.1. Hypotheses ................................................................................................ .57
8.2. Study Design Considerations ...................................................................... 58
8.2.1. Sample Size Assumptions ........................................................... 58
8.2.2. Sample Size Sensitivity ................................................................ 58
8.2.3. Sample Size Re- Estimation ......................................................... 58
8.3. Data Analysis Considerations ..................................................................... 58
8.3.1. Analysis Populations .................................................................... 58
8.3.2. Analysis Data Sets ....................................................................... 58
8.3.3. Treatment Comparisons .............................................................. 58
8.3.3.1. Primary Comparisons of Interest ................................ 58
8.3.3.2. Other Comparisons of Interest .................................... 59
8.3.4. Interim Analysis ........................................................................... 59
8.3.5. Key Elements of Analysis Plan .................................................... 59
8.3.5.1. Safety Analyses .......................................................... 59 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
108.3.5.1.1. Outcomes ............................................... 59
8.3.5.1.2. Serious Adverse Events ......................... 60
8.3.5.2. Health Outcomes Analyses ........................................ 60
8.3.5.3. Genetic Analyses ....................................................... 60
9.STUDY CONDUCT CONSID ERATIONS ............................................................... 60
9.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 60
9.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 60
9.2.1. Release of Participant Medical Information .................................. 61
9.2.2. Subject Confidentiality ................................................................ .61
9.3. Quality Control (Study Monitoring) .............................................................. 61
9.4. Quality Assurance ....................................................................................... 62
9.5. Study and RCC Site Closure ....................................................................... 62
9.6. Records Retention ...................................................................................... 62
9.7. Provision of Study Results to RCC -PIs, Posting of Information on 
Publicly Available Clinical Trials Registers and Publication ......................... 63
9.8. Independent Data Monitoring Committee .................................................... 63
10.REFERENCES ....................................................................................................... 64
11.APPENDICES ........................................................................................................ 67
11.1. Appendix 1: Protocol Changes .................................................................... 67 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
11LIST OF A BBREVIATIONS A ND DEFINITIONS
AE adverse event
ADD attention deficit disorder
ADHD attention deficit hy peractivity  disorder
ASEBA Achenbach Sy stem of Empirically  Based Assessment
ASD autism spectrum disorder
ASQ-3 Ages and S tages Questionnaire-3
BSID-III Bayley Scale for Infant Development, third edition
CBCL/1.5–5 Child Behavior Checklist for Ages 1.5 to 5
CDC Centers for Disease Control and Prevention
CHI Child Health I nventory
CI confidence interval
CV cardiovascular
DSM Diagnostic and Statistical Manual
eCRF electronic case report form
eDC electronic data capture
EDD estimated date of delivery
EPDS Edinburgh Postnatal Depression Scale
ER/UC emergency  room/urgent care 
EUROCAT European Surveillance of Congenita l Anomalies
FSFV first subject first visit
GCP Good Clinical Practice
GMFCS Gross Motor Functional Classification Sy stem
HCP health care provider
IB Investigator’s Brochure
ICH International Council for Harmonisation
ICU intensive care unit
IDMC independent data monitoring c ommittee
IEC Independent Ethics Committee
IRB Institutional Review B oard
kg kilogram
MACDP Metropolitan Atlanta Congenital Defects Program 
M-CHAT-R/F Modified Checklist for Autism in Toddlers -Revised with 
Follow-Up
MedDRA Medical Dictionary  for Regulatory  Activities
mg milligram
NICU neonatal intensive care unit
PI principal investigator
PICU pediatric intensive care unit
RAP reporting and anal ysis plan
RCC research coordinating center
RCC-PI research coordinating ce nter-principal investigator
SAE serious adverse event
SPM Study Procedures Manual
SPTL spontaneous preterm labor 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
12DEFINITIONS
Child Aged from 2 years to up to 12 y ears, per definition of the 
US Food and Drug Administration
Chronological age Defined as the time elapsed after birth; it is usually  
described in day s, weeks, months, and y ears
Corrected age Calculated b y subtracting the number of weeks an infant is 
born before 400/7weeks’ gestation from the chronological 
age. This term is used to describe children up to 3 y ears of 
age who were born preterm.
End of the Phase III SPTL 
treatment studiesThe cut-off date for final review of the neonatal record, 
signifying the end of Phase III spontaneous preterm labor
(SPTL) treatment studies, is the estimated date of delivery  
(EDD) plus 28 day s; this is referred to as 28 day s post EDD
Estimated date of delivery Defined as 400/7 weeks’ gestation for all subjects in the 
PhaseIII SPTL treatment studies
Gestational age Determined b y (1) known fertilization dat e, either invitro 
fertilization or intrauterine insemination, (2) last menstrual 
period confirmed b y the earliest ultrasound prior to 
240/7weeks’ gestation, or (3) the earliest ultrasound alone 
prior to 240/7weeks’ gestation, whichever is the most 
accurate method available for each subject in the Phase III 
SPTL treatment studies
Infant Aged from 1 month to up to 2 y ears, per definition of the 
US Food and Drug Administration
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
NONE MedDRA 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
13PROTOCOL SUMMA RY
Rationale
Advances in perinatal intensive care have resulted in increased survival rates for high risk 
newborns but limited improvement in morbidity . The immaturity of organs, such as the 
brain, lungs, and gastrointestinal tract, render these newborns susceptible to injury  and 
abnormal development and function, which often leads to long- term health problems and 
disability. The risk for medical disability  is inversely related to the gestational age at 
birth; the most common disabilities include cerebral pals y, cognitive d ysfunction, 
blindness and impaired vision, hearing loss, and disorders of ps ychological development 
(i.e., behavior and emotion).
Over the past decade s, few medical interventions have been designed to prevent preterm 
birth and/or reduce the severity  of prematurity  complications. Such treatments may  also 
improve long-term outcomes. One of the major advances in perinatal medicine has been 
the finding that antenatal corticosteroids given to women at risk of imminent preterm 
birth reduces the risks for neonatal mortality  and morbidity . Corticosteroids now 
represent the standard of care for an acute antenatal intervention to improve neonatal 
outcomes in the developed world [RCOG, 2011; ACOG , 2012].
However, there is an increasing awareness that the intended beneficial effects of perinatal 
interventions do not necessarily  correlate with long -term outcomes. Dexamethasone in 
high daily doses appears to reduce mortality and the incidence of bronchopulmonary 
dysplasia but treatment is associated with numerous short- and long-term adverse 
outcomes, including neurodevelopmenta l impairment. As a result, treatment with high 
dose dexamethasone is not recommended [ Watterberg , 2010]. The ORACLE II Stud y is 
an example of a perinatal treatment that was associated with adverse long -term outcom es 
and no neonatal benefit. ORACL EII studied the effect of antibiotics to improve neonatal 
outcomes in women with spontaneous preterm labor (SPTL ) with intact membranes and 
no evidence of clinical infection. No reduction in neonatal complications was obse rved. 
However, the long -term follow -up revealed an increase in functional impairment and a 
higher risk for cerebral palsy  in children whose mothers had received antibiotics 
[Kenyon, 2001; Ken yon, 2008]. These observations have led to an appreciation that 
perinatal interventions may  affect growth and development and have highlighted the 
importance of long- term safet y and outcome studies after randomized, controlled studies 
of perinatal interventions. 
The goal of this study (ARIOS), therefore, is to assess the safet y and outcomes of infants 
and children who were exposed to retosiban (GSK221149) or comparator in utero in the 
PhaseIII SPTL treatment studies and provide assurance that treatment is not associated 
with significant adverse outcomes in earl y childhood.
InMay 2017, the corresponding treatment trials 200719 ( NEWBORN -1, placebo 
comparison) and 200721 ( ZINN, atosiban comparison) were terminated early due to poor 
recruitment a nd the length of time needed to complete the studies. The placebo -controlled 
trial enrolled only 23 of the target 900 participants over 17 months, and the atosiban 
comparator trial enrolled 97 of the target 330 participants over 29 months. Maternal,  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
14fetal,and neonatal adverse events were no more common with retosiban than placebo or 
atosiban. The development program was subsequently  terminated with no further in utero 
exposure of retosiban planned.
Objectives
The study  objective is to assess the safety  andoutcomes in infants and children who were 
exposed to retosiban or comparator in the Phase III SPTL treatment studies.
Specific objectives include the following:
Primary
To characterize the clinical safet y in terms of infant and child morbidity  and 
mortality in infants and children exposed to retosiban or comparator in utero
To characterize the clinical safet y in terms of neurodevelopment in infants and 
children exposed to retosiban or comparator in utero
Exploratory
To characterize parental productivity  loss related to a sick child and infant resource 
utilization in terms of hospital admissions, length of stay , emergency  room/urgent 
care (ER/UC) visits, surgical procedures, and referral to specialt y care or therap y 
visits for infants (up to age 2 years)exposed to retosiban or comparator in utero
Study Design
ARIOS is a long -term infant and child follow-up study that will prospectively  assess 
safety and outcomes of all infants and children born to women who received at least 
1dose of retosiban or comparator in any of the Phase III SPTL treatment studies. The 
final assessment of the Phase III SPTL treatment studies is a collection of neonatal 
morbidity  data and will occur at 28 days after the estimated date of delivery  (EDD), 
where EDD is defined as 400/7weeks’ gestation. After this time, infants become eligible 
for this follow- up study. Ideally, the Phase III SPTL study investigators will obtain 
consent and medical release for this stud y when the women’s acute episode of preterm 
labor has resolved and prior to discharge from the hospital for the treatment of preterm 
labor. The infant will be able to be consented into the study  until the later date of either 
the date of discharge from the birth hospitalization or up to 9 months corrected age. 
Infants and children will be followed at prespecified intervals until they  have reached 
24monthschronological age. This study does not require medical interventions or study 
visits to an investigational site. I nstead, parents or legal guardians will be prompted at 
certain time points to complete developmental questionnaires and other data regarding 
their child’s health status via an electronic device. Data collected during this follow-up 
study will be managed by  a centralized research coordinating center (RCC). Regionall y
based pediatricians will serve as the study  principal investigators (referred to as RCC -PIs) 
for the follow -up study. All communications the RCC -PI has with the parent/legal 
guardian or the child’s health care provider (HCP) will occur remotel y; there wil l be no 
clinic visits. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
15The child’s parent/legal guardian will be asked to complete a Child Health I nventory 
(CHI) at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s chronological age . The CHI 
questionnaire completed upto the 24-month time point willscreen for infant mortality  
and morbidity  and will capture data on resource utilization. I f the parent/legal guardian 
indicates that the child has been newl y diagnosed (after 28 days post EDD) with chronic 
conditions or congenital anomalies, follow- up by the RCC-PI will be undertaken with the 
applicable HCP to confirm the parent report. Persistence or resolution of conditions will 
be determined in subsequent questionnaires after the initial report. 
If the parent/legal guardian indicates that the child has had a hospital visit or surgery  or 
that the child has died, the RCC- PI will confirm by  obtaining medical and other records 
from HCPs or medical facilities, including a death certificate, if applicable. If the 
parent/legal guardian indicates that the child has had an ER/UC visit, the RCC -PI will use 
discretion and obtain medical records when the reported indication suggests a true 
emergency . Additional details regarding ER/UC visits will be provided in the S tudy 
Procedures Manual. After review of all records, the RCC -PI may request additional 
targeted follow -up data from the relevant HCP or medical facility  if clarification is 
needed on an y reported study  endpoints or serious adverse events.
During the 24 months of participation in the study, if the parent/l egal guardian indicates 
that the infant has been treated b y specialists or has had ER/UC visits or hospitalizations, 
he/she will be asked to complete a productivity  questionnaire to evaluate loss of parental 
productivity .
When a congenital anomaly  is reported, it will be reviewed b y an expert in teratology  
who is engaged by the RCC -PI to serve as the birth defect evaluator for this study . The 
birth defect evaluator’s responsibilities will include the review, evaluation, and 
classification of all reports of birth defects.
To screen for a delay  in the areas of communication, gross motor, fine motor, 
problem-solving, and personal- social skills, the parent/legal guardian will be asked to 
complete the 9 -, 18-, and 24-month Ages and Stages Questionnaire- 3 (ASQ-3) when the 
infant’s corrected age corresponds to 9, 18, and 24 months ;for example, parents/legal 
guardians of an infant born 3 months premature will complete the 9 -month ASQ -3 at 
12months chronological age. An y child with a score in the black zone ( 2SD below the 
mean) in an y of the 5 domains of the ASQ -3 will be referred to a qualified assessor for a 
developmental evaluation (e.g., using the Bay ley Scale for Infant Development, third 
edition [BSI D-III]), unless the child is alread y under the care of a spe cialist who has 
recently conducted a BSID -III evaluation. Based on results from the ASQ -3 administered 
at 24 months corrected age and if no cerebral palsy  diagnosis has been made to date , the 
infant may  be referred to a qualified examiner for a formal asse ssment of cerebral pals y.
The Modified Checklist for Autism in Toddlers –Revised with Follow -Up 
(M-CHAT-R/F) will be completed for all infants at 18 and 24 months (corrected age) and 
the Child Behavior Checklist for Ages 1.5 to 5 (CBCL /1.5–5) will be comple ted for all 
infants at 24 months ( corrected age)to assess the risk for other behavioral problems or 
autism spectrum disorder (ASD). If at any of these time points a child has an 
M-CHAT-R/Fscore that indicates further evaluation is required and/or a CBCL/1.5–5  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
16score above the 97th percentile for a subset of prespecified questions , the child will be 
referred to a specialist for a formal assessment. 
Study Endpoints/Assessments
Studyprimaryendpoints include the following and are further defined in Section 6.2.2:
Morbidity  and mortalit y endpoints:
Proportion of infants and children with newl y diagnosed (after 28 days post EDD) 
chronic medical conditions by  type of condition will be recorded and include the 
following:
Respiratory  conditions
Neurological conditions
Sensory conditions
Gastrointestinal conditions
Cardiovascular conditions
Renal conditions
Growth parameters
Proportion of infants and children with newl y diagnosed (after 28 days post EDD) 
congenital anom alies
Proportion of infant and child deaths after 28 days post EDD and until 24 months 
chronological age
Neurodevelopment endpoints:
Neurodevelopment endpoints assessed at ages 9, 18, and 24 months, corrected for 
prematurit y:
Proportion of infants with an ASQ-3 score in the black zone in any  domain
Proportion of infants with an ASQ -3 score in the black zone for gross motor 
skills
Proportion of infants with an ASQ -3 score in the black zone for fine motor skills
Proportion of infants with an ASQ -3 score in the black zone for communication
Proportion of infants with an ASQ -3 score in the black zone for problem -solving
Proportion of infants with an ASQ -3 score in the black zone for personal- social 
skills
Proportion of infants referred for developmental evaluatio n (using BSID -III)
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
cognitive impairment (< 4) 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
17Proportion of infants with BSID -III score > 2 SDs below the mean score for the 
gross motor scale (< 4)
Proportion of infants with BSI D-III score > 2 SDs below the mean score for the 
fine motor scale (< 4)
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
language scale (<70 )
Proportion of infants with a CBCL /1.5–5 score above the 97th percentile for a 
subset of prespecified questions that relate to attention and hyperactivit y 
problems 
Proportion of infants indicated as needing further evaluation after completion of 
the M-CHAT-R/F
Proportion of infants referred for neurological evaluation to determine diagnosi s 
of cerebral palsy
Proportion of infants with at least 1 of the following indicators of 
neurodevelopmental impairment:
Hearing impaired, uncorrected even with aids (at 24 months chronological age)
Blindness in 1 or both eyes, or sees light only (at 24 mon ths chronological age)
Cerebral palsy  (moderate and severe) (at 24 months corrected age)
Cognitive impairment: BSI D-III Cognitive Scale Score of >2SDs below mean 
score (<4)(at 24 months corrected age)
Motor impairment: BSID -III Motor Composite Scale Scor e of >2SDs below 
mean score (< 70)(at 24 months corrected age)
Diagnosis of ASD, attention deficit disorder ( ADD), or attention deficit 
hyperactivit y disorder ( ADHD)
Exploratory  resource utilization endpoints include:
Number of hospital admissions, propo rtion of infants and children with an y hospital 
admission, post -birth hospitalization discharge, b y principal and secondary discharge 
diagnosis, t ype of hospital unit admitted to (e.g., neonatal intensive care unit [ NICU], 
Pediatric, pediatric intensive ca re unit [PICU], Nursery level3, intensive care unit 
[ICU]), and length of hospital stay  per unit after 28 days post EDD anduntil 24 
months chronological age . 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
18Combined length of hospital stay  in days for all hospital admissions (for infants 
discharged from the delivery  hospitalization and for babies who were never 
discharged home post -delivery) after 28 days post EDD and until 24 months 
chronological age .Number of surgical procedures ( details of ty pe and whether 
performed on an inpatient basis or at an out patient/surgical center will be collected 
up to 24 months chronological age onl y) after 28 days post EDD and until 24 months 
chronological age .
Number of ER/UC visits and proportion of infants with any  ER/UC visit after 
28days post EDD and up to 24 months chronological age .
Number of specialty  care or therapy  visits and proportion of infants referred for 
specialty care or therapy  by type of care/therap y after 28 days post EDD and up to 
24monthschronological age .
Parental productivit y loss related to infa nt hospital admissions, ER/UC visits, or 
specialist care after 28 days post EDD and up to 24 months chronological age . 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
191. INTRODUCTION
1.1. Background
Gestational age at birth is considered the most important predictor of a newborn’s 
subsequent health and survival . Infants born too early  and too small have a much greater 
risk of death and both short -and long-term disability  than those born at term [ Saigal, 
2008]. Early  morbidity  due to prematurit y includes respiratory distres s syndrome, 
intraventricular hemorrhage, necrotizing enterocolitis, and sepsis. Late consequences of 
prematurit y include chronic lung disease, cerebral palsy , sensory impairment, and 
cognitive deficits. An estimated 14.9 million babies were born prematurel y in 2010, 
representing 11% of all live births worldwide [ Blencowe , 2012]. Preterm birth rates 
ranged from approximately  5% in several European countries to 18% in some African 
countries. In 201 3, nearly 450 000 pre term births, defined as childbirth occurring before 
37 completed weeks’ gestation, occurred in the United States [ Martin, 2015]. These 
preterm infants had an infant mortality  rate approximately  15times the rate for full -term 
infants; the highest infant mortality  rate occurs in infants born prior to 32 weeks’ 
gestation [ Matthews, 2010]. Although the risk for complications decreases with 
increasing gestational age, infants born just a few weeks b efore term carry  an increased 
risk for developing medical complications, resulting in excessive mortalit y and morbidity  
rates during the birth hospitalization, as compared with the rates in full -term infants 
[Engle, 2007].  
Prematurity  directly influences the level of medical care, length of hospitalization, and 
associated costs; prematurity  sequelae extend the need for continued medical care into 
childhood. Estimates for 2005 placed the annual economic cost in the Uni ted States at a 
minimum of 26.2 billion dollars or 51 600 dollars per infant born preterm; roughl y 
two-thirds of this cost was for medical care [ Behrman, 2007]. 
Oxytocin plays a key role in term and preterm labor. I t is a potent uterotonic whose role 
in the initiation and progression of human labor, both term and preterm, has been activel y 
investigated for man y years. Although preterm labor may  well be a s yndrome with 
various etiologies, ox ytocin action on the uterus , in all likelihood, represents a common 
step in activation of the my ometrium. Paracrine rather than endocrine mechanisms are 
thought to mediate this process, in which the effects of ox ytocin are governed by  
tissue-specific ox ytocin receptor expression, wh ich leads to direct contractile effects in 
myometrium and prostaglandin formation in the decidua. Prostaglandins in turn mediate 
myometrial contractions and cervical ripening [ Fuchs, 1982; Benedetto , 1990].
Retosiban (GSK221149) is a potent, competitive, and highl y selective ox ytocin receptor 
antagonist. Retosiban inhibits spontaneous and oxytocin -induced contractions in human 
myometrial tissue. Retosiban wasbeing developed for the treatment of spontaneous 
preterm labor (SPTL ) in women with intact membranes.
Phase III SPTL treatment studies wereconducted to demonstrate the ability  of retosiban 
to prolong pregnancy  and improve neonatal health, as well as to describe the maternal , 
fetal, and neonatal safet y profiles. The treatment studies were terminated due to limited  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
20recruitment andthe development program was subsequently  terminated with no further in
utero exposure planned.
1.1.1. Previous Human Experience
Retosiban has been administ ered to 219 healthy subjects. A review of the safet y data in 
these health y subjects showed no effects on vital signs, electrocardiogram parameters, or 
laboratory  values that were attributable to study  drug.
No clinically  significant adverse events (AEs) or serious AEs (SAEs) have been reported 
in the completed Phase I studies of healthy  volunteers.
Study OTA105256 was the first Phase II clinical study  of retosiban in preterm labor 
(n=93)[Thornton, 2015; GlaxoSmithKl ine Document Number CM2006/00201/06] . The 
study was designed to investigate the safety  and dose response of retosiban given 
intravenously  to women with intact membranes in preterm labor between 300/7 and 356/7 
weeks of gestation. Final results showed that intravenous retosiban treatment was 
associated with a significant difference in day s to delivery  and significant reduction in 
preterm births. The mean difference in day s to delivery  was 8.2days relative to placebo 
(95%credible i nterval: 2.7, 13.74). Median prolongation of pregnancy  was 35days in 
women treated with retosiban, compared with 25 day s in women assigned to the placebo 
group. The treatment difference was consistent across gestational ages. The proportion of 
preterm bir ths was 18.7% in the retosiban group and 47.2% in the placebo group. The 
relative risk for preterm birth in the retosiban group was 0.38 (95% credible interval : 
0.15, 0.81).
The Phase 3 program included 2global blinded, randomized, controlled trials (2007 21 
[ZINN] and 200719 [NEWBORN -1]) and a single infant follow -up trial (200722 
[ARIOS]). Eligible subjects were aged 12 to 45 years with an uncomplicated singleton 
pregnancy  and intact membranes in spontaneous preterm labor at 240/7to 336/7weeks’ 
gestation. ZINN (N=330) aimed to show superiority  of retosiban (IV) over atosiban on 
time to delivery  (first subject first visit [ FSFV]wasMarch2015). NEWBORN -1 
(N=900) was designed to demonstrate neonatal benefit (based on a composite endpoint) 
as well as time to delivery  or time to treatment failure over placebo (FSFV 
February2016). The intervention trials were terminated early  on 11May2017 because of 
slow recruitment and the retosiban project was discontinued permanently . Last subject 
last visit ( LSLV)was 24July2017 for NEWBOR N-1 and 25August 2017 for ZINN. 
Meaningful anal yses of these well -controlled trials could not be performed due to small 
numbers of completing participants. Mean time to delivery  or treatment failure in the 
placebo-controlled trial w as 18.9 day s with retosiban (n=10) versus 11.1 day s with 
placebo (n=13). Two neonates in the retosiban and 4 in the placebo group had 
≥1component of the neonatal composite endpoint. The adjusted mean time to delivery in 
the atosiban comparator trial was 32.51 day s with retosiban (n=50) compared with 
33.71days with atosiban (n=47; P>0.05). Maternal, fetal, and neonatal AEs were no 
more common with retosiban than placebo or atosiban. 
In NEWBORN -1, 1 participant in the retosiban group provided cord blood and breast 
milk samples; retosiban was found in both (cord blood, 1.9 µg/L ; breast milk, 3.6 µg/L ).  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
21In ZINN, 1 2 women in the retosiban group provided cord blood samples, none of which 
had detectable levels of retosiban. One participant also provided a breast milk/colostrum 
sample. The retosiban concentration was 0.3 g/L.
1.2. Rationale
Advances in perinatal intensive care have resulted in increased survival rates for high risk 
newborns but limited improvement in morbidity . The immaturity  of organs, such as the 
brain, lungs, and gastrointestinal tract, render these newborns susceptible to injury  and 
abnormal development and function, which often leads to long -term health problems and 
disability. The risk for medical disability  is inversely  related to the gestational age at 
birth; the most common disabilities include cerebral pals y, cognitive d ysfunction, 
blindness and im paired vision, hearing loss, and disorders of ps ychological development 
(i.e., behavior and emotion).
Over the past decades, few medical interventions have been designed to prevent preterm 
birth and/or reduce the severity  of prematurity  complications. Such treatments may  also 
improve long-term outcomes. One of the major advances in perinatal medicine has been 
the finding that antenatal corticosteroids given to women at risk of imminent preterm 
birth reduces the risks for neonatal mortality  and morbidity . Corticosteroids now 
represent the standard of care for an acute antenatal intervention to improve neonatal 
outcomes in the developed world [ACOG, 2012; RCOG , 2011].
However, there is an increasing awareness that the intended beneficial effects of perinatal 
interventions do not necessarily  correlate with long -term outcomes. Dexamethasone in 
high daily doses appears to reduce mortality and the incidence of bronchopulmon ary 
dysplasia but treatment is associated with numerous short- and long-term adverse 
outcomes, including neurodevelopmental impairment. As a result, treatment with 
high-dose dexamethasone is not recommended [ Watterberg , 2010]. The ORACL E II 
Study is an example of a perinatal treatment that was associated with adverse long -term 
outcomes and no neonatal benefit. ORACL E II studied the effect of antibiotics to 
improve neonatal outcomes in women with SPTL  with intact me mbranes and no evidence 
of clinical infection. No reduction in neonatal complications was observed. However, the 
long-term follow -up revealed an increase in functional impairment and a higher risk for 
cerebral pals y in children whose mothers had received a ntibiotics [ Kenyon, 2001; 
Kenyon, 2008]. These observations have led to an appreciation that perinatal 
interventions may  affect growth and development and have highlighted the importance of 
long-term outcome studies after randomized, controlled studies of perinatal interventions. 
The goal of this study (ARIOS), therefore, is to assess the safet y and outcomes of infants 
and children who were exposed to retosiban or comparator in utero in the Phase III SPTL 
treatment studies and provide assurance that treatment is not associated with significant 
adverse outcomes in early childhood.
1.3. Benefit:Risk A ssessment
Summaries of findings from both clinical and nonclinical studies conducted wit h 
GSK221149 can be found in the IB and the Phase III SPTL treatment clinical study  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
22reports.The following section outlines the risk assessment and mitigation strategy  for this 
protocol.
1.3.1. Risk Assessment
This study  is a follow-up safet y study of infants and children exposed to treatment while 
in utero during their mother’s participation in a Phase III SPTL treatment study  of 
retosiban or comparator for SPTL . Infants and children enrolled in this study  will not be 
administered an y investigational product; ther efore, there are no anticipated or known 
risks to the infants and children who participate in this safety  study. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
23The intent of this study  is to ensure there have been no unintended consequences to the 
infants and children from exposure to retosiban or comp arator during their mother’s 
participation in the Phase III clinical stud y of retosiban, specifically  with respect to the 
following:
Potential Risk of 
Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
Fetal exp osure 
through placental 
transferFor both N EWBORN -1 and ZINN, cord 
blood samples were requested from 
subjects who delivered at the 
investigative center within 12hours 
after discontinuation of study drug. 
Samples were only analyzed for 
subjects randomized to retosiban. A 
total of 4 cord samples were collected 
within N EWBORN -1 (3 placebo:
1retosiban) and 27 within ZINN 
(12retosiban: 15 atosiban). Within both 
studies, only 1cord blood sample 
tested positive for retosiban at a 
concentration of 1.9 µg/L. The 1.9 µg/L 
is approximately 0.006x to 0.01x the 
cord blood concentrations that were 
observed in the pregnant monkey 
toxicity studies (cord blood 
concentrations = 159 to 313 µg/L). 
There were no adverse effects 
observed in the offspring in monkey 
studies, wh ere growth and development 
included a full assessment of reflexive 
behaviors, infant ECG and blood 
chemistry were analyzed. Furthermore, 
a rat post -natal study starting in juvenile 
rats that were 1day old did not show 
any adverse effects on growth and 
development, including neurobehavior 
and reproductive assessments at 
exposure levels that were 
approximately 800 -fold of what was 
observed in the cord blood (gender 
averaged C max =1535 µg/L). Day 1 
old rats were used in this study as they 
were developmentall y similar to late 
third term human fetuses. The overall 
animal data indicate that potential risk 
for a fetus exposed gestationally to 
retosiban is negligible.Analysis of maternal blood and cord 
blood samples wasperformed to test for 
levels of retosiban i n women who 
deliver edat an investigative center 
within 12 hours of the completion of 
study treatment infusion as part of the 
Phase III SPTL treatment studies .
Surveillance for signals indicating 
adverse fetal or neonatal effects with 
inutero exposure to retosiban will be 
performed throughout this study.
Infants exposed to retosiban in utero 
will be followed for up to 24months in 
this study to assess safety and 
neurodevelopmental outcomes. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
24Potential Risk of 
Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
Neonatal exposure 
via breast milkPositive breast milk samples we re 
detected within 1maternal subject in 
NEWBORN -1 and 1 subject in ZINN, 
with the highest concentration being 
0.36 µg/L. Assuming a standardized 
milkconsumption of 0.150 L/kg/day ( the 
mean milk intake of a fully brea st-fed 
2-month old infant [Begg ,1999; 
Bennett, 1988; Hagg ,2000; Kristensen ,
1999]), the worst -case dose of 
retosiban that a breast -fed child would 
be exposed to is 0.54 µg/kg/day 
(3.6µg/L x 0.15 L/kg/day). This is 
approximately 0.5% of the human dose. 
This is the worst -case scenario because 
the mother is not being administered 
retosiban post -partum during the 
lactation period, and ret osiban is 
cleared rapidly ,which would rapidly 
diminish the amount retosiban presen t 
circulation and in the milk. Furthermore, 
based on body surface area ,this 
potential infant dose is greater than 
8000- fold,the dose where no adverse 
effects were seen in growth and 
development in the rat post -natal 
development study (rat post -natal 
development study NOAEL = 
30mg/kg/day; human equivalent dose = 
4800 µg/kg/day). The potential 
lactational dose of retosiban that would 
therefore pose any significant risk to a 
newborn is negligible .Breast milk/colostrum samples were
collected for measurement of retosiban 
when delivery occurred and lactation 
hadstarted within 12 hours of receiving 
study treatment infusion as part of the 
Phase III SPTL treatment studies.
Infants exposed to retosiban via breast 
milk will be followed for up to 24 months
in this study to assess safety and 
neurodevelopmental outcomes.
ECG = electrocardiogram; NOAEL = no-observed -adverse -effect -level; SPTL = spontaneous preterm labor.
1.3.2. Benefit A ssessment
Babies born prematurel y are at risk for death, short -term medical complications, 
long-term disabilities, and developmental problems; these risks are inversely  related to 
gestational age. Although babies born before 32 weeks have the greatest risk for death 
and poor health outcomes [ Saigal, 2008; Lundqvist, 2009; Ma tthews, 2010], late preterm 
infants (defined as 340/7 to 366/7 weeks)are now known to carry  a higher risk of morbidity  
and mortality  than term infants [ Engle, 2007]. Approximately  40% to 45% of preterm 
births are preceded b y SPTL; the remainder is associated with preterm premature rupt ure 
of membranes and clinical indications for delivery [ Romero, 2000; Goldenberg , 2008]. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
25Treatment of SPTL is aimed at improving outcomes for the child and should be 
considered in women for whom a delay  in delivery will provide benefit to the newborn. 
Tocolytic therapy  is currently  recommended for short -term delay  of delivery  in order to 
administer antenatal corticosteroids, which reduce the risks for neonatal mortality  and 
morbidity, and transfer the mother to a neonatal specialized care unit. However, there is 
no evidence that current tocoly tic regimens improve neonatal or infant outcomes bey ond 
the effect of antenatal corticosteroids [ RCOG, 2011; ACOG, 2012; Roos, 2013].
Given the inverse relationship between the risks for prematurit y complications and 
gestational age at birth, the development of a treatment that significantl y prolongs 
pregnancy  in women with SPTL  would be invaluable if associated with improved 
perinatal outcomes. Results from the Phase II study  OTA105256 offer hope that retosiban 
may prolong pregnancy  to such a degree that perinata l outcomes could be favorabl y 
affected[Thornton, 2015].However, t he results from the Phase III interventional studies
didnot provide compelling evidence that retosiban couldprolong time to delivery  of 
retosiban relative to placebo or atosiban , but b
ecause of the low enrollment numbers and 
inadequate statistical power, results should be interpreted with caution.
The benefit to infants and children participating in this study  is the focus on following 
morbidity  andneurodevelopment for up to 24monthsfollowing exposure to retosiban or 
comparator medication. Participating infants and children will have the benefit of access 
to developmental screening (Ages and Stages Questionnaire -3 [ASQ-3], Child Behavior 
Checklist for Ages 1.5 to 5 [CBCL /1.5–5], and the Modified Checklist for Autism in 
Toddlers–Revised with Follow -Up [M-CHAT-R/F]), which may not be routinely  
provided and will allow parents/legal guardians to monitor and track the child’s 
developmental milestones ina formalized manner. I n addition, screening results may  be 
shared with the child’s phy sician (HCP or other) as requested b y the parent/legal 
guardian. In the event a potential issue is identified and further follow -up is warranted, 
the child will be refer red to developmental specialists/qualified assessors for further 
evaluations as part of this study. In this manner, neurodevelopmental issues may  be 
identified earlier than would have been normally .
1.3.3. Overall Benefit:Risk Conclusion
For detailed information on the identified risks and benefit:risk assessment of retosiban, 
refer to the Investigator’s Brochure ( IB)[GlaxoSmithKline Document Number 
CM2006/00201/06]. The overall benefit:risk assessment of retosiban appears favorable 
for the mother and fetus/infant. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
262. OBJECTIVES
The study  objective is to assess the safety  and outcomes in infants and children who were 
exposed to retosiban or comparator in the Phase III SPTL treatment studies. Table 1
summarizes the specific study  objectives and the corresponding endpoints, which are 
described in detail in Section 6.2(Safety) and Section 6.3(Health Outcomes).
Table 1Summary  of Study  Objectives and Corresponding Endpoints
Objective Endpoints
Primary
To characterize the clinical safety in terms of infant 
and child morbidity and mortality in infants and 
children exposed to retosiban or com parator in 
utero Proportion of infants and children with newly diagnosed 
(after 28 days post EDD) chronic medical conditions by type 
of condition will be recorded and include the following:
 Respiratory conditions
o Chronic lung disease
o Reactive airway disease
o Vocal cord paralysis
o Airway obstruction 
 Neurological conditions
o Cerebral palsy
o Seizure disorder
o Hydrocephalus requiring shunt
 Sensory conditions
o Vision
o Vision impairment
o Blindness in 1 or both eyes, or sees light 
only
o Hearing 
o Hearing impairment
o Deafnes s in 1 or both ears
o Hearing impaired, uncorrected even with 
aids
 Gastrointestinal conditions
o GERD (moderate to severe)
o Tube/parenteral feeding 
o Short bowel syndrome
 Cardiovascular conditions
o Pulmonary hypertension
o Hypertension
 Renal conditions
o Renal impair ment requiring dialysis
 Growth parameters
o Poor weight gain
o Reduced length
o Reduced head circumference
o Failure to thrive
 Proportion of infants and children with newly diagnosed 
(after 28 days post EDD) congenital anomalies
 Proportion of infant and child deaths that occur after 
28days post EDD and until 24 months chronological age 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
27Objective Endpoints
 Neurodevelopment endpoints assessed at ages 9, 18, and 
24 months, corrected for prematurity:
 Proportion of infants with an ASQ -3 score in the black 
zone in any domain
 Proportion o f infants with an ASQ -3 score in the black 
zone for gross motor skills
 Proportion of infants with an ASQ -3 score in the black 
zone for fine motor skills
 Proportion of infants with an ASQ -3 score in the black 
zone for communication
 Proportion of infants wit h an ASQ -3 score in the black 
zone for problem -solving
 Proportion of infants with an ASQ -3 score in the black 
zone for personal -social skills
 Proportion of infants referred for developmental 
evaluation (using BSID -III)
 Proportion of infants with a BSID -IIIscore > 2SDs 
below the mean score for the cognitive scale (< 4)
 Proportion of infants with BSID- III score > 2SDs below 
the mean score for the gross motor scale (< 4)
 Proportion of infants with BSID- III score > 2SDs below 
the mean score for the fine motor scale (< 4)
 Proportion of infants with a BSID -III score > 2SDs 
below the mean score for the language scale (<70)
 Proportion of infants with a CBCL/1.5 -5 score above 
the 97th percentile for a subset of prespecified 
questions that relate to attention and hypera ctivity 
problems
 Proportion of infants indicated as needing further 
evaluation after completion of the M -CHAT -R/F
 Proportion of infants referred for neurological 
evaluation to determine diagnosis of cerebral palsy
 Proportion of infants with at least 1 of t he following 
indicators of neurodevelopmental impairment:
 Hearing impaired, uncorrected even with aids (at 
24months chronological age)
 Blindness in 1 or both eyes, or sees light only (at 
24months chronological age)
 Cerebral palsy (moderate and severe) (at 24 months 
corrected age)
 Cognitive impairment: BSID -III Cognitive Scale Score 
of >2SDs below mean score (< 4)(at 24 months 
corrected age)
 Motor impairment: BSID- III Motor Composite Scale 
Score of >2SDs below mean score (< 70)(at 
24months corrected age )
 Diagnosis of ASD,ADD ,or ADHD 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
28Objective Endpoints
Exploratory
To characterize parental productivity loss related 
to a sick child and infant resource utilization in 
terms of hospital admissions, length of stay, 
ER/UC visits, surgical procedures, and referral to 
specialty care or therapy visits for infants (up to 
age 2 years) exposed to retosiban or comparator 
in utero Number of hospital admissions, proportion of infants and 
children with any hospital admission, post -birth 
hospitalization discharge, by principal and second ary 
discharge diagnosis, type of hospital unit admitted to (e.g., 
NICU, Pediatric, PICU, Nursery level 3, ICU), and length of 
hospital stay per unit after 28 days post EDD and until 
24months chronological age
 Combined length of hospital stay in days for a ll hospital 
admissions (for infants discharged from the delivery 
hospitalization and for babies who were never discharged 
home post- delivery) after 28 days post EDD and until 
24months chronological age
 Number of surgical procedures ( details of type and wh ether 
performed on an inpatient basis or at an outpatient/surgical 
center will be collected up to 24 months chronological age 
only) after 28 days post EDD and until 24 months 
chronological age
 Number of ER/UC visits and proportion of infants with any 
ER/UC visit after 28 days post EDD and up to 24 months
chronological age
 Number of specialty care or therapy visits and proportion of 
infants referred for specialty care or therapy by type of 
care/therapy after 28 days post EDD and up to 24 months
chronological age
 Parental productivity loss related to infant hospital 
admissions, ER/UC visits, or specialist care after 28 days 
post EDD and up to 24 months chronological age
ADD = attention deficit disorder; ADHD = attention deficit hyperactivity disorder; ASD = a utism spectrum disorder ;
ASQ -3 = Ages and Stages Questionnaire -3; BSID -III = Bayley Scales of Infant Development, third edition; 
CBCL/1.5 -5= Child Behavior Checklist for Ages 1.5 to 5; EDD = estimated date of delivery; ER/UC = emergency 
room/urgent care; GERD = gastroesophageal reflux disease; ICU = intensive care unit; M -CHAT -R/F = Modified 
Checklist for Autism in Toddlers -Revised with Follow -Up; NICU = neonatal intensive care unit; PICU = pediatric 
intensive care unit.
3. INVESTIGA TIONAL PLA N
3.1. Study Design
ARIOS is a long -term infant and child follow-up study that will prospectively  assess 
safety and outcomes of all infants and children born to women who received at least 
1dose of retosiban or comparator in an y of the Phase III SPTL treatment studies. The 
final assessment of the Phase III SPTL treatment studies is a collection of neonatal 
morbidity  data and will occur at 28 day s after the EDD, where EDD is defined as 400/7
weeks’ gestation. The end date of the Phase III SPTL treatment studies is referred to as 
28 days post EDD. Either the obstetrician investigators or neonatologist subinvestigators 
from the Phase III SPTL studies or their delegate will be responsible for obtaining 
consent for the infant to participate in the follow -up study; they also will be responsible 
for obtaining the signed medical release forms from all hospitals and HCPs providing 
follow-up care to the infant. Ideally, the Phase III SPTL study investigators will obtain  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
29consent and medical release when the woman’s acute episode of prete rm labor has 
resolvedand prior to discharge from the hospital for the treatment of preterm labor . The 
infant will be allowed to be consented into the study  until the later date of either the date 
of discharge from the birth hospitalization or up to 9 months corrected age (to allow for 
the infant’s 9 -month Child Health Inventory  [CHI] and ASQ -3 data collection) via 
follow-up contact from the research coordinating center -principal investigator (RCC -PI) 
to the parent/legal guardian. This follow -up contact and informed consent discussion may  
occur via telephone with signed consent and medical releases transmitted via mail or 
courier. Infants and children will be followed at prespecified intervals until they  reach 
24monthschronological age (see Table 2). This study  does not require medical 
interventions or study  visits to an investigational site. I nstead, parents or legal guardians 
will be prompted at certain time points to complete developmental questionnaires and 
other data on their children’s health status via an electronic device. Data collected during 
thisfollow-up study will be managed b y a centralized RCC. Regionally  based 
pediatricians will serve as study  principal investigators (referred to as RCC -PIs) for this
study. All communications the RCC -PI has with the parent/legal guardian or the child’s 
HCP will occur remotel y; there will be no clinic visits. An overview of the study  design 
is shown in Figure 1.
Figure 1Study Design
EDD = estimated date of delivery; HCP = health care provider; RCC = research coordinating center; 
RCC -PI=research coordinating center -principal investigator; SPTL = spontaneous preterm labor.
Electronic data capture (eD C) tools and processes including electronic case report forms 
(eCRF) and electronic patient- reported outcome devices will allow entry  of data, 
regardless of when it is obtained. If at any  time the data suggest an y developmental delay , 
the RCC-PI will refer the child to a specialist (if not alread y under the care of a specialist) 
for formal evaluation and additional assessments. The child’s local primary care pediatric  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
30provider will be asked to provide routinel y available data on the child to the RCC. 
Additional contacts may  occur at the discretion of the RCC personnel to complete the 
data collection. 
The child’s parent/legal guardian will be asked to complete the CHI at 2, 6, 9, 12, 15, 18, 
21, and 24 months of the child’s chronological age. The CHI questionnaire completed up 
to the 24-month time point will screen for infant mortality  and morbidity  and will capture 
data on resource utilization .If the parent/legal guardian indicates that the child has been 
newly diagnosed (after 28 day s post EDD) with chroni c conditions or congenital 
anomalies, follow-up will be undertaken with the applicable HCP to confirm the 
parent/legal guardian report. Persistence or resolution of conditions will be determined in 
subsequent questionnaires after the initial report. If pro tocol-specific evaluations are in 
progress at the end of the child’s protocol -defined participation in this study  (24months
chronological age) and results have not y et been received or reported, the time period 
may be extended to collect those reports.
Ifthe parent/legal guardian indicates that the child has had an y emergency room/urgent 
care (ER/UC) visits, he/she will be asked to record the number of visits and to indicate if 
the visit resulted in hospitalization. If the parent/legal guardian indicates that the child has 
been hospitalized or has had an y surgeries, medical records from the applicable medical 
facility will be obtained and abstracted for pertinent details, including principal and 
secondary  discharge diagnoses, ty pe of hospital unit admitted to (e.g., neonatal intensive 
care unit [NICU], Pediatrics, pediatric intensive care unit [PI CU], Nursery  level3, ICU), 
and length of stay . If the parent/legal guardian indicates that the child died after 28 day s 
post EDD, details of the death will be obtained from the death certificate or appropriate 
HCP or medical records if the death certificate is not available. Note that all infant deaths 
that occur before 28 day s post EDD will be captured and reported as part of the Phase III 
SPTL treatment studies.
During the 24 months of participation in the study, if the parent/legal guardian indicates 
that the infant has been treated b y specialists or has had ER/UC visits or hospitalizations, 
he/she will be asked to complete a productivity  questionnaire to evaluat e loss of parental 
productivity .
The RCC -PI will review all data including medical records, death certificates, data 
provided by the parent/legal guardian, and an y follow-up confirmatory  data provided by  
HCPs. The RCC -PI may request targeted follow -up datafrom the relevant HCP or 
medical facility  if clarification is needed on an y reported study  endpoints or SAEs. 
When a congenital anomaly  is reported, it will be reviewed by  an expert in teratology  
who is engaged by the RCC -PI to serve as the birth defect evaluator for this study . The 
birth defect evaluator’s responsibilities will include the review, evaluation, and 
classification of all reports of birth defects.
To screen for developmental issues, the parent/legal guardian will be asked to complete 
the 9-, 18- , and 24-month ASQ -3 when the infant’s corrected age corresponds to 9, 18, 
and 24 months, for example, parents/legal guardians of an infant born 3 months 
premature will complete the 9 -month ASQ -3 at 12 months chronological age. Any  child  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
31who scores in the black zone ( 2 SD below the mean) (see Section 6.2.5.1) in any of the 
5domains of the ASQ -3 will be referred to a qualified assessor for a developmental 
evaluation (e.g., using the Bay ley Scales of Infant Development, third edition 
[BSID-III]), and a neurologic examination will be conducted, if indicated. An overall 
assessment of delay  in the areas of communication, gross and fine motor, 
problem-solving, and personal- socialdevelopment will be rendered. As p art of normal 
management, some infants may  already have undergone a formal developmental 
evaluation using the BSID- III; in these cases, if testing was recent ( 3 months), the 
BSID-III will not be repeated and RCC- PI will request results from the relevant H CP. 
BSID-III retesting will be requested if the child’s ASQ -3 scores are in the black zone on a 
subsequent ASQ -3 test following the first BSID III referral. Based on results from the 
ASQ-3 administered at 24 months corrected age and if no cerebral pals y diagnosis has 
been made to date (see Section 6.2.5.1), the infant may  be referred to a qualified 
examiner for a formal assessment of cerebral pals y.
The M-CHAT-R/F will be completed for all infants at 18 and 24 mo nths (corrected age) 
and the CBCL/1.5–5 will be completed for all infants at 24 months ( corrected age) to 
assess the risk for other behavioral problems or autism spectrum disorder (ASD).If at 
any of these time points a child has an M- CHAT-R/Fscore that i ndicates further 
evaluation is required and/or a CBCL /1.5–5 score above the 97th percentile for a subset 
of prespecified questions, the child will be referred to a specialist for a formal 
assessment.
Protocol A mendment 2 has updated the total study duratio n to 24 months . Babies or 
infants that have passed the 24-monthassessment saftertheamendment implementation
are not required to continue further within the study , nor do they  need to complete any  
subsequent study -related assessments. Following completion of the study , the neonate s
will continue their normal pediatric standard of care with their primary  care pediatrician 
or health care provider.
The 24-monthdata will form the final study endpoint assessment timing; h owever, if data 
havebeen collected fr om a baby /infant after they  have passed the 24- monthendpoint, 
then this data will be included as a data listing within the clinicalstudyreport.
Data and genetic samples from the Phase III SPTL treatment studies may  be used as part 
of a genetic anal ysis using data collected in this study , if relevant. No additional genetic 
samples are required. 
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including t hose 
specified in the Time and Events Table ( Table 2), are essential and required for study  
conduct. All specified completion windows for applicable questionnaires (CHI , ASQ-3, 
CBCL/1.5–5, M-CHAT-R/F, and productivity ) are provided to help standardize the data 
and avoid overlap. Information captured outside of these windows will be collected and 
analyzed separatel y, and questionnaires completed outside the completion window will 
not be considered protocol deviations. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
32Supplementary  study conduct information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM). The SPM will provide 
the site personnel with administrative and detailed technical information that does no t 
impact subject safet y.
3.2. Discussion of Design
Longitudinal infant outcome studies are often fraught with a high rate of loss to follow-up 
that can introduce ascertainment bias [ Callanan, 2001; Tin , 1998]. The design of this 
study takes into account the operational and practical challenges involved in retaining 
infants, especiall y those who may have a diverse set of outcomes due to varying 
gestational age at birth. Rather than requi ring visits for formal outcome interviews and 
assessments of the infants and children, parent/legal guardian- reported outcomes will be 
the first-line source of health and developmental information, and parents will record data 
using an eDC sy stem to allow entry of data regardless of where it is obtained. The child’s 
primary HCP will be asked to provide data when the parent/legal guardian reports a 
chronic condition, birth defect, genetic condition or syndrome; or a change in a 
previously  reported condition. If the child’s primary HCP is unable to provide the 
information, another relevant HCP involved with the care of the child will also be asked 
to provide data. All congenital anomalies will be reviewed b y an expert in teratology  who 
is engaged b y the RCC -PIto serve as the birth defect evaluator.
Studies have affirmed that parents are a reliable source of information regarding their 
child’s health and development. The validity  of parental reports of infant and child 
hospital admissions and chronic health con ditions has been shown to be high [ Spencer, 
2000]. Likewise, it has been demonstrated with validated tools such as the ASQ -3 that 
parents’ observations are useful in performing developmental screening [ Squires, 1998; 
Rydz, 2005]. Using the parents/legal guardians as first-line reporters will ensure the 
quality of data and enhance long -term retention in the safet y follow-up. Furthermore, 
because parents tend to spend more time with their child than an yone else, their 
assessments are likel y to be reliable. To guard against reporting bias, the parent/legal 
guardian, child’s HCPs, and all study  staff will be masked until completion of the 
follow-up study with respect to the mother/ child’s Phase III SPTL treatment assignment 
(see Section 5.3).
4. SUBJECT SELECTION A ND WITHDRA WAL CRITERI A
Enrollment of infants into this follow -up study will depend upon enroll ment of mothers 
into the Phase III SPTL  treatment studies. Efforts will be taken in those studies to 
maximize enrollment of all infants.
4.1. Number of Subjects
The sample size for this study  will depend on the total number of subjects enrolled in the 
Phase III SPTL treatment studies.  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
334.2. Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent information on the GSK investigational product or other stud y treatment that 
may impact subject eligibility  is provided in the IB[GlaxoSmithKline Document Number
CM2006/00201/06] .
Deviations from inclusion criteria are not allowed because they  can potentially  jeopardize 
the scientific integrit y of the study, regulatory acceptability, or sub ject safety . Therefore, 
adherence to the criteria as specified in the protocol is essential. 
Infants eligible for enrollment in the study  must meet all of the following criteria:
1.Mother is randomly  assigned and dosed (retosiban or comparator) in 1 of the 
PhaseIII SPTL retosiban clinical studies.
2.Infant is alive at 28 day s post EDD.
3.Written informed consent is obtained from the parent(s) or legal guardian(s) of the 
infant. The parent/legal guardian of participants aged 12 to 17 y ears must also 
provide writ ten agreement for the infant to participate in the study  where required by  
applicable regulatory  and country  or state requirements.
4.3. Exclusion Criteria
Because this study  is focused on safet y and infant outcomes, all infants who meet the 
inclusion criteria will be eligible to enroll in the study
. There are no formal exclusion 
criteria for participation.
4.4. Withdrawal Criteria
Achild may be withdrawn from the study  due to loss to follow -up or if the child’s 
parent/legal guardian voluntarily  withdraws consent. A ll data collected up to the time of 
withdrawal will be included in the anal ysis. If a parent/legal guardian fails to complete an 
assessment, but wishes to remain in the study , they will be allowed to continue by  
completing future assessments.
5. STUDY TREA TMENTS
5.1. Investigational Product and Other Study  Treatment
This is a safet y follow-up study of infants and children exposed to treatment during their 
mother’s participation in a Phase III SPTL treatment study  of retosiban or comparator for 
SPTL. Infantsand childrenenrolled in this study  will not be administered any  
investigational product. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
345.2. Treatment A ssignment
The Phase III SPTL treatment study  treatment group and strata to which mothers were 
assigned will be maintained during anal ysis of data from the child follow-up study.
5.3. Blinding
The parent/legal guardian, child, the child’s HCPs, and all study  personnel (from this 
study) will remain blinded to the treatment the mother received in the Phase III SPTL 
study and will remain blinded throughout the duration of t his child follow-up study.
The child will be given a new subject identification number at the start of this follow -up 
study. The child’s subject identification number from the Phase III SPTL treatment 
studies will be masked to maintain the blind of the fol low-up study as treatment 
assignment will be unblinded at the conclusion of the Phase III SPTL treatment studies. 
The details of maintaining stud y blinding will be provided in the SPM.
There is no formal interim analy sis planned for this study . The indepen dent data 
monitoring committee (IDMC) will review unblinded data from this study  along with 
data from an y ongoing Phase III SPTL treatment study  periodically  in accordance with 
the IDMC charter. Unblinded data will be provided by  an independent statistical data 
analysis committee.
The RCC -PI or treating phy sician may  unblind a subject’s treatment assignment in the 
case of an emergency  OR in the event of a serious medical condition when knowledge of 
the study treatment is essential for the appropriate clinic al management or welfare of the 
subject as judged b y the RCC -PI. 
RCC-PIs have direct access to the subject’s individual study  treatment by  contacting a 
designated PPD unblinded safet y specialist via the SAE 24 -Hour Safet y Hotline; the 
designated unblinded safety specialist will perform the emergency  unblinding and inform 
the RCC-PI of the mother’s treatment assignment (refer to the SPM for details). 
It is preferred (but not required) that the RCC- PI first contact the PPD medical monitor to 
discuss options before unblinding the subject’s treatment assignment. 
After the subject has been unblinded, the investigator should not reveal the treatment 
assignment to the PPD medical monitor unless that information is important for the safety  
of subjects currently  enrolled in the study  (refer to the SPM for details). 
The date and reason for the unblinding must be fully documented in the eCRF.
This protocol will be filed to the Investigational New Drug Application of the United 
States. Serious AEs requiring an expedi ted investigational new drug safet y report 
(blinded for investigational drug treatment) will be sent to all participating RCC -PIs. 
Further reporting to RCC- PIs or regulatory  authorities will be performed in accordance 
with local regulations. If the SAE req uires that an expedited regulatory  report be sent to 
one or more regulatory  agencies, a copy  of the report, identify ing the subject’s treatment  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
35assignment, may  be sent to RCC -PIs in accordance with local regulations and/or GSK 
policy. 
5.4. Product A ccountabili ty
Not applicable
5.5. Treatment Compliance
Not applicable
5.6. Concomitant Medications and Nondrug Therapies
There are no restrictions regarding permitted medications or nondrug therapies. I nfants 
will be followed and treated according to HCP standard of care.
5.7. Treatment A fter the End of the Study
Not applicable
5.8. Treatment of Study  Treatment Overdose
Not applicable
6. STUDY A SSESSMENTS A ND PROCEDURES
The child’s parent/legal guardian will be the primary  data reporter to the study . 
Confirmation of key  study endpoints will be obtained from applicable HCPs or health 
care facilities. The infants and children will be followed beginning from after 28 days 
post EDD and until 24monthschronological age. Baseline characteristics and 
demographic data will be captured from the Phas e III SPTL  treatment studies and 
combined with child follow-up data for analy ses. Refer to Table 2for a summary  of data 
points to be collected and the time frame for assessment.
The time points for parent -completed questionnaires are scheduled to maintain the 
participant’s interest in study  continuation and minimize losses to follow -up. 
Questionnaires will be associated with the child’s age; in some cases
, the age will be 
chronological and in other cases, it will b e corrected for prematurity . The timing of the 
first questionnaire is scheduled to begin at 2 months chronological age and end at 
24monthschronological age. Contingent on the infant’s chronological age at the time of 
entry into the follow -up study, all of the questionnaires may  not be completed for each 
participant. The SPM will provide explicit details on study procedures to ensure proper 
timing of questionnaires.
It is noted that as part of the Phase III SPTL treatment studies, the infant’s mother will be 
asked to complete the Edinburgh Postnatal Depression Scale (EPDS) using the same eDC  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
36system as will be utilized for this study . The EPDS should ideally  be completed at 
6weeks (-2 weeks/+6 weeks) post -delivery but may be completed as earl y as 4weeks
post-delivery or as late as 12 weeks post- delivery. While the timing for EPDS may  fall 
into the time period for this study , data will be captured as part of the Phase III SPTL 
treatment study , and the SPTL  treatment study  investigator will be responsible for
reviewing information and any  action required. As such, the EPDS is not reflected in
Table 2. The SPM will provide details on the EPDS completion and process. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
37Table 2Time and Events Table
Event 28Days Post EDD Months
2 6 9 12 15 18 21 24
Written informed consent1
Baseline characteristics and demographic data X2
RCC confirms and updates contact information from the 
parent/legal guardianX
Parent/legal guardian completes CHI3 X X X X X X X X
RCC -PI follows up with HCP and reviews medical or other 
records to confirm parent -reported outcomes
RCC -PI reviews CHI results and refers to birth -defect evaluator 
based on results
Parent/legal guardian completes p roductivity questionnaire4
Parent/legal guardian completes ASQ -36 X5 X5 X5
RCC -PI reviews ASQ -3 results and refers for developmental 
evaluation based on results6
Parent/legal guardian completes M -CHAT -R/F7 X X
Parent/legal guardian completes CBCL/1.5 –57 X
RCC -PI refers child to specialist for cerebral palsy assessment (if 
required)8X 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
38ASQ -3 = Ages and Stages Questionnaire -3; CBCL/1.5 –5 = Child Behavior Checklist for ages 1.5 to 5; CHI = Child Health Inventory; EDD =estimated date of delivery; HCP =health 
care provider; M -CHAT -R/F = Modified Checklist for Autism in Toddlers -Revised with Follow -Up; RCC = research coordinating center; RCC- PI = research coordinating center -
principal investigator.
Note:  All specified completion windows for applicable questionnaires (CHI, ASQ -3, CBCL/1.5 –5, M-CHAT -R/F, and productivity) are provided to help standardize the data and avoid 
overlap. Information captured outside of these windows will be collected and analyzed separately, an d questionnaires completed outside the completion window will not be 
considered protocol deviations.
1. Collected at the start of the Phase III spontaneous preterm labor (SPTL) treatment studies until the later date of either the date of discharge from th e birth hospitalization or up to 
9months corrected age (to allow for the infant’s 9 -month CHI and ASQ- 3 data collection).
2. Captured in Phase III SPTL treatment studies and combined with child follow -up data for analyses.
3. A positive response by the pa rent/legal guardian may trigger follow -up with the relevant HCP and/or medical record review for confirmation or more details on the condition or 
hospitalization . At each time point, the completion window of the CHI is +6 weeks.
4. Completed if infant has been treated by a specialist or has had an emergency room/urgent care or hospital visit. The completion window for the produc tivity questionnaire is 
+2weeks from the date of completion of the relevant CHI.
5. Based on infant’s corrected age. The completio n window for the ASQ -3 is +30 days at Month 9 and ±30 days at Months 18 and 24.
6. If the parent/legal guardian receives a referral, then a qualified specialist will complete required assessments.
7. The CBCL/1.5 –5 and M -CHAT -R/F questionnaires will be com pleted for all infants. The completion window for the CBCL/1.5 –5 and M -CHAT -R/F is + 6 weeks at 18 months 
(M-CHAT -R/F only) and + 12weeks at 24 months . 
8. Referral will be made for infants who score in the black zone for the gross motor skills domain on th e 24-month corrected age ASQ -3 and do not have an existing diagnosis of 
cerebral palsy. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
396.1. Critical Baseline A ssessments
The final assessment of the Phase III SPTL treatment studies will occur at 28 days post 
EDD when neonatal morbidity  assessments are coll ected. Select data from this 
assessment will serve as baseline data for this study, in addition to data collected from the 
maternal medical record and newborn medical record during the Phase III SPTL 
treatment studies. These data will be transferred in a blinded manner from the Phase III 
SPTL database to the child follow-up study database.
At Baseline, the Phase III SPTL treatment study  investigator will obtain updated contact 
information from the parent/legal guardian; contact information will also be coll ected for 
at least 1 additional person (as described in the SPM) to minimize the number of infants 
and children lost to follow -up.
6.2. Safety
The focus will be on collecting the safety  outcomes as defined in the objectives (e.g., 
hospitalization, death) and SA Es, including congenital anomalies. Nonserious AEs will 
not be tracked. All SAEs and safet y outcomes will be followed until resolution, 
stabilization, or loss to follow -up.
6.2.1. Morbidity and Mortality Endpoints
The main objective of the study  is to characteriz e the clinical safet y in terms of infant 
morbidity  and mortality  in infants and children exposed to retosiban or comparator during 
the Phase III SPTL treatment studies. The morbidity  endpoints will be assessed at 2, 6, 9, 
12, 15, 18, 21, and 24 months of t he child’s chronological age. Based on the discretion of 
the RCC-PI, medical records may  need to be obtained from the applicable medical 
facility for any infants who have not y et been discharged from their birth hospitalization 
(see Section 6.2.1.1.1and Section 6.3).
6.2.1.1. Parent/Legal Guardian -Completed Child Health Inventory
The child’s parent/legal guardian will be asked to complete the CHI at 2, 6, 9, 12, 15, 18, 
21, and 24 months of the child’s chronological age. At each time point, the completion 
window is +6 weeks; however, CHI questionnaires completed outside the completion 
window will not be considered a protocol deviation.
The CHI administered at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s 
chronological age will screen for infant mortalit y and morbidity  and capture data on 
resource utilization. To facilitate data collection, parents/legal guardians will be provided 
with an electronic device that will enabl e them to provide the protocol -required data. 
They will have the option to use alternative way s to access the same s ystem (e.g., their 
own personal devices). Further details will be provided in the SPM.
The CHI will collect information about the child’s overall health after the child has 
reached 28 day s post EDD. The child’s parent/legal guardian will be asked to relate  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
40information from contacts with the health care s ystem including ER/UC visits, 
hospitalizations, surgeries, use of special equipment, nonmedical therap y, and visits to 
medical specialists. Simple questions will be asked to ascertain whether chronic 
conditions or congenital anomalies related to the study  endpoints are affecting the child’s 
health. 
At the initial completion of the CHI, the pare nt/legal guardian will be asked about all 
morbidity  and mortality  endpoints and, if required based on the child’s age, the resource 
utilization endpoints. At subsequent completions of the CHI, up to 24 months 
chronological age, the parent/legal guardian will be asked the status of previously  
reported conditions (e.g., worse, better, or resolved), as appropriate. They  will also be 
asked if an y of the other morbidity  and mortality  endpoints and resource utilization 
endpoints , as required, have occurred since the last assessment.
The parent/legal guardian will be asked to record anthropometric data such as weight, 
length, and head circumference for the child at each well-child visit in a special electronic 
diary. Data from the diary  will be extracted to correspond with study  data collection time 
points (e.g., 6 -month well-child visit anthropometric data will be associated with the 
6-month study  data collection).
6.2.1.1.1. Confirmation of Parent -Reported Data
If the parent/legal guardian indicates that the child has been n ewly diagnosed (after 
28days post EDD) with chronic conditions or congenital anomalies via the CHI , 
follow-up will be undertaken via the RCC- PI with the applicable HCP to confirm the 
parent report. At subsequent CHI s, if the parent/legal guardian indicate s that a previousl y 
reported condition has worsened or resolved, the HCP will also be asked to provide 
confirmation. If the condition qualifies as an SAE, additional information will be 
requested to assist the RCC -PI with the process of SAE reporting.
The specific process by  which confirmation with HCPs and health care facilities will be 
obtained is presented in the SPM. 
All morbidity  and mortality  endpoints (defined in Section 6.2) will require medical 
confirmation. All hospitalizations and deaths require medical confirmation by  medical 
records or death certificate. All surgeries, except routine, simple outpatient procedures 
(e.g., circumcision), require confirmation b y medical records. If the parent/legal guardian 
indicates that the child has had an ER/UC visit, the RCC -PI will use discretion and obtain 
medical records when the reported indication suggests a true emergency . Additional 
details regarding ER/UC visits will be provided in the SPM. I f follow-up with the HCP is 
recommended, medical confirmation of the follow -up is required. 
The confirmation process is iterative and may  be triggered at multiple times throughout 
the study to provide confirmation of parent-reported conditions and events. Medical input 
will override parent -reported data. An overview for the collection and review of data for 
the CHI is provided in Figure 2. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
41Figure 2Child Health Inventory : Flow Chart of Data Collection and Review
CHI = Child Health Inventory; HCP = health care provider; RCC -PI = research coordinating center -principal investigator.
1. The CHI completed at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s chronological age will screen for infant mortalit y and morbidity and capture data on resource utilization.  
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
426.2.2. Chronic Medical Conditions
The proportion of infants and children with newl y diagnosed (after 28 day s post EDD) 
chronic medical conditions by  type of condition will be recorded.
6.2.2.1. Respiratory  Conditions
Respiratory  conditions will include the following:
Chronic lung disease newly  diagnosed (after 28 day s post EDD) defined as 
increased ox ygen requirements (i.e., an y increase in previously documented O 2
use, and/or a change to how the child receives su pplemental O 2)
Reactive airway  disease, defined as a chronic lung condition associated with 
inflammation of the airway s associated with wheezing and requiring episodic 
ongoing treatment with bronchodilators and/or inhaled or s ystemic steroids
Paralyzed vocal cords, defined as impairment of the vocal cords that result in 
acute or chronic respiratory compromise or abnormalities in the infant’s voice
Airway obstruction
6.2.2.2. Neurological Conditions
Neurological conditions will include the following:
Cerebral palsy , defined as a chronic, nonprogressive neurologic disorder 
encompassing impaired motor function affecting movement, posture, balance 
muscle control, coordination, tone, or reflexes.  
Seizure disorder, defined as episodic occurrence of seizure activity requi ring 
ongoing anticonvulsant therap y
Hydrocephalus requiring shunt, defined as abnormal accumulation of 
cerebrospinal fluid in the ventricles of the brain requiring permanent shunt 
placement to prevent irreversible neurologic sequelae
ASD, defined as a neur odevelopmental disorder that impairs a child’s ability  to 
communicate and interact with others
Attention deficit disorder (ADD), defined as a disorder of attention, 
organization, and impulse control, characterized by  a persistent pattern of 
impulsiveness a nd a short attention span.
Attention deficit disorder with hy peractivity  (ADHD), defined as ADD with the 
addition of hy peractive behavior
Learning difficulties, defined as a significantly reduced ability to understand 
new or complex information or to learn new skills
Behavior disorders, defined as a general term to denote behavioral d ysfunction 
that do not fall under the category  of ADD or ADHD 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
436.2.2.3. Sensory  Conditions
Sensory conditions will include the following:
Vision
Vision impairment, defined as reduced vis ual capacity  requiring corrective 
lenses
Blindness in 1 or both eyes, defined as absence of all or most vision or sees light 
only
Hearing
Hearing impairment, defined as diminished sensitivity  to sounds normally  heard 
requiring amplification and not explain ed by middle ear effusion or chronic 
otitis media
Deafness in 1 or both ears, defined as complete inability  to hear even with 
amplification
Hearing impaired, defined as uncorrected even with aids
6.2.2.4. Gastrointestinal Conditions
Gastrointestinal conditions will include the following:
Gastroesophageal reflux disease, defined as reflux of gastric contents into the 
esophagus causing troublesome sy mptoms or complications and requiring 
ongoing treatment or surgical intervention
Tube feeding, defined as the use of a n asogastric, orogastric, or gastrostomy 
tube to accomplish some or all infant feedings
Short bowel sy ndrome, defined as inabilit y to absorb enough nutrients and fluids 
from enteral intake to maintain good health, due to prior removal b y surgery of a 
large section of the small intestine
6.2.2.5. Cardiovascular Conditions
Cardiovascular conditions will include the following:
Pulmonary  hypertension, defined as a chronic disorder of the pulmonary  
vasculature characterized by  elevated pulmonary  vascular resistance 
Hypertension requiring pharmacologic treatment 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
446.2.2.6. Renal Conditions
Renal conditions will be defined as the following:
Renal impairment requiring dial ysis
6.2.2.7. Growth Parameters
Growth parameters will include the following:
Poor weight gain, defined as less than the thir d percentile on standard weight 
chart based on the WHO Child Growth Standards 
(http://www.who.int/childgrowth/standards/en/)
Reduced length, defined as less than the third percentile on standard length chart 
based on the WHO Child Growth Standards 
(http://www.who.int/childgrowth/standards/en/)
Reduced head circumference, defined as 2 or more standard deviations below 
the median based on the WHO Child Growth Standards 
(http://www.who.int/childgrowth/standards/en/)
Failure to thrive as diagnosed by  an HCP
6.2.3. Congenital A nomalies
The proportion of infants with newly  diagnosed (after 28 day s post EDD) congenital 
anomalies will be assessed. Note: A congenital anomaly is a condition present at birth 
that results from malformation, deformation, or disruption in 1 or m ore parts of the bod y, 
a chromosomal abnormality , or a known clinical syndrome. Major congenital anomalies 
have a serious adverse effect on health, development, and functional ability  or may 
require surgical or medical management. Minor anomalies are ph ysical findings that vary  
from norms in the general population but do not cause increased morbidit y.
When a congenital anomaly  is reported, it will be reviewed by  an expert in teratology  
who is engaged by the RCC -PI to serve as the birth defect evaluator for this study . The 
birth defect evaluator’s responsibilities will include the review, evaluation, and 
classification of all reports of birth defects. Additionally , he/she will provide an opinion 
regarding the possible etiologies for the development of the obs erved anomalies. The 
birth defect evaluator will reference medicall y confirmed reports from the child’s HCP in 
making the evaluation and issue targeted queries to the HCP when necessary . If medical 
data are deemed insufficient to complete the evaluation, t he birth defect evaluator may  
ask that the RCC -PI request additional medical evaluation of the child. 
For the purpose of this study , the Centers for Disease Control and Prevention (CDC) 
Metropolitan Atlanta Congenital Defects Program (MACDP) criteria and the European 
Surveillance of Congenital Anomalies (EUROCAT) criteria will be used by  the birth 
defect evaluator to code and classify  congenital anomalies [ EUROCAT ,2005; CDC, 
2007]. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
456.2.4. Infant and Child Deaths
This study  will assess the proportion of infant and child deaths that occur after 28 days 
post EDD and up to 24monthschronological age. 
6.2.5. Parent/Legal Guardian -Completed A SQ-3, M-CHAT-R/F, and 
CBCL/1.5 –5 and Possible Referral to a Specialist
The parent/legal guardian will be asked to complete standardized developmental 
screening of the infant through completion of the ASQ- 3. The ASQ -3 was developed and 
validated to be used as a developmental screening tool; it has been used global ly and 
translated into a number of different languages. The tool has been demonstrated to 
reliably and accuratel y identify children with delays who should receive further in -depth 
assessment. The ASQ -3 includes a series of questions designed to assess 5 ar eas of 
development: communication, gross motor, fine motor, problem -solving, and 
personal-social. The questions target behaviors that are appropriate for particular 
developmental milestones; there are individual ASQ -3 questionnaires for age intervals 
ranging from 2 to 66 months. These behaviors are eas y for parents to observe, and they  
are asked to indicate whether or not the child can perform the behavior.
The 9-, 18-, and 24-month ASQ -3 questionnaires will be used in this study . These time 
points comply  with recommended developmental screening assessment guidelines from 
the American Academ y of Pediatrics [ Council on Children with Disabilities , 2006]. The 
parent/legal guardian will be asked t o complete the 9 -, 18-, and 24-month ASQ -3 when 
the infant’s corrected age corresponds to 9, 18, and 24 months, for example, parents/legal 
guardians of an infant born 3 months premature will complete the 9 -month ASQ -3 at 
12months chronological age. To fac ilitate data collection, the parent/legal guardian will 
be provided with an electronic device that will enable them to provide the 
protocol-required data. They  will have the option to use alternative way s to access the 
same system (e.g., their own personal devices). Further details will be provided in the 
SPM. The completion window for the ASQ -3 is +30 day s at Month 9 and ±30 day s at 
Months 18 and 24; however, questionnaires completed outside the completion window 
will not be considered a protocol deviation . It is essential to make age adjustments for 
prematurit y when selecting the appropriate ASQ -3. Based on results from the ASQ-3 
administered at 24 months corrected age and if no cerebral pals y diagnosis has been made 
to date(see Section 6.2.5.1), the infant may  be referred to a qualified examiner for a 
formal assessment of cerebral pals y. 
The M-CHAT-R/F will be completed for all infants at 18 and 24 months ( corrected age) 
and the CBCL/1.5 –5 will be completed fo r all infants at 24 months ( corrected age) to 
assess the risk for other behavioral problems or ASD. If at any of these time points a 
child has an M- CHAT-R/Fscore that indicates further evaluation is required and/or a 
CBCL/1.5–5 score above the 97th percen tile for a subset of prespecified questions, the 
child will be referred to a specialist for a formal assessment. An overview for the 
collection and review of data for the M -CHAT-R/F and CBCL/1.5–5 is provided in 
Figure 3. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
46The M-CHAT-R/F is a parent -reported autism screening tool designed to identify  
children 16 to 30 months of age who should receive a more thorough assessment for 
possible earl y signs of ASDor developmental delay  [Robins, 2014]. The M -CHAT-R/F 
consists of 20 questions that are answered with either “y es” or “no.” Total scores on the 
M-CHAT-R/F between 0 and 2 indicate a low risk, scores between 3 and 7 indicate a 
medium risk and triggers administration of the fol low-up questionnaire, and scores 
between 8 and 20 indicate a high risk. In this study , infants with test scores that indicate 
that further evaluation is required (either after an initial medium -risk score and further 
follow-up or an initial high -risk score ) will be considered to have possible signs of ASD
or developmental delay  and will be referred to a developmental specialist for a formal 
assessment.
The CBCL /1.5–5 is a widely  used parent -completed questionnaire of the Achenbach 
System of Empiricall y Based Assessment (ASEBA). The ASEBA is based on carefully  
conducted empirical studies and is designed to assess, in a standardized format, 
behavioral problems and social competencies ( Achenbach, 2001). The CBCL /1.5-5 
includes approximately  100 items that describe specific kinds of behavioral, emotional, 
and social problems that characterize preschool children between the ages of 1.5 and 
5years. Scores on the full CBCL /1.5-5 between the 93rd and 97th percentile are in t he 
borderline range and scores above the 97th percentile are in the significant range of 
clinical concern. In this study , infants with test scores above the 97th percentile for a 
subset of prespecified questions that relate to attention or hyperactivit y problems 
syndrome or the American Psy chiatric Association's Diagnostic and Statistical Manual 
(DSM)-oriented attention -deficit/hyperactivity disorder scale will be considered to have a 
behavior problem, which will trigger a referral to a developmental specia list for a formal 
assessment. 
The completion window for the CBCL/1/5- 5 and M-CHAT-R/F is +6 weeksat 
18months (M -CHAT-R/Fonly) and +12 weeks at 24 months; however, questionnaires 
completed outside the completion window will not be considered a protocol deviation.
For further details regarding the CBCL/1.5 –5 and M-CHAT-R/F, refer to the SPM.
6.2.5.1. The ASQ-3 Score Interpretation and Possible Specialist Referral 
Recommendations
The ASQ -3 scores for this study  will be interpreted and recommendations will be offered 
according to the following:
The child’s development will be considered to be on schedule if the child’s 
ASQ-3 scores are in the white zone (higher than 1 SD below the mean), and no 
further action is required.
If the child’s ASQ -3 scores are in the grey  zone (1 SD below the mean), the 
parent/legal guardian may share the ASQ -3 test results with the child’s HCP. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
47If any of the child’s ASQ -3 scores are in the black zone ( 2 SD below the 
mean), then the child’s parent/legal guardian will be asked if the child is already 
under the care of a developmental specialist who can or has made a formal 
assessment (e.g., using the BSID -III). If a recent ( 3months) BSID -III was 
conducted, the BSID -III will not be repeated and the RCC- PI will request results 
from the relev ant HCP. If the child is not currently under the care of a 
developmental specialist, then the parent/legal guardian will be referred to a 
qualified assessor for developmental evaluation (e.g., using the BSID -III), and a 
neurologic examination will be conducted, if indicated. 
BSID-III retesting will be performed if the child’s ASQ- 3 scores are in the black 
zone on a subsequent ASQ -3 test following the first BSID -III referral.
If, at 24 months corrected age, the child’s ASQ -3 gross motor domain score is in 
the black range and the child has not alread y been diagnosed with cerebral palsy, 
the parent/legal guardian will be referred to a qualified examiner for a formal 
assessment to determine if this condition is present.
Reports from all specialists will be incl uded in the subject’s source documents. For 
further details regarding the ASQ -3refer to the SPM.
An overview for the collection and review of data for the ASQ- 3 is provided in Figure 3. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
48Figure 3ASQ-3, M-CHAT-R/F, and CBCL/1.5 –5: Flow Chart of Data Collection and Review
ASQ -3 = Ages and Stages Questionnaire -3; BSID -III = Bayley Scales of Infant Development, third edition; CBCL/1.5 –5 = Child Behavior Checklist for ages 1.5 to 5; HCP = hea lth care 
provider; M -CHAT -R/F = Modified Checklist for Autism in Toddlers -Revised with Follow -Up; RCC -PI = research coordinating center -principal investigator.
1. A neurologic examination will also be conducted, if indicated . 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
496.2.5.2. Neurodevelopment
Neurodevelopment will be assessed b y determining the proportions of infants diagnosed 
with developmental delays listed below at 9, 18, and 24 months of age, corrected for 
prematurit y. 
Proportion of infants with an ASQ -3 score in the black zone for an y domain
Proportion of infants with an ASQ -3 score in the black zone for gross motor 
skills
Proportion of infants with an ASQ -3 score in the black zone for fine motor skills
Proportion of infants with an ASQ -3 score in the black zone for communication
Proportion of infants with an ASQ- 3 score in the black zone for problem -solving
Proportion of infants with an ASQ -3 score in the black zone for personal- social 
skills
Proportion of infants referred for developmental evaluation (using BSID -III)
Proportion of infants with a BSID -III score >2 SDs below the mean score for 
cognitive impairment (< 4)
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
gross motor scale (< 4)
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
finemotor scale (<4 )
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
language scale (<70 )
Proportion of infants with a CBCL /1.5–5 above the 97th percentile for a subset 
of prespecified questions that relate to attention and hy peractivity problems
Proportion of infants indicated as needing further evaluation after completion of 
the M-CHAT-R/F
Proportion of infants referred for neurological evaluation to determine diagnosis 
of cerebral palsy
6.2.6. Overall Measure of Neurodevelopmental I mpairment
Proportion of infants with at least 1 of the following indicators of 
neurodevelopmental impairment: 
Hearing impaired, uncorrected even with aids (at 24 months chronological age)
Blindness in 1 or both eyes, or sees light only(at 24 months chronological age)
Cerebral palsy  (moderate defined as grade 2 or 3 and severe defined as grade 4 
or 5 using the Gross Motor Functional Classification Sy stem [GMFCS]) (at 
24months corrected age) 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
50Cognitive impairment: BSI D-III Cognitive Scale Score of >2 SDs below mean 
score (<4)(at 24months corrected age)
Motor impairment: BSID -III Motor Composite Scale Score of >2 SDs below 
mean score (< 70)(at 24months corrected age)
Diagnosis of ASD, ADD, or ADHD
6.2.7. Adverse Events
The RCC -PI or RCC site staff will be responsible for detecting, documenting, and 
reporting events that meet the definition of an SAE. Nonserious AEs will not be tracked.
The outcomes for this study  may represent a number of potential adverse drug 
experiences or events that include but may  not be limited to the following:
Reports of child hospitalizations (see Section 6.3)
Reports of chronic health conditions in the child (see Section 
6.2.2)
Reports of congenital anomalies in the child (see Section 6.2.3)
Reports of child death (see Section 6.2.4)
Reports of developmental delays in the child (see Section 6.2.5.2)
Reports of an y other SAEs in the 
child (see Section 6.2.7.2)
6.2.7.1. Definition of an AE
Any untoward medical occurrence in a patient or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temp orally 
associated with the use of a medicinal product.
Events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre-
existing condition including either an 
increase in frequency  and/or intensity  of the condition
New conditions detected or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study
Signs, symptoms, or the clinical sequelae of a suspected interaction
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE) unless this is an intentional overdose taken with possible 
suicidal/self-harming intent. This should be reported regardless of sequelae. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
51Events that do notmeet the definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
leads to the procedure is an AE
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital)
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen
The disease/disorder being studied, or expected progression, signs, or s ymptoms of 
thedisease/disorder being studied, unless more severe than expected for the subject’s 
condition
6.2.7.2. Definition of an SA E
An SAE is any  untoward medical occurrence that, at any  dose:
a.Results in death
b.Is life threatening
NOTE: The term “life threatening” in the definition of “serious” refers to an event in 
which the subject was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires hospitalization or prolongation of ex isting hospitalization
NOTE: In general, hospitalization signifies that the subject has been detained 
(usually involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriate in the physician’s 
office or out -patient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalization or fulfills any  other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” o ccurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from Baseline is not considered an AE.
d.Results in disability /incapacity , or
NOTE: The term disability  means a substantial disruption of a person’s ability  to 
conduct normal life functions. This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and ac cidental trauma (e.g., sprained ankle) which 
may interfere or prevent every day life functions but do not constitute a substantial 
disruption.
e.Is a congenital anomal y/birth defect
f.Medical or scientific judgment should be exercised in deciding whether report ing is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life threatening or result in death or hospitalization but may  jeopardize 
the subject or may  require medical or surgical intervention to prevent 1 of the o ther  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
52outcomes listed in the aforementioned definition. These should also be considered 
serious. Examples of such events are invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or co nvulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
6.2.8. Laboratory  and Other Safety  Assessment A bnormalities 
Reported as SA Es
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e.g., electrocardiograms, radiological scans, vital sign 
measurements), including those that worsen from Baseline, felt to be clinically  significant 
in the medical and scientific judgment of the RCC -PI are to be recorded as SAEs. 
However, an y clinicall y significant safet y assessments that are associated with the 
underlying disease, unless judged by  the RCC-PI to be more severe than expected for the 
subject’s condition, are notto be reported as SAEs.
6.2.9. Cardiovascular Events
The RCC -PI will be required to fill out event specific data collection tools for the 
following SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrhythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
This information should be recorded in the specific cardiovascular eCRF within 1 week 
of when the SAE(s) are first reported.
6.2.10. Death Events
The proportion of deaths that occur after 28 day s post EDD and up to 24 months
chronological age will be collected.
In addition, all deaths will require a specific death data collection tool to be completed. 
The death data collection tool includes questions regarding cardiovascular (including 
sudden cardiac death) and noncardiovascular death. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
53This information should be recorded in the specific death eCRF within 1 week of when 
the death is first reported.
6.2.11. Time Period and Frequency  of Detecting SA Es
The RCC -PI or RCC site s taff is responsible for detecting, documenting, and reporting 
events that meet the definition of an SAE.
Child SAEs will be collected from after 28 days post EDD until 24monthschronological 
age. All SAEs will be reported to GSK /PPDwithin 24 hours, as indicated in 
Section6.2.12. 
6.2.12. Method of Detecting SA Es
Serious AEs will be primarily  collected through the CHI questionnaire in an electronic 
device. Designated events and/or responses will be followed b y the HCP as discussed in 
Section6.2.7.2. Care must be taken not to introduce bias when detecting SAEs. If phone 
contact needs to be made with a parent/legal guardian by  the RCC-PI, open-ended and 
nonleading verbal questioning of the subject is the preferred method to clarify  reported 
SAEs.
6.2.13. Follow-up of SA Es
Any SAEs or AEs of special interest that were ongoing at the end of the Phase III 
treatment studies and an y new SAEs reported during this study will be followed until
resolution, until the condition stabilizes, until the event is otherwise explained, or until 
the subject is lost to follow -up.
6.2.14. Prompt Reporting of SA Es and Other Events to GSK/PPD
Serious AEs meeting predefined criteria will be reported promptly  by the RCC-PI to 
GSK, as described in the following table, once the RCC -PI determines that the event 
meets the protocol definition for that event. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
54Initial Reports Follow -Up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours “SAE” data 
collection tool24 hours Updated “SAE” 
data collection tool
Cardiovascular or 
death eventInitial and 
follow -up 
reports to be 
completed 
within 1 week 
of when the 
cardiovascular 
event or death 
is reported “CV events” 
and/or “d eath” 
data collection 
tool(s), if 
applicableInitial and 
follow -up reports 
to be completed 
within 1 week of 
when the 
cardiovascular 
event or death is 
reportedUpdated “CV 
events” and/or 
“death” data 
collection tool(s), if 
applicable
CV = cardiovascular; SAE = serious adverse event.
The contact information for reporting SAEs is as follows:
Issue North America 
ContractLatin America Contact Europe/Asia Contact
Serious Adverse 
Event Reporting24-Hour Safety Hotline:
Safety Fax:24-Hour Safety Hotline:
Safety Fax:24-Hour Safety Hotline:
Safety Fax:
The method of recording, evaluating, and following up of SAEs including procedures for 
completing and transmitting S AE reports to GSK are provided in the SPM. Procedures 
for poststudy  SAEs are provided in the SPM.
6.2.14.1. Regulatory  Reporting Requirements for SA Es
Prompt notification of SAEs by  the RCC-PI to GSK is essential so that legal obligations 
and ethical responsibilitie s towards the safet y of subjects are met.
GSK has a legal responsibility  to notify both the local regulatory  authority and other 
regulatory  agencies about the safet y of a product under clinical investigation. GSK will 
comply with country  specific regulator y requirements relating to safet y reporting to the 
regulatory  authority, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and RCC -PIs.
The RCC -PI safety reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and GSK policy  and are forwarded 
to other RCC -PIs as necessary . 2019N413355_00
PPD
PPD
PPD
PPD
PPD
PPD
2014N194466_02 CONFIDENTIA L
200722
55The RCC -PI who receives a safet y report describing an SAE(s) or other specific safet y 
information (e.g., summary  or listing of SAEs) from GSK will file it with t he IB and will 
notify the IRB/IEC, if appropriate according to local requirements.
6.2.15. Other Safety  Outcomes
6.2.15.1. Laboratory  Assessments
Not applicable
6.2.15.2. Ad Hoc Maternal Reports
It is possible that during contact with the study  staff (RCC staff or RCC -PI), the mother
of the child being followed in this study  may report her own AEs/SAEs resultant from 
retosiban or comparator treatment from Phase III SPTL  treatment studies in an ad hoc
manner to the RCC study staff or the RCC -PI. The RCC -PI will be responsible for 
conveying such events to the Phase III SPTL treatment study  investigator where the 
intervention was given to ensure that all safet y outcomes are captured.
6.3. Health Outcomes
Resource utilization exploratory  endpoints include the following: 
Number of hospital admi ssions, proportion of infants and children with an y 
hospital admission, post -birth hospitalization discharge, b y principal and 
secondary  discharge diagnosis, ty pe of hospital unit admitted to (e.g., NI CU, 
Pediatric, PICU, Nursery level 3, I CU), and length of hospital stay  per unit after 
28days post EDD and up to 24 months chronological age .
Combined length of hospital stay  in days for all hospital admissions (for infants 
discharged from the delivery  hospitalization and for babies who were never 
discharged home post -delivery) after 28 day s post EDD and up to 24 months 
chronological age .
Number of surgical procedures ( details of ty pe and whether performed on an 
inpatient basis or at an outpatient/surgical center will be collected up to 
24months chronological age only) after 28 days post EDD and up to 24 months 
chronological age .
Number of ER/UC visits and proportion of infants with any  ER/UC visit after 
28days post EDD and up to 24 months chronological age .
Number of specialty  care or therapy  visits and proportion of infants referred for 
specialty care or therapy  by type of care/therapy after 28 days post EDD and up 
to 24 months chronological age .
Parental productivit y loss related to infant hospital admissions, ER/UC visits, or 
specialist care after 28 days post EDD and up to 24 months chronological age . 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
566.3.1. Parent/Legal Guardian -Completed Productivity Questionnaire
Duringthe 24 months of participation in the study, if the infant's parent/legal guardian 
reports in one of the CHI questionnaires that the child is being treated b y a specialist or 
has had emergency department visits or hospitalizations, they  will be asked to complete 
the productivity  questionnaire. This assessment asks about the impact of the child’s 
health problems on their ability  to work and perfo rm regular daily  activities. The same 
tool/process as the other parent/legal guardian -reported outcomes will be used for 
collection of this assessment. The completion window for the productivity  questionnaire 
is +2 weeks from the date of completion of the relevant CHI; however, questionnaires 
completed outside the completion window will not be considered a protocol deviation.
7. DATA MANAGEMENT
7.1. Data Handling Conventions
For this study , child data will be entered into GSK/PPD -defined eCRFs, transmitted 
electronically  to GSK/PPD, and combined with data provided from other sources, e.g., 
data obtained directly  from the parent/legal guardian via an electronic device provided by  
the sponsor, its designated vendor, or the patient’s own devices using a secure and 
validated data s ystem. The RCC staff will enter data provided on paper into the 
specificall y designed eCRF pages. 
Management of clinical data will be performed in accordance with applicable GSK/PPD 
standards and data cleaning procedures to ensure the integrit y of the data, e.g., removing 
errors and inconsistencies in the data. Adverse events and concomitant medications terms 
will be coded using the Medical Dictionary  for Regulatory  Activities (MedDRA) and an 
internal validated medication dictionary , GSKDrug.
All eCRFs (including queries and audit trails) will be retained b y GSK. In all cases, 
subject initials will not be collected or transmitted to GSK according to GSK policy .
7.1.1. Attempts to Obtain the Follow -Up Information
When follow -up data are due, the applica ble reporter will be contacted and asked to 
provide follow -up information. Subsequent attempts, as necessary , will be made through 
various modes of communication. If there is still no response, a final communication will 
be sent indicating the case is lost to follow-up. If this communication prompts a response 
or the requested data are later received before the study  closes, the case will be re- opened 
and will no longer be considered lost to follow- up. Once re -opened, an y data from 
assessments that had not been entered at the time the participant was lost to follow-up 
may be collected, if appropriate. If at any  point in the follow -up process the reporter 
indicates that the participant is lost to follow -up, no further attempts will be made. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
577.1.2. Loss to Follow -Up
Children for whom follow -up information is never obtained will be considered lost to 
follow-up. These cases will be tallied in the applicable sections of the stud y reports. All 
other cases with some follow- up data will be analyzed up to the length of childfollow-up.
7.2. Validation Procedures
The ongoing data collection from parents/legal guardians will follow a specific script to 
elicit information from contacts with the health care s ystem. The child’s HCP will also be 
contacted to provide data on the child’shealth and resource utilization when triggered b y 
information from the parent/legal guardian. As indicated in the previous sections, for 
conditions or events that may meet SAE criteria, medical confirmation and/or medical 
records will be obtained to provid e details of the conditions. All study  data will be 
captured in carefully  designed eCRFs specific to the study  objectives.
The ASQ -3, CBCL/1.5 -5, and M- CHAT-R/F questionnaires that parents/legal guardians 
will administer at the specific ages or time points have been validated in English and 
selected languages.
Ensuring that the data obtained and delivered to GSK are of high qualit y will be an 
ongoing, multistep process involving programming of edit checks for critical data 
variables in the data management s ystem and visual review for completeness, logic, 
consistency , and accuracy . As is recommended in regulatory  guidance documents, eCRFs 
will be carefully  designed to ensure data quality  and integrit y.
7.2.1. Follow-Up Process for Clarification of Information
If there are discrepancies in the data, the RCC -PI will contact the appropriate HCP for 
clarification. Subsequent attempts will be made, if necessary. If no further information is 
obtained on an otherwise evaluable case, the discrepant information in the data fi elds may 
be left blank, identified as “unspecified.” On a case- by-case basis, qualified study  staff or 
the RCC-PI may make a determination regarding discrepant information (e.g., 
determination of partiall y illegible word or illogical year).
8. DATA ANALYSIS A ND STATISTICAL CONSI DERATIONS
8.1. Hypotheses
The objective of the study is to describe the safet y and morbidity  and mortality  outcomes 
of children exposed to treatment during Phase III SPTL  studies investigating retosiban or 
comparator for the treatment of SPT L. These mortality  and morbidit y endpoints (as 
described in Section 6.2) will be descriptivel y summarized.
No type I error adjustments are planned. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
588.2. Study Design Considerations
8.2.1. Sample Size A ssumptions
The sample size for this study  will depend on the total number of subjects enrolled in the 
Phase III SPTL treatment studies. In May 2017, the 2 Phase III SPTL treatment studies 
were terminated earl y due to the feasibility of recruiting the studies in a timely manner,
meaning that thesize of the sestudies was lower than originally planned.This has 
resulted in a greatly  reduced sample size for this study . 
8.2.2. Sample Size Sensitivity
Not applicable
8.2.3. Sample Size Re -Estimation
Not applicable
8.3. Data Analysis Considerations
8.3.1. Analysis Populations
The primary  population for safet y assessment will be all infants whose mothers have 
been randomized and received retosiban or comparator in an y of the Phase III treatment 
trials. Of these mothers, the infant safety  population includes the mother/infant pairs who 
enrolled into the study, the mother/infant pairs who decline to consent to the study , and 
the mother/infant pairs whose fetus/neonates/infants died prior to the enrol lment of the 
study. Subjects will be analy zed according to their a ctual treatment in case this differs 
from their randomized treatment.
8.3.2. Analysis Data Sets
In this stud y, the anal ysis data set is the primary  population.
8.3.3. Treatment Comparisons
8.3.3.1. Primary Comparisons of Interest
The primary  treatment groups are retosiban, place bo, and atosiban.
The primary  comparisons between these treatment groups will be:
Retosiban versus placebo 
Retosiban versus atosiban 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
598.3.3.2. Other Comparisons of Interest
A secondary  treatment group will include the pooling of placebo and atosiban into a 
group called “all comparators.” The secondary  comparison will be the following:
Retosiban versus all comparators
8.3.4. Interim A nalysis
There is no formal interim analy sis planned for this study . The IDMC will review 
unblinded data from this study  along with data from a ny ongoing Phase III SPTL 
treatment study  periodically  in accordance with the IDMC charter. The unblinded 
periodic safety  updates will be performed and delivered to the IDMC by  an independent 
statistical data anal ysis committee. 
In the event of earl y stopping of the Phase III SPTL development program due to safet y 
and/or lack of efficacy , children will continue to be followed until they  have reached 
24monthschronological age. 
For any subject for which the CHI questionnaire at 3, 4, and 5 y ears of the child’s 
chronological age was completed prior to Amendment 2, data will be reported.
Further anal ysis details will be provided in the reporting and anal ysis plan (RAP) and/or 
IDMC charter.
8.3.5. Key Elements of A nalysis Plan
8.3.5.1. Safety Analyses
8.3.5.1.1. Outcomes
The primary  objective of the planned analy sis will be to use descriptive statistics to 
describe the safet y and morbidity  and mortalit y outcomes of children exposed to 
treatment during the Phase III SPTL studies investigating retosiban or comparator for the 
treatment of SPTL . The endpoints to be descriptively  summarized are those described in 
Section6.2. Descriptive statistics will be calculated by  treatment group and by  treatment 
group and time, where appropriate.
For binary  outcomes, all summary  tables will include the number and percentage of 
subjects with the response/event . For continuous variables, all summary  tables will 
include: n, mean, median, standard deviation, minimum and maximum. All summary 
tables will include N for each group (i.e., the total number of subjects randomized to each 
group within the appropriate population).
Full details of all planned anal yses will be provided in the RAP. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
608.3.5.1.2. Serious Adverse Events
Serious AEs as described in Section 6.2.7.2will be coded using MedDRA and grouped 
by body system. Serious AEs will be summarized by  treatment group as described in 
Section 8.3.3. Within each group, SAEs will be summarize d by frequency  and proportion 
of total subjects, by  event type, and by category of body system. Separate summaries will 
be given for all SAEs, drug -related SAEs, and SAEs leading to withdrawal. Where 
appropriate, SAEs b y month will be tabulated separatel y.
Full details of all safety  analyses will be provided in either the final protocol and/or RAP.
8.3.5.2. Health Outcomes A nalyses
The objective of the exploratory planned anal ysis is to characterize resource utilization in 
infants exposed to retosiban or comparator in the Phase III SPTL treatment studies. 
Exploratory  endpoints are those described in Section 6.3. Descriptive statistics maybe 
calculated b y treatment group and b y treatment group and time, where appropriate. Full 
details of the planned exploratory  analyses will be provided in the RAP.
8.3.5.3. Genetic A nalyses
Data and genetic samples from the Phase III SPTL treatment studies may  be used as part 
of a genetic anal ysis using data collected in this study , if relevant. No additional genetic 
samples are required.
9. STUDY CONDUCT CONSID ERATIONS
9.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
9.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of the study , GSK will obtain favorable opinion/approval from the 
appropriate regulatory  agency to conduct the stud y in accordance with the International 
Council for Harmonisation (I CH) Good Clinical Practice (GCP) and applicable 
country-specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in acc ordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the current version of the 
Declaration of Helsinki, including, but not limited to: 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
61IRB/IEC review and favorable opinion/approval of study  protocol and any 
subsequent amendments
Subject informed consent
RCC-PI reporting requirements
GSK/PPD will provide full details of the above procedures, either verball y, in writing, or 
both.
Written informed consent must be obtained for each infant prior to p articipation in the 
study.
9.2.1. Release of Participant Medical Information
In order to collect data from the participant’s HCPs, medical release forms for each 
clinician who will report data to the study  must be completed and signed by  the child’s 
parent/legal guardian.
9.2.2. Subject Confidentiality
Each participant’s identity will be known onl y to the third -party contractor, RCC -PIs, and 
relevant HCPs (e.g., pediatrician or specialist). Child identification numbers will be 
assigned and used to identify  study participants. The dataset used in the analy sis of data 
will contain coded participant identifiers only .
Regulatory  authorities or GSK -approved auditors may  inspect the study  data files, which 
may include personal identifier information of participants.
9.3. Quality Control (Study  Monitoring)
This study  will be outsourced to a contract research organization (PPD), which will 
perform stud y management, clinical operations, data collection, data management, data 
analysis, and report authoring under the guidance of GSK.
In accordance with applicable regulations, GCP, and GSK/PPD procedures, PPD 
monitors will contact the RCC site prior to the start of the study  to review with the RCC 
site staff the protocol, study  requirements, and their responsibilities to satisfy  regulatory ,
ethical, and GSK/PPD requirements. When reviewing data collection procedures, the 
discussion will include identification, agreement, and documentation of data items for 
which the eCRF will serve as the source document.
PPD will monitor the study  to ensure that the:
Data are authentic, accurate, and complete
Safety and rights of subjects are being protected
Study is conducted in accordance with the currently  approved protocol and any  other 
study agreements, GCP, and all applicable regulatory  requirements 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
629.4. Quality Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, GSK/PPD 
may conduct a quality  assurance assessment and/or audit of the RCC site records, and the 
regulatory  agencies may  conduct a regulatory  inspection at any  time during or after 
completion of the study . In the event of an assessment, audit, or inspection, the RCC -PI 
(and institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct 
access to all relevant documents and to allocate their time andthe time of their staff to 
discuss the conduct of the study , any findings/relevant issues and to implement any  
corrective and/or preventative actions to address any  findings/issues identified.
9.5. Study and RCC Site Closure
Recruitment in participating countr ies will begin with initiation of the Phase III SPTL 
treatment studies. Recruitment will continue until the Phase III SPTL treatment studies 
end recruitment. Follow -up will continue until each child enrolled completes the 
24-monthquestionnaire at 24monthschronological age. For any subject that was 
enrolled prior to Amendment 2, those subjects who have completed the 24 months 
assessments will not be required to complete the CHI questionnaire at 3, 4, and 5 y ears of 
the child’s chronological age . Study close-out and final reporting activities will be 
initiated on completion of the follow- up on the last study  participant.
Upon completion or termination of the study , the PPD monitor will conduct RCC site 
closure activities with the RCC -PI or RCC site staff (a s appropriate), in accordance with 
applicable regulations, GCP, and GSK/PPD Standard Operating Procedures.
GSK reserves the right to temporaril y suspend or terminate the stud y at any time for 
reasons including (but not limited to) safety  issues, ethical issues, or severe 
noncompliance. If GSK determines that such action is required, GSK will discuss the 
reasons for taking such action with the RCC -PI. When feasible, GSK will provide 
advance notice to the RCC -PI of the impending action. 
If any study with ret osiban is suspended or terminated, GSK/PPD will promptly  inform 
all RCC-PIs. GSK/PPD will also promptly  inform the relevant regulatory authorities of 
the suspension/termination along with the reasons for such action. Where required b y 
applicable regulation s, the RCC -PI must inform the I RB/IEC promptl y and provide the 
reason(s) for the suspension/termination.
9.6. Records Retention
Following closure of the study , the RCC -PI must maintain all RCC site study  records 
(except for those required by  local regulations t o be maintained elsewhere) in a safe and 
secure location. The records must be easily  accessible when needed (e.g., for a GSK/PPD 
audit or regulatory  inspection) and must be available for review in conjunction with 
assessment of the facility, supporting s ystems, and relevant RCC site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained in a format other than hard copy  (e.g., microfiche, scanned,  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
63electronic); however, caution must be exercised before such action is taken. The RCC -PI 
must ensure that all reproductions are legible and are a true and accurate copy  of the 
original. In addition, they must meet accessibility  and retrieval standards, including 
regeneration of a hard copy , if required. The RCC -PI must also ensure that an acceptable 
back-up of the reproductions exists and that there is an acceptable quality  control 
procedure in place for creating the reproductions.
GSK/PPD will inform the RCC -PI of the time period for retaining the RCC site records 
in order to compl y with all applicable regulatory requirements. The minimum retention 
time will meet the strictest standard applicable to a particular RCC site, as dictated b y 
local laws/regulations and GSK/PPD standard operating procedures.
TheRCC-PI must notify GSK/PPD of any  changes in the archival arrangements, 
including but not limited to archival of records at an off- site facility  or transfer of 
ownership of the records in the event that the RCC -PI is no longer associated with the 
RCC site.
9.7. Provision of Study  Results to RCC-PIs, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an RCC -PI signatory  will be 
identified for the approval of the clinical st udy report. The RCC -PI will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a GSK site or other mutually  
agreeable location.
GSK will also provide the RCC-PI with the full summary  of the study  results. The 
RCC-PI is encouraged to share the summary  results with the parent/legal guardian of the 
participating child, as appropriate.
The results summary  will be posted to the Clinical Study  Register no later t han 8months 
after the final primary completion date, the date that the final subject was examined, or 
received an intervention for the purposes of final collection of data for the primary  
outcome. In addition, a manuscript will be submitted to a peer- reviewed journal for 
publication no later than 18 months after the last subject’s last visit. When manuscript 
publication in a peer reviewed journal is not feasible, a statement will be added to the 
register to explain the reason for not publishing.
9.8. Independen t Data Monitoring Committee
This study  will be conducted under the auspices of an IDMC. The membership and 
activities are outlined in the IDMC charter. This committee will review the accumulating 
data as the stud y progresses, as well as data across the retosiban program. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
6410. REFERENCES
Achenbach T, Rescorla L. Manual for the ASEBA school-age forms and profiles. 
University  of Vermont, Research Center for Children, Youth, and Families; Burlington, 
VT:2001.
American College of Obstetricians and Gy necologists; Comm ittee on Practice Bulletins –
Obstetrics. ACOG practice bulletin no. 127. Management of preterm labor. Obstet 
Gynecol. 2012;119(6):1308 -17.
Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human m ilk.Br J Clin 
Pharmacol . 1999;48 (2):142-7
Behrman RE, S tith BA, eds; Committee on Understanding Premature Birth and Assuring 
Healthy Outcomes. Preterm birth: causes, consequences, and prevention. Washington 
(DC): National Academies Press; 2007.
Benedetto MT, De Cicco F, Rossiello F, et al. Oxytocin receptor in human fetal 
membranes at term and during labor. J Steroid Biochem. 1990;35(2):205 -8. 
BennettPN (ed). 1988. Drugs and human lactation, Amsterdam: Elsevier.
Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide 
estimates of prete rm birth rates in the year 2010 with time trends since 1990 for selected 
countries: a s ystematic analy sis and implications. Lancet. 2012;379(9832):2162-72.
Callanan C, Doy le L, Rickards A, et al. Children followed with difficulty : how do they  
differ? J Pae diatr Child Health. 2001;37(2):152 -6.
Centers for Disease Control and Prevention (CDC). Metropolitan Atlanta Congenital 
Defects Program (MACDP) birth defects and genetic diseases branch 6 -digit code for 
reportable congenital anomalies. August 2007. Availab le from: 
http://www.cdc.gov/ncbddd/birthdefects/documents/macdpcode0807.pdf. (Accessed 
07May 2014).
Council on Children with Disabilities; Section on Developmental Behavioral Pediatrics; 
Bright Futures Steering Committee; Medical Home I nitiatives for Chil dren With Special 
Needs Project Advisory  Committee. I dentifying infants and y oung children with 
developmental disorders in the medical home: an algorithm for developmental 
surveillance and screening. Pediatrics. 2006;118(1):405-20.
Engle WA, Tomashek KM, W allman C; Committee on Fetus and Newborn, American 
Academy of Pediatrics. "Late -preterm" infants: a population at risk. Pediatrics. 
2007;120(6):1390 -1401.
Engle WA; American Academ y of Pediatrics Committee on Fetus and Newborn. Age 
terminology  during the p erinatal period. Pediatrics. 2004;114(5):1362 -4. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
65European Surveillance of Congenital Anomalies (EUROCAT). Guide 1.3: instructions 
for registration of congenital anomalies. EUROCAT Central Registry , University  of 
Ulster, 2005. Available from: http://www.eur ocat-network.eu/content/EUROCAT-Guide-
1.3.pdf (Accessed 30 Apr 2014).
Fuchs AR, Fuchs F, Husslein P, et al. Ox ytocin receptors and human parturition: a dual 
role for ox ytocin in the initiation of labor. Science. 1982;215(4538):1396 -8.
GlaxoSmithKline Docum ent Number CM2006/00201/06 . Retosiban I nvestigator's 
Brochure Version 06. Jun 2018 .
Goldenberg RL, Culhane JF, I ams JD, et al. Epidemiology  and causes of preterm birth. 
Lancet. 2008;371(9606):75 -84.
Hagg S, SpigsetO. Anticonvulsant use during lactation, D rug Saf. 2000;22 (6):425-40.
Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics 
to pregnant women with spontaneous preterm labour: 7- year follow-up of the ORACL E 
II trial. Lancet. 2008;372(9646):1319 -27.
Kenyon SL, Taylo r DJ, Tarnow -Mordi W; ORACLE Collaborative Group. Broad -
spectrum antibiotics for spontaneous preterm labour: the ORACL E II randomised trial. 
Lancet. 2001;357(9261):989-94.
Kristensen JH, I lett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and 
norfluoxetine in human m ilk.Br J Clin Pharmacol . 1999; 48(4):521-7.
Lundqvist P, Källen K, Hallström I , et al. Trends in outcomes for very  preterm infants in 
the southern region of Sweden over a 10 -year period. Acta Paediatr. 2009;98(4):648-53.
MarlowN.Is survival and neurodevelopmental impairment at 2 years of age the gold 
standard outcome for neonatal studies? Arch Dis Child Fetal Neonatal Ed .
2015;100(1):F82 -4.
Martin JA, Hamilton BE, Osterman MJ, et al.Births: final data for 2013. Natl Vital Sta t 
Rep. 2015;64(1):1 -65.
Matthews TJ, MacDorman MF. Infant mortality  statistics from the 2006 period linked 
birth/infant death data set. Natl Vital Stat Rep. 2010;58(17):1-31.
Robins DL , Casagrande K, Barton M, et al. Validation of the modified checklist fo r 
autism in toddlers, revised with follow- up (M-CHAT-R/F). Pediatrics. 
2014:133(1):37 -45.
Romero R, Sibai BM, Sanchez -Ramos L, et al. An oxytocin receptor antagonist 
(atosiban) in the treatment of preterm labor: a randomized, double -blind, placebo -
controlled trial with tocolytic rescue. Am J Obstet Gy necol. 2000;182(5):1173 -83. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
66Roos C, Spaanderman ME, Schuit E, et al; APOSTELL -II Study Group. Effect of 
maintenance tocol ysis with nifedipine in threatened preterm labor on perinatal outcomes: 
a randomized cont rolled trial. JAMA. 2013;309(1):41-7.
Royal College of Obstetricians and Gy naecologists (RCOG). Green- top Guideline 1B. 
Tocolysis for women in preterm labour. February 2011. 13 p.
Rydz D, Shevell MI, Majnemer A, et al. Developmental screening. J Child Neur ol. 
2005;20(1):4 -21.
Saigal S, Do yle LW. An overview of mortality  and sequelae of preterm birth from 
infancy to adulthood. Lancet. 2008;371(9608):261 -9.
Spencer NJ, Coe C. Validation of the Warwick Child Health and Morbidity profile in 
routine child health surveillance. Child Care Health Dev. 2000;26(4):323 -36.
Squires JK , Potter L, Bricker D D, et al. Parent-completed developmental questionnaires: 
effectiveness with low and middle income parents. Earl y Childhood Res Q. 
1998;13(2):345 -54.
Thornton S, Miller H, Valenzuela G, et al. Treatment of spontaneous preterm labour with 
retosiban: a phase 2 proof -of-concept stud y. Br J Clin Pharmacol. Br J Clin Pharmacol. 
2015;80(4):740 -9.
Tin W, Fritz S, Wariy ar U, et al. Outcome of very preterm birth: children reviewed with 
ease at 2 years differ from those followed up with difficulty . Arch Dis Child Fetal 
Neonatal Ed. 1998;79(2):F83 -7.
Watterberg KL; American Academ y of Pediatrics; Committee on Fetus and Newborn. 
Policy statement –postnatal corticosteroids to prevent or treat bronchopulmonary  
dysplasia. Pediatrics. 2010;126(4) :800-8. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
6711. APPENDICES
11.1. Appendix 1: Protocol Changes
Protocol Amendment Number 01
Protocol Amendment Number 01 is applicable to all RCCsitesparticipating in this study. 
Protocol changes specified in Amendment Number 01 are summarized as follows: 
Extended the study duration from 24 months to 5 y ears. The rationale for this change 
was to identify  any potential neurodevelopmental and behavioral disorders through 
annual assessments at years 3, 4, and 5, s pecifically  autism and attention deficit 
hyperactivit y disorder .
Added an assessment using a modified version of the CHI  questionnaire at 3, 4, and 
5years of the child’s chronological age. The rationale for this change is to address 
US Food and Drug Administration recommendations to extend the duration of the 
follow-up period to 5 years. Amodified CHI questionnaire will be used to collect 
data to identify any potential neurodevelopmental and behavioral disorders at3, 4, 
and 5years of the child’s chronol ogical age .
Added an additional time point for the assessment of the M- CHAT-R/F at 18 months 
(in addition to the assessment at 24 months). The rationale for this change was to 
follow current recommendations from the American Academ y of Pediatrics for the 
assessment of the M -CHAT-R/F[Council on Children with Disabilities, 2006].
Revised criteria for assessment using the M-CHAT-R/F, which is assessed at 18 and 
24months, and CBCL /1.5-5, which is assessed at 24 months, to make these 
assessments mandatory  forall infants, regardless of ASQ -3 results. Previous 
requirement for CBCL/1.5–5 and M -CHAT-R/F was limited to children with ASQ -3 
nonmotor (communication, problem -solving, and/or personal- social) domain scores 
in the black zone at 24 months corrected age. The rationale for this change was to 
follow current recommendations from the American Academ y of Pediatrics [Council 
on Children with Disabilities , 2006].
Removed as a neurodevelopment endpoint the proportion of infants referred for an 
additional behaviorassessment using the M- CHAT-R/F and CBCL/1.5-5. Because 
the CBCL /1.5-5 and M-CHAT-R/F will be assessed for all infants at specified time 
points, regardless of ASQ- 3 results, this endpoint is no longer applicable to this 
study.
Clarified that an y infant SAEsand/orAEs of special interest that were unresolved at 
the end of the Phase III treatment studies and an y new SAEs reported during this 
study should be followed to stabilization or resolution in those children participating 
in the follow -up study.   2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
68Removed standard care tocoly tic therapy  as a subgroup that may  be explored as part 
of the safet y analysis. This subgroup is no longer relevant because the PhaseIII 
SPTL Study 200719(NEWBORN -1)prohibits concomitant tocoly tic treatment 
during stud y drug admini stration.
Added the following subgroups that may  be explored as part of the safet y analysis: 
established progesterone use, magnesium sulphate use, and tocol ytic usefollowing 
study drugdiscontinuation . The rationale for this change was to align endpoints with 
thosein Phase III SPTL Study  200719(NEWBORN -1).
Incorporated administrative changes as detailed in a Protocol Clarification Letter 
dated 19-Jan-2015, clarifying that there is no requirement for the investigator to 
discuss unblinding with the PPD med ical monitor in order to rapidl y unblind a 
child's treatment assignment if needed.
Incorporated other administrative changes. The rationale for these changes is to 
ensure a clear and complete protocol for use at the RCCsites.
Specific Changes in the Text
Title Page:
Title: Follow-Up Study  to Assess L ong-Term Safety  and Outcomes in Infants 
and Children Born to Mothers Participating in Retosiban Treatment 
Studies
Study Name: ARIOS
Authors (GSK):  
 
Authors (PPD):  
Sponsor Information Page:
Clinical Study  Identifier: 200722 (ARIOS)
List of Abbreviations and Definitions
ADD attention deficit disorder
ADHD attention deficit hyperactivity disorder
ASEBA Achenbach Sy stem of Empirically  Based Assessment
ASD autism spectrum disorder
. . .
GSK GlaxoSmithKline 2019N413355_00
PPD
PPD
2014N194466_02 CONFIDENTIA L
200722
69Definitions
Child Aged from 2 years to up to 12 years, per definition of the US Food and 
Drug Administration
Infant Aged from 1 month to up to 2 years, per definition of the US Food and 
Drug Administration
Summary , Rationale :
One of the major advances in perinatal medicine has been the finding that antenatal 
corticosteroids given to women at risk of imminent preterm birth reduces the risks for 
neonatal mortality  and morbidity . Corticosteroids now represent the standard of care for 
an acute antenatal intervention to improve neonatal outcomes in the developed world
[RCOG, 2011; ACOG, 2012].
The goal of this study  (ARIOS) , therefore, is to assess the safet y and outcomes of infants 
and children who were exposed to retosiban (GSK221149) or comparator in the planned 
Phase III SPTL treatment studies and provide assurance that treatment is not associated 
with significant adverse outcomes in earl y childhood.
Summary, Objectives
The study  objective is to assess the safety  and outcomes in infants and children who 
were expose d to retosiban or comparator in the Phase III SPTL treatment studies.
Specific objectives include the following:
To characterize the clinical safet y in terms of infant morbidity  and mortality  in 
infants and children exposed to retosiban or comparator in utero
To characterize the clinical safet y in terms of neurodevelopment in infants and 
children exposed to retosiban or comparator in utero
To characterize parental productivity  loss related to a sick child and infant resource 
utilization in terms of hospital admissions, length of stay , emergency  room/urgent 
care (ER/UC) visits, surgical procedures, and referral to specialt y care or therap y 
visits for infants (up to age 2 years) exposed to retosiban or comparator in utero
Summary , Study Design :
ThisARIOS is a long-term infant and child follow-up study thatwill prospectivel y 
assess safet y and outcomes of all infants and children born to women who received at 
least 1 dose of retosiban or comparator in any of the Phase III SPTL treatment studies. . . 
. The infa nt will be able to be consented into the study  until the later date of either the 
date of discharge from the birth hospitalization or up to 9 months corrected age. Infants 
and children will be followed at prespecified intervals until they  have reached 5 years  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
70chronological age 24 months corrected age for preterm infants (i.e., an infant born 3 
months preterm will complete the final 24 month study  questionnaire at 27 months 
chronological age) and 24 months chronological age for term infants . This study  does not 
require medical interventions or study  visits to an investigational site. Instead, parents or 
legal guardians will be prompted at certain time points to complete developmental 
questionnaires and other data regarding their child’s health status via an e lectronic 
device. Data collected during theinfant thisfollow-up study will be managed by  a 
centralized research coordinating center (RCC). Regionally based pediatricians will serve 
as the study  principal investigators (referred to as RCC -PIs) for the fol low-up study. All 
communications the RCC -PI has with the parent/legal guardian or the infant’s child’s 
health care provider (HCP) will occur remotel y; there will be no clinic visits.
The infant'schild’sparent/legal guardian will be asked to complete a Ch ild Health 
Inventory  (CHI)at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s chronological age 
and a modified CHI at 3, 4, and 5 years of the child’s chronological age . ThisThe 
CHIquestionnaire completed up to the 24-month time point will screen f or infant 
mortality and morbidity  and will capture data on resource utilization. At the 3 -, 4-, and 
5-year time points, the CHI will screen for child mortality and morbidity , including 
any indicators of neurodevelopmental impairment. If the parent/legal gu ardian 
indicates that the child has been newl y diagnosed (after 28 days post EDD) with chronic 
conditions or congenital anomalies, follow- up by the RCC-PI will be undertaken with the 
applicable HCP to confirm the parent report. Persistence or resolution of conditions will 
be determined in subsequent questionnaires after the initial report. 
If the parent/legal guardian indicates that the child has had a hospital visit or surgery  or 
that the infantchildhas died, the RCC- PI will confirm by  obtaining medical and other 
records from HCPs or medical facilities, including a death certificate, if applicable. If the 
parent/legal guardian indicates that the child has had an ER/UC visit, the RCC -PI will use 
discretion and obtain medical records when the reported indi cation suggests a true 
emergency . Additional details regarding ER/UC visits will be provided in the SPM. After 
review of all records, the RCC -PI may request additional targeted follow -up data from 
the relevant HCP or medical facility  if clarification is ne eded on an y reported study  
endpoints or serious adverse events (SAEs).
During the first 24 months of participation in the study, Iif the parent/legal guardian 
indicates that the infant has been treated b y specialists or has had ER/UC visits or 
hospitalizat ions, he/she will be asked to complete a productivity questionnaire to evaluate 
loss of parental productivity .
To screen for a delay  in the areas of communication, gross motor, fine motor, 
problem-solving, and personal- social skills, the parent/legal guar dian will be asked to 
complete the 9 -, 18-, and 24-month Ages and Stages Questionnaire- 3 (ASQ-3) when the 
infant’s corrected age corresponds to 9, 18, and 24 months, for example, parents/legal 
guardians of an infant born 3 months premature will complete th e 9-month ASQ -3 at 
12months chronological age. An y child with a score in the black zone ( 2SD below 
the mean) in an y of the 5 domains of the ASQ -3 will be referred to a qualified assessor  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
71for a developmental evaluation (e.g., using the Bayley  Scale for Infant Development, 
third edition [BSI D-III]), unless the child is already  under the care of a specialist who has 
recently conducted a BSID -III evaluation. Based on results from the ASQ -3 administered 
at 24 months corrected age , parents/legal guardians may be asked to complete the Child 
Behavior Checklist for Ages 1.5 to 5 (CBCL /1.5–5) and the Modified Checklist for 
Autism in Toddlers–Revised with Follow -Up (M-CHAT-R/F) to assess the risk for other 
behavioral problems or autism spectrum disorder or, alterna tively,and if no cerebral 
palsy diagnosis has been made to date , the infant may  be referred to a qualified 
examiner for a formal assessment of cerebral pals y.
The Modified Checklist for Autism in Toddlers –Revised with Follow- Up 
(M-CHAT-R/F) will be comple ted for all infants at 18 and 24 months (corrected 
age) and the Child Behavior Checklist for Ages 1.5 to 5 (CBCL/1.5 –5) will be 
completed for all infants at 24 months (corrected age) to assess the risk for other 
behavioral problems or autism spectrum disorder( ASD). If at any of these time 
points a child has an M -CHAT-R/F score that indicates further evaluation is 
required and/or a CBCL/1.5 –5 score at or above the 97th percentile for a subset of 
prespecified questions, the child will be referred to a specialist for a formal 
assessment.
Summary , Study Endpoints/Assessments
Morbidity  and mortalit y endpoints:
Proportion of infants and children with newly  diagnosed (after 28 day s post EDD) 
chronic medical conditions by  type of condition will be recorded and incl ude the 
following:
Respiratory  conditions
Neurological conditions
Sensory conditions
Gastrointestinal conditions
Cardiovascular conditions
Renal conditions
Growth parameters (only up to 24 months chronological age)
Proportion of infants and children with newly diagnosed (after 28 days post EDD) 
congenital anomalies
Proportion of infant and child deaths after 28 days post EDD and until the end of the 
study 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
72Neurodevelopment endpoints:
Neurodevelopment endpoints assessed at ages 9, 18, and 24 months, corrected for 
prematurit y:
Proportion of infants referred for developmental evaluation (using BSID -III)
Proportion of infants with a BSID -III score <>2 SDs below the mean score for 
the cognitive impairment (<70)
Proportion of infants with BSID -III score < >2 SDs below the mean score for the 
gross motor scale (<70)
Proportion of infants with BSID -III score < >2 SDs below the mean score for the 
fine motor scale (<70)
Proportion of infants with a BSID -III score <>2 SDs below the mean score for 
the language scale (<70)
Proportion of infants referred for an additional behavioral assessment using the 
CBCL/1.5-5 and M-CHAT-R/F
Proportion of infants with a CBCL /1.5–5 score at orabove the 97th percentile 
for a subset of prespecified questions that relate to attention and hy peractivity 
problems 
Proportion of infants indicated as needing further evaluation after completion of 
the M-CHAT-R/F
Proportion of infants referred for neurological evaluation to determine diagnosis 
of cerebral palsy
Proportion of infants with at least 1 o f the following indicators of 
neurodevelopmental impairment atthe end of the study :
Hearing impaired, uncorrected even with aids (at 24 months chronological 
age)
Blindness in 1 or both eyes, or sees light only (at 24 months chronological age)
Cerebral pal sy (moderate and severe) (at 24 months corrected age)
Cognitive impairment: BSI D-III Cognitive Scale Score of <>2 SDs below mean 
score (<70) (at 24 months corrected age)
Motor impairment: BSID -III Motor Composite Scale Score of <>2 SDs below 
mean score (<70) (at 24 months corrected age)
Proportion of infants and children with at least 1 of the following indicators of 
neurodevelopmental impairment at the end of the study:
Hearing impaired, uncorrected even with aids 
Blindness in 1 or both eyes or sees light only
Cerebral palsy (moderate and severe) 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
73Diagnosis of ASD ,attention deficit disorder (ADD) ,or attention deficit 
hyperactivity disorder (ADHD)
Resource utilization endpoints:
Number of hospital admissions, proportion of infants and children with any hos pital 
admission, post -birth hospitalization discharge, b y principal and secondary discharge 
diagnosis, t ype of hospital unit admitted to (e.g., NICU, Pediatric, PI CU, Nursery  
level 3, ICU), and length of hospital stay  per unit after 28 day s post EDD and un til 
the end of the study .
Combined length of hospital stay  in days for all hospital admissions (for infants 
discharged from the delivery  hospitalization and for babies who were never 
discharged home post -delivery) after 28 day s post EDD and until the end o f the 
study.
Number of surgical procedures ( bydetails of type and whether performed on an 
inpatient basis or at an outpatient/surgical center will be collected up to 24 months 
chronological age only) after 28 days post EDD and until the end of the study .
Number of ER/UC visits and proportion of infants with any  ER/UC visit after 
28days post EDD and up to 24 months chronological age .
Number of specialty  care or therapy  visits and proportion of infants referred for 
specialty care or therapy  by type of care/ therapy after 28 day s post EDD and up to 
24 months chronological age .
Parental productivit y loss related to infant hospital admissions, ER/UC visits, or 
specialist care after 28 days post EDD and up to 24 months chronological age .
Section 1.1, Background
Preterm birth rates ranged from approximately  5% in several European countries to 18% 
in some African countries. I n 20123, overnearly450 000 preterm births, defined as 
childbirth occurring before 37 completed weeks’ gestation, occurred in the United Stat es 
[Martin, 20 1315].
Section 1.1.1, Previous Human Experience
Study OTA105256 was the first Phase II clinical study  of retosiban in preterm labor 
(n=93) [Thornton, 2015 ; GlaxoSmithKline Document Number CM2006/00201/03 ]. 
The study  was designed to investigat e the safet y and dose response of retosiban given 
intravenously  to women with intact membranes in preterm labor between 300/7and 356/7
weeks of gestation. Final results showed that intravenous retosiban treatment was 
associated with a significant differen ce in days to delivery  and significant reduction in 
preterm births. The mean difference in day s to delivery  was 8.2days relative to placebo 
(95% confidence credibleinterval [CI]: 2.7, 13.74). Median prolongation of pregnancy  
was 35 day s in women treated with retosiban, compared with 25 day s in women assigned 
to the placebo group. The treatment difference was consistent across gestational ages. 
The proportion of preterm births was 18.7% in the retosiban group and 47.2% in the  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
74placebo group. The relative risk for preterm birth in the retosiban group was 0.38 (95% 
CIcredibleinterval: 0.15, 0.81).
The emerging safet y profile for retosiban appears favorable. Results from protocol 
specified maternal- fetal and neonatal safet y assessments were absent of an y concerns and 
were similar between the retosiban and placebo groups. Furthermore, no clinically  
significant disparities in AEs were noted between groups [Thornton, 2015] . All reported 
AEs, whether maternal, fetal, or neonatal, were generall y consistent with those reported 
eitherin the Investigator’s Brochure (IB) [GlaxoSmithKline (GSK)Document Number 
CM2006/00201/03] , IB Supplement 1 [GlaxoSmithKline Document Number 
2015N228508_00], or in the study  population.
Section 1.2, Rationale :
One of the major advances in perinatal medicine has been the finding that antenatal 
corticosteroids given to women at risk of imminent preterm birth reduces the risks for 
neonatal mortality  and morbidity . Corticosteroids now represent the standard of care for 
an acute antenatal int ervention to improve neonatal outcomes in the developed world
[RCOG, 2011; ACOG, 2012].
The goal of this study  (ARIOS) , therefore, is to assess the safet y and outcomes of infants 
and children who were exposed to retosiban (GSK221149) or comparator in uteroin the 
planned Phase III SPTL treatment studies and provide assurance that treatment is not 
associated with significant adverse outcomes in early  childhood.
Section 1.3.1., Risk Assessment
This study  is a follow-up safet y study of infants and children exposed to treatment while 
in uteroduring their mother’s participation in a Phase III SPTL treatment study  of 
retosiban or comparator for SPTL . Infants and children enrolled in this study will not be 
administered an y investigational product; therefore, ther e are no anticipated or known 
risks to the infants and children who participate in this safety stud y.
The intent of this study  is to ensure there have been no unintended consequences to the 
infants and children from exposure to retosiban or comparator duri ng their mother’s 
participation in the Phase III clinical stud y of retosiban, specifically  with respect to the 
following:
Potential Risk of 
Clinical SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
Fetal exposure 
throu gh placental 
transferPreclinical data indicate very minimal, if 
any, maternal central nervous system 
(CNS) penetration or placental transfer 
of retosiban as supported by the 
following: 
In pregnant monkeys there was no Analysis of maternal blood and cord 
blood samples will be performed to test 
for levels of retosiban in women who 
deliver at an investigative center within 
12hours of the completion of study 
treatment infusion as part of the  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
75Potential Risk of 
Clinical SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
detectable retosiban in the cord 
blood when mothers were dosed up 
to 100 mg/kg (approximately 
7times the human exposure). 
However, approximately 4% of 
circulating drug was detected in the 
cord blood when mothers were 
dosed at 300 mg/kg (approximately 
24-fold the human exposure).
Retosiban i s a substrate of 
P-glycoprotein and breast cancer 
resistant protein transporters, which 
are thought to play a role in keeping 
xenobiotics out of the CNS and out 
of the fetal blood, thereby limiting 
fetal exposure to retosiban.
In reproductive toxicology st udies in 
pregnant monkeys, there were no 
adverse mother and infant 
behavioral or locomotor effects 
observed that were suggestive of 
CNS toxicity. 
In rodent neurobehavioral safety 
studies, there were no adverse 
clinical signs observed at doses up 
to 1000 m g/kg.Phase III SPTL treatment studies.
Surveillance for signals indicating 
adverse fetal or neonatal effects with 
inutero exposure to retosiban will be 
performed throughout this study.
Infants exposed to retosiban in utero 
will be followed for a miniumum of 24 
months up to 5 years in this study to 
assess safety and neurodevelopmental 
outcomes.
Neonatal exposure 
via breast milkWhile there are no clinical data on the 
degree of retosiban transfer into breast 
milk, the available data based on 
physiochemical properties suggest 
retosiban w ill be excreted into breast 
milk if dosed close to or during the time 
of milk production. Given the rapid 
clearance of retosiban, the risk for 
neonatal drug exposure via breast milk 
appears low but could occur in the 
situation where the infant is fed breas t 
milk/colostrum produced within 
12hours of treatment. Since 
lactogenesis is typically delayed 30 to 
48 hours postpartum in mothers going 
to term (and is further delayed in 
mothers who deliver preterm), it seems 
unlikely that any drug would be in the 
plasma postpartum to transfer into the 
milk.Breast milk/colostrum samples will be 
collected for measurement of retosiban 
when delivery occurs and lactation has 
started within 12 hours of receiving 
study treatment infusion as part of the 
Phase III SPTL treatme nt studies.
Infants exposed to retosiban via breast 
milk will be followed for a miniumum of 
24 months up to 5 years in this study to 
assess safety and neurodevelopmental 
outcomes.
SPTL = spontaneous preterm labor. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
76Section 1.3.2., Benefit Assessment
Giventhe inverse relationship between the risks for prematurit y complications and 
gestational age at birth, the development of a treatment that significantl y prolongs 
pregnancy  in women with SPTL  would be invaluable if associated with improved 
perinatal outcomes. Results from the Phase II study  OTA105256 offer hope that retosiban 
may prolong pregnancy  to such a degree that perinatal outcomes could be favorabl y 
affected [Thornton, 2015] . There are currentl y no safet y findings that would preclude 
further developm ent of retosiban for an indication for the treatment of SPTL in 
conjunction with standard of care treatments in women with an uncomplicated, singleton 
pregnancy .
The benefit to infants and children participating in this study is the focus on following 
morbidity  and neurodevelopment for a miniumum of 24 months up to 5 years following 
exposure to retosiban or comparator medication. Participating infants and children will 
have the benefit of access to developmental screening (Ages and Stages Questionnaire -3 
[ASQ-3], Child Behavior Checklist for Ages 1.5 to 5 [CBCL /1.5–5], and the Modified 
Checklist for Autism in Toddlers– Revised with Follow -Up [M-CHAT-R/F]), which may  
not be routinely  provided and will allow parents/legal guardians to monitor and track the 
infant’schild’sdevelopmental milestones in a formalized manner. In addition, screening 
results may  be shared with the infant’schild’sphysician (health care providers [HCPs] or 
other) as requested b y the parent/legal guardian. In the event a potential issueis identified 
and further follow -up is warranted, the infantchildwill be referred to developmental 
specialists/qualified assessors for further evaluations as part of this study . In this manner, 
neurodevelopmental issues may be identified earlier than would have been normally .
Section 1.3.3., Overall Benefit:Risk Conclusion
For detailed information on the identified risks and benefit:risk assessment of retosiban, 
refer to the IB and IB Supplement 1 [GlaxoSmithKline Document Number 
CM2006/00201/03 ; GlaxoSm ithKline Document Number 2015N228508_00 ]. The 
overall benefit:risk assessment of retosiban appears favorable for the mother and 
fetus/infant. Although, experience in pregnant women is limited, no clinical or preclinical 
safety issues have been identified t hat preclude further development.
Section 2, Objectives
The study  objective is to assess the safety  and outcomes in infants and children who 
were exposed to retosiban or comparator in the Phase III SPTL treatment studies. Table 1
summarizes the specific st udy objectives and the corresponding endpoints, which are 
described in detail in Section 6.2 (Safety) and Section 6.3 (Health Outcomes). 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
77Objective Endpoints
To characterize the clinical safety in terms of infant 
and child morbidity and mortality in infant s and 
children exposed to retosiban or comparator in 
utero Proportion of infants and children with newly diagnosed 
(after 28 days post EDD) chronic medical conditions by type 
of condition will be recorded and include the following:
 Respiratory conditions
o Chronic lung disease
o Reactive airway disease
o Vocal cord paralysis
o Airway obstruction 
 Neurological conditions
o Cerebral palsy
o Seizure disorder
o Hydrocephalus requiring shunt
 Sensory conditions
o Vision
o Vision impairment
o Blindness in 1 or both eyes, or sees ligh t 
only
o Hearing 
o Hearing impairment
o Deafness in 1 or both ears
o Hearing impaired, uncorrected even with 
aids
 Gastrointestinal conditions
o GERD (moderate to severe)
o Tube/parenteral feeding 
o Short bowel syndrome
 Cardiovascular conditions
o Pulmonary hypertension
o Hypertension
 Renal conditions
o Renal impairment requiring dialysis
 Growth parameters (only up to 24 months 
chronological age)
o Poor weight gain
o Reduced length
o Reduced head circumference
o Failure to thrive
 Proportion of infants and children with newly diagnose d 
(after 28 days post EDD) congenital anomalies
 Proportion of neonatal and infant and child deaths that 
occur after 28 days post EDD and until the end of the study 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
78Objective Endpoints
To characterize the clinical safety in terms of 
neurodevelopment in infants and children 
exposed to retosiban or comparator in utero Neurodevelopment endpoints assessed at ages 9, 18, and 
24 months, corrected for prematurity:
 Proportion of infants with an ASQ -3 score in the black 
zone in any domain
 Proportion of infants with an ASQ -3 score in th e black 
zone for gross motor skills
 Proportion of infants with an ASQ -3 score in the black 
zone for fine motor skills
 Proportion of infants with an ASQ -3 score in the black 
zone for communication
 Proportion of infants with an ASQ -3 score in the black 
zone for problem -solving
 Proportion of infants with an ASQ -3 score in the black 
zone for personal -social skills
 Proportion of infants referred for developmental 
evaluation (using BSID -III)
 Proportion of infants with a BSID -III score <>2SDs 
below the mean score for the cognitive scale (<70)
 Proportion of infants with BSID- III score <>2SDs 
below the mean score for the gross motor scale (<70)
 Proportion of infants with BSID- III score <>2SDs 
below the mean score for the fine motor scale (<70)
 Proportion of infant s with a BSID -III score <>2SDs 
below the mean score for the language scale (<70)
 Proportion of infants referred for an additional 
behavioral assessment using the CBCL/1.5 -5 and 
M-CHAT -R/F
 Proportion of infants with a CBCL/1.5 -5 score at or
above the 97th percentile for a subset of prespecified 
questions that relate to attention and hyperactivity 
problems
 Proportion of infants indicated as needing further 
evaluation after completion of the M -CHAT -R/F
 Proportion of infants referred for neurological 
evaluatio n to determine diagnosis of cerebral palsy
 Proportion of infants with at least 1 of the following 
indicators of neurodevelopmental impairment atthe end of 
the study :
 Hearing impaired, uncorrected even with aids (at 
24months chronological age)
 Blindness i n 1 or both eyes, or sees light only (at 
24months chronological age)
 Cerebral palsy (moderate and severe) (at 24 months 
corrected age)
 Cognitive impairment: BSID -III Cognitive Scale Score 
of <>2 SDs below mean score (<70) (at 24 months 
corrected age)
 Motor impairment: BSID- III Motor Composite Scale 
Score of <>2SDs below mean score (<70) (at 
24months corrected age) 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
79Objective Endpoints
 Proportion of infants and children with at least 1 of the 
following indicators of neurodevelopmental impairment 
at the end of the study:
 Hearing impaired, uncorrected even with aids 
 Blindness in 1 or both eyes, or sees light only
 Cerebral palsy (moderate and severe)
 Diagnosis of ASD, ADD, or ADHD
To characterize parental productivity loss related 
to a sick child and infant resource utilizati on in 
terms of hospital admissions, length of stay, 
ER/UC visits, surgical procedures, and referral to 
specialty care or therapy visits for infants (up to 
age 2 years) exposed to retosiban or comparator 
in utero Number of hospital admissions, proportion of infants and 
children with any hospital admission, post -birth 
hospitalization discharge, by principal and secondary 
discharge diagnosis, type of hospital unit admitted to (e.g., 
NICU, Pediatric, PICU, Nursery level 3, ICU), and length of 
hospital stay per unit after 28 days post EDD and until the 
end of the study.
 Combined length of hospital stay in days for all hospital 
admissions (for infants discharged from the delivery 
hospitalization and for babies who were never discharged 
home post- delivery) after 28 days post EDD and until the 
end of the study.
 Number of surgical procedures ( bydetails of type and 
whether performed on an inpatient basis or at an 
outpatient/surgical center will be collected up to 
24months chronological age only ) after 28 days post 
EDD and until the end of the study.
 Number of ER/UC visits and proportion of infants with any 
ER/UC visit after 28 days post EDD and up to 24 months 
chronological age.
 Number of specialty care or therapy visits and proportion of 
infants referred for specialty care or therapy by type of 
care/therapy after 28 days post EDD and up to 24 months
chronological age.
 Parental productivity loss related to infant hospital 
admissions, ER/UC visits, or specialist care after 28 days 
post EDD and up to 24 months chronologi cal age.
ADD = attention deficit disorder; ADHD = attention deficit hyperactivity disorder; ASD = autism spectrum 
disorder; ASQ -3 = Ages and Stages Questionnaire -3; BSID -III = Bayley Scales of Infant Development, third 
edition; CBCL/1.5 -5= Child Behavior Checklist for Ages 1.5 to 5; EDD = estimated date of delivery; ER/UC = 
emergency room/urgent care; GERD = gastroesophageal reflux disease; ICU = intensive care unit; M -CHAT -R/F 
= Modified Checklist for Autism in Toddlers -Revised with Follow- Up; NICU = neo natal intensive care unit; PICU = 
pediatric intensive care unit.
Section 3.1., Study Design
ThisARIOSis along-term infant and child follow-up study thatwill prospectivel y 
assess safet y and outcomes of all infants and children born to women who receiv ed at 
least 1 dose of retosiban or comparator in any of the Phase III SPTL treatment studies. . . 
. The infant will be able to be consented into the study  until the later date of either the 
date of discharge from the birth hospitalization or up to 9 months corrected age. Infants 
will be followed at prespecified intervals until they have reached 5 yearschronological 
age 24 months corrected age for preterm infants (i.e., an infant born 3 months preterm 
will complete the final 24 month study  questionnaire at 27 months chronological age) and 
24 months chronological age for term infants . . . . Infants and children will be followed  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
80at prespecified intervals until they  reach 5 years chronological age (see Table 2). This 
study does not require medical interventions or study visits to an investigational site. 
Instead, parents or legal guardians will be prompted at certain time points to complete 
developmental questionnaires and other data on their children’s health status via an 
electronic device. Data collected duri ng the infant thisfollow up study  will be managed 
by a centralized RCC. Regionall y based pediatricians will serve as stud y principal 
investigators (referred to as RCC -PIs) for this study . All communications the RCC -PI has 
with the parent/legal guardian or the infant’s child’s HCP will occur remotely; there will 
be no clinic visits. An overview of the study  design is shown in Figure 1.
Figure 1, Study Design
Electronic data capture (eDC) tools and processes including electronic case report forms 
(eCRF) an d electronic patient- reported outcome devices will allow entry  of data, 
regardless of when it is obtained. If at any  time the data suggest an y developmental delay  
of an infant , the RCC -PI will refer the infantchild to a specialist (if not already  under the 
care of a specialist) for formal evaluation and additional assessments. The infant’schild’s 
local primary  care pediatric provider will be asked to provide routinely  available data on 
the infant childto the RCC. Additional contacts may  occur at the disc retion of the RCC 
personnel to complete the data collection. 
The infant'schildparent/legal guardian will be asked to complete the CHI at 2, 6, 9, 12, 
15, 18, 21, and 24 months of the child’s chronological age and a modified CHI at 3, 4, 
and 5 years of t he child’s chronological age . The CHI questionnaire completed up to 
the 24-month time point will screen for infant mortality  and morbidit y and will capture 
data on resource utilization. At the 3-, 4-, and 5-year time points, the CHI will screen 
for child mortality and morbidity, including any indicators of neurodevelopmental 
impairment .If the parent/legal guardian indicates that the child has been newly 
diagnosed (after 28 day s post EDD) with chronic conditions or congenital anomalies  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
81follow up will be und ertaken with the applicable HCP to confirm the parent/legal 
guardian report. Persistence or resolution of conditions will be determined in subsequent 
questionnaires after the initial report. If protocol specific evaluations are in progress at 
the end of th e child’s protocol defined participation in this study  (24 months corrected 
age for preterm infants or 24 months5 yearschronological age for term infants) and 
results have not yet been received or reported, the time period may be extended to collect 
those reports.
If the parent/legal guardian indicates that the child has had an y emergency room/urgent 
care (ER/UC) visits, he/she will be asked to record the number of visits and to indicate if 
the visit resulted in hospitalization. If the parent/legal guardi an indicates that the infant
childhas been hospitalized or has had an y surgeries, medical records from the applicable 
medical facility  will be obtained and abstracted for pertinent details, including principal 
and secondary  discharge diagnoses, t ype of hospital unit admitted to (e.g., neonatal 
intensive care unit [NI CU], Pediatrics, pediatric intensive care unit [PI CU], Nursery  
level3, ICU), and length of stay . If the parent/legal guardian indicates that the infant
childdied after 28 days post EDD, details of the death will be obtained from the death 
certificate or appropriate HCP or medical records if the death certificate is not available. 
Note that all infant deaths that occur before 28 days post EDD will be captured and 
reported as part of the Phase I II SPTL treatment studies.
Duringthe first 24 months of participation in the study, Iif the parent/legal guardian 
indicates that the infant has been treated b y specialists or has had ER/UC visits or 
hospitalizations, he/she will be asked to complete a pro ductivity questionnaire to evaluate 
loss of parental productivity .
To screen for developmental issues, the parent/legal guardian will be asked to complete 
the 9-, 18- , and 24-month ASQ -3 when the infant’s corrected age corresponds to 9, 18, 
and 24 months, for example, parents/legal guardians of an infant born 3 months 
premature will complete the 9 -month ASQ -3 at 12 months chronological age. Any  child 
who scores in the black zone ( 2 SD below the mean) (see Section 6.2.5.1) in any  of the 
5domains of the AS Q-3 will be referred to a qualified assessor for a developmental 
evaluation (e.g., using the Bay ley Scales of Infant Development, third edition 
[BSID-III]), and a neurologic examination will be conducted, if indicated. An overall 
assessment of delay  in theareas of communication, gross and fine motor, 
problem-solving, and personal- socialdevelopment will be rendered. As part of normal 
management, some infants may  already have undergone a formal developmental 
evaluation using the BSID- III; in these cases, if testing was recent ( 3 months), the 
BSID-III will not be repeated and RCC- PI will request results from the relevant HCP. 
BSID-III retesting will be requested if the child’s ASQ -3 scores are in the black zone on a 
subsequent ASQ -3 test following the first BSID III referral. Based on results from the 
ASQ-3 administered at 24 months corrected age , parents/legal guardians may  be asked to 
complete the Child Behavior Checklist for Ages 1.5 to 5 (CBCL /1.5–5) and the Modified 
Checklist for Autism in Toddlers– Revised with Follow -Up (M-CHAT-R/F) to assess the 
risk for other behavioral problems or autism spectrum disorder or, alternatively ,and if no 
cerebral palsy diagnosis has been made to date , the infant may  be referred to a 
qualified examiner for a formal assessm ent of cerebral pals y. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
82The Modified Checklist for Autism in Toddlers –Revised with Follow- Up 
(M-CHAT-R/F) will be completed for all infants at 18 and 24 months (corrected 
age) and the Child Behavior Checklist for Ages 1.5 to 5 (CBCL/1.5 –5) will be 
completed for all infants at 24 months (corrected age) to assess the risk for other 
behavioral problems or autism spectrum disorder (ASD). If at any of these time 
points a child has an M -CHAT-R/F score that indicates further evaluation is 
required and/or a CBCL/1.5 –5 score at or above the 97th percentile for a subset of 
prespecified questions, the child will be referred to a specialist for a formal 
assessment.
Section 3.2., Discussion of Design
Longitudinal infant outcome studies are often fraught with a high rate o f loss to follow up 
that can introduce ascertainment bias [Callanan, 2001; Tin, 1998]. The design of this 
study takes into account the operational and practical challenges involved in retaining 
infants, especiall y those who may have a diverse set of outcom es due to vary ing 
gestational age at birth. Rather than requiring visits for formal outcome interviews and 
assessments of the infants and children , parent/legal guardian -reported outcomes will be 
the first-line source of health and developmental informatio n, and parents will record data 
using an eDC sy stem to allow entry  of data regardless of where it is obtained. The child’s 
primary HCP will be asked to provide data when the parent/legal guardian reports a 
chronic condition, birth defect, genetic condition or syndrome; or a change in a 
previously  reported condition. I f the child’s primary  HCP is unable to provide the 
information, another relevant HCP involved with the care of the infantchildwill also be 
asked to provide data. All congenital anomalies will be reviewed b y an expert in 
teratology  who is engaged by  the RCC-PI to serve as the birth defect evaluator.
Studies have affirmed that parents are a reliable source of information regarding their 
infant’s child’s health and development. The validity  of parental reports of infant and 
childhospital admissions and chronic health conditions has been shown to be high 
[Spencer, 2000]. L ikewise, it has been demonstrated with validated tools such as the 
ASQ-3 that parents’ observations are useful in performing de velopmental screening 
[Squires, 1998; Ry dz, 2005]. Using the parents/legal guardians as first -line reporters will 
ensure the quality of data and enhance long -term retention in the safet y follow-up. 
Furthermore, because parents tend to spend more time with their infants childthan 
anyone else, their assessments are likel y to be reliable. To guard against reporting bias, 
the parent/legal guardian, infant’schild’sHCPs, and all study  staff will be masked until 
completion of the follow -up study with respect to the mother/ infant’schild’sPhase III 
SPTL treatment assignment (see Section 5.3).
Section 4.2, Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent information on the GSK investigational pr oduct or other stud y treatment that 
may impact subject eligibility  is provided in the IB and IB Supplement 1
[GlaxoSmithKline Document Number CM2006/00201/03 ; GlaxoSmithKline Document 
Number 2015N228508_00 ]. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
83Section 4.4., Withdrawal Criteria
Aninfantschildmay be withdrawn from the study  due to loss to follow -up or if the 
infant’schild’s parent/legal guardian voluntaril y withdraws consent. All data collected 
up to the time of withdrawal will be included in the anal ysis. If a parent/legal guardian 
fails to complete an assessment, but wishes to remain in the study , they will be allowed to 
continue by  completing future assessments.
Section 5.1., Investigational Product and Other Study Treatment
This is a safet y follow-up study of infants and children exposedto treatment during their 
mother’s participation in a Phase III SPTL treatment study  of retosiban or comparator for 
SPTL. Infants and children enrolled in this study will not be administered any  
investigational product.
Section 5.2., Treatment Assignment
The Phase III SPTL treatment study  treatment group and strata to which mothers were 
assigned will be maintained during anal ysis of data from the infantchildfollow-up study.
Section 5.3, Blinding
The parent/legal guardian, infantchild, the infant’s child’sHCPs, and all study  personnel 
(from this study ) will remain blinded to the treatment the mother received in the Phase III 
SPTL study and will remain blinded throughout the duration of this infantchild
follow-up study.
The infantchildwill be given a n ew subject identification number at the start of this 
follow-up study. The infant’schild’s subject identification number from the Phase III 
SPTL treatment.
The RCC -PI or treating physician may unblind an infant’s a subject’s treatment 
assignment only in the case of an emergency  OR in the event of a serious medical 
condition when knowledge of the stud y treatment is essential for the appropriate clinical 
management or welfare of the subject as judged by the RCC -PI. 
The RCC -PI must first discuss options wit h GSK/PPD medical monitor or appropriate 
GSK/PPD study  personnel before unblinding the infant’s treatment assignment. The PPD 
unblinded medical monitor will authorize the unblinding, and the treatment assignment 
will be provided. The date and reason for th e unblinding must be recorded in the 
appropriate data collection tool.
GSK’s Global Clinical Safet y and Pharmacovigilance department may  unblind the 
treatment assignment for any  infant with an SAE. The PPD medical monitor may  unblind 
the treatment assignme nt after discussing the rationale for unblinding with the RCC -PI. 
Notification of unblinding will be sent to GSK, PPD, and the RCC site. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
84This protocol will be filed to the Investigational New Drug Application of the United 
States. Serious AEs requiring an expedited investigational new drug safet y report 
(blinded for investigational drug treatment) will be sent to all participating RCC -PIs. 
Further reporting to RCC- PIs or regulatory  authorities will be performed in accordance 
with local regulations. If the S AE requires that an expedited regulatory  report be sent to 
one or more regulatory  agencies, a copy  of the report, identify ing the subject’s treatment 
assignment, may  be sent to RCC -PIs in accordance with local regulations and/or GSK 
policy.
RCC-PIs have di rect access to the subject’s individual study treatment by 
contacting a designated PPD unblinded safety specialist via the SAE 24 -Hour Safety 
Hotline; the designated unblinded safety specialist will perform the emergency 
unblinding and inform the RCC -PI ofthe mother’s treatment assignment (refer to 
the SPM for details). 
It is preferred (but not required) that the RCC- PI first contact the PPD medical 
monitor to discuss options before unblinding the subject’s treatment assignment. 
After the subject has been unblinded, the investigator should not reveal the 
treatment assignment to the PPD medical monitor unless that information is 
important for the safety of subjects currently enrolled in the study (refer to the SPM 
for details). 
The date and reason for the unblinding must be fully documented in the eCRF.
Section 6, Study Assessments and Procedures
The infant’schild’sparent/legal guardian will be the primary  data reporter to the study . 
Confirmation of key  study endpoints will be obtained from applicable H CPs or health 
care facilities. The infants and children will be followed beginning from after 28 day s 
post EDD and until 24 months corrected age (for preterm infants) or 24 months 5 years
chronological age (for term infants) . Baseline characteristics and d emographic data will 
be captured from the Phase III SPTL treatment studies and combined with infantchild
follow-up data for anal yses. Refer to Table 2 for a summary  of data points to be collected 
and the time frame for assessment.
The time points for pare nt-completed questionnaires are scheduled to maintain the 
participant’s interest in study  continuation and minimize losses to follow up. 
Questionnaires will be associated with the infant’schild’sage; in some cases the age will 
be chronological and in oth er cases, it will be corrected for prematurity . The timing of the 
first questionnaire is scheduled to begin at 2 months chronological age and end at 24 
months corrected age (for preterm infants) or 24 months 5 yearschronological age (for 
term infants) . Contingent on the infant’s chronological age at the time of entry  into the 
follow up study , all of the questionnaires may  not be completed for each participant. The 
SPM will provide explicit details on study  procedures to ensure proper timing of 
questionnair es. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
85Table 2 Time and Events Table
Event 28Days Post 
EDDMonths Years1
2 6 9 12 15 18 21 24 3 4 5
Written informed consent12
Baseline characteristics and demographic data X23
RCC confirms and updates contact information from 
theparent/legal guardianX
Parent/legal guardian completes CHI34 X X X X X X X X X34 X34 X34
RCC -PI follows up with HCP and reviews medical or 
other records to confirm parent -reported outcomes
RCC -PI reviews CHI results and refers to bir th-defect 
evaluator based on results
Parent/legal guardian completes productivity 
questionnaire45
Parent/legal guardian completes ASQ -356 X56 X56 X56
RCC -PI reviews ASQ -3 results and refers for 
developmental evaluation based on resu lts67
Parent/legal guardian completes M -CHAT -R/F78 X X
Parent/legal guardian completes CBCL/1.5 –578 X
RCC -PI refers child to specialist for cerebral palsy 
assessment (if required)89X
ASQ -3 = Ages and Stages Que stionnaire- 3; CBCL/1.5 –5 = Child Behavior Checklist for ages 1.5 to 5; CHI = Child Health Inventory; EDD =estimated date of delivery; HCP =health 
care provider; M -CHAT -R/F = Modified Checklist for Autism in Toddlers -Revised with Follow -Up; RCC = research coordinating center; RCC -PI = research coordinating center -
principal investigator.
Note:  All specified completion windows for applicable questionnaires (CHI, ASQ -3, CBCL/1.5 –5, M-CHAT -R/F, and productivity) are provided to help standardize the data and a void 
overlap. Information captured outside of these windows will be collected and analyzed separately, and questionnaires complete d outside the completion window will not be 
considered protocol deviations.
1. Assessments performed at years 3, 4, and 5 are based on the child’s chronological age.
12. Collected at the start of the Phase III spontaneous preterm labor (SPTL) treatment studies until the later date of either the date of discharge from the birth ho spitalization or up to 
9months corrected age (to allow for the infant’s 9 -month CHI and ASQ- 3 data collection).
23. Captured in Phase III SPTL treatment studies and combined with infant child follow -up data for analyses.
34. A positive response by the parent/legal guardian may trigger follow -up with the relevant HCP and/or medical record review for confirmation or more details on the condition or 
hospitalization. A modified CHI will be completed at 3, 4, and 5 years of the child’s chronological age. At each time point, the completion window of the CHI is +6 weeks. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
8645. Completed if infant has been treated by a specialist or has had an emergency room/urgent care or hospital visit. The completi on window for the productivity questionnaire is +2 
weeks from the date of completion of the relevant CHI.
56. Based o n infant’s corrected age. The completion window for the ASQ -3 is +30 days at Month 9 and ±30 days at Months 18 and 24.
67. If the parent/legal guardian receives a referral, then a qualified specialist will complete required assessments.
78. The CBCL/1.5 –5 and M -CHAT -R/F questionnaires will only be completed for all infants who score in the black zone on the 24 month corrected age ASQ -3 in any of the following 
domains: communication, problem solving, or personal social scale . The completion window for the CB CL/1.5 –5 and M -CHAT -R/F is +6 weeks at 18 months (M -CHAT -R/F only)
and+12weeks at 24 months . 
89. Referral will be made for infants who score in the black zone for the gross motor skills domain on the 24 -month corrected age ASQ -3 and do not have an exist ing diagnosis of 
cerebral palsy. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
87Section 6.1., Critical Baseline Assessments
The final assessment of the Phase III SPTL treatment studies will occur at 28 days post 
EDD when neonatal morbidity  assessments are collected. Select data from this 
assessment w ill serve as baseline data for this study , in addition to data collected from the 
maternal medical record and newborn medical record during the Phase III SPTL 
treatment studies. These data will be transferred in a blinded manner from the Phase III 
SPTL database to the infantchildfollow-up study database.
At Baseline, the Phase III SPTL treatment study  investigator will obtain updated contact 
information from the parent/legal guardian; contact information will also be collected for 
at least 1 additional pe rson (as described in the SPM) to minimize the number of infants 
and children lost to follow -up.
Section 6.2.1., Morbidity and Mortality Endpoints
The main objective of the study  is to characterize the clinical safet y in terms of infant 
morbidity  and morta lity in infants and children exposed to retosiban or comparator 
during the Phase III SPTL treatment studies. The morbidity  endpoints will be assessed at 
2, 6, 9, 12, 15, 18, 21, and 24 months and 3, 4, and 5 years of the child’s chronological 
age. Based on the discretion of the RCC -PI, medical records may  need to be obtained 
from the applicable medical facility  for any infants who have not y et been discharged 
from their birth hospitalization (see Section 6.2.1.1.1 and Section 6.3).
Section 6.2.1.1., Parent/ Legal Guardian- Completed Child Health Inventory
The child’s parent/legal guardian will be asked to complete the CHI at 2, 6, 9, 12, 15, 18, 
21, and 24 months of the child’s chronological age and a modified CHI at 3, 4, and 5 
years of the child’s chronologi cal age. At each time point, the completion window is +6 
weeks; however, CHI questionnaires completed outside the completion window will not 
be considered a protocol deviation.
The CHI will be administered at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s 
chronological age will toscreen for infant mortality  and morbidity  and tocapture data on 
resource utilization. At 3, 4, and 5 years of the child’s chronological age, the CHI will 
screen for child mortality and morbidity, including any indicators o f 
neurodevelopmental impairment .To facilitate data collection, parents/legal guardians 
will be provided with an electronic device that will enable them to provide the protocol 
required data. They  will have the option to use alternative way s to access the same 
system (e.g., their own personal devices). Further details will be provided in the SPM.
. . .
At the initial completion of the CHI, the parent/legal guardian will be asked about all 
morbidity  and mortality  endpoints and, if required based on the child’sage,the 
resource utilization endpoints. At subsequent completions of the CHI , up to 24 months 
chronological age, the parent/legal guardian will be asked the status of previously  
reported conditions (e.g., worse, better, or resolved), as appropriate. Th ey will also be  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
88asked if an y of the other morbidity  and mortality  endpoints and resource utilization 
endpoints , as required, have occurred since the last assessment. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
89Figure 2 Child Health Inventory : Flow Chart of Data Collection and Review
HCP = health care provider; RCC -PI = research coordinating center -principal investigator.
1. The CHI completed at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s chronological age will screen for infant mortality and morbidity and capture data on resource 
utiliz ation. At 3, 4, and 5 years of the child’s chronological age, the CHI will screen for child mortality and morbidity, including any indicators of neurodevelopmental 
impairment . 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
90Section 6.2.2., Chronic Medical Conditions
The proportion of infants and childr enwith newly diagnosed (after 28 days post EDD) 
chronic medical conditions by  type of condition will be recorded.
Section 6.2.2.1., Respiratory Conditions
Respiratory  conditions will include the following:
Chronic lung disease newly  diagnosed (after 28 da ys post EDD) defined as 
increased ox ygen requirements (i.e., an y increase in previously documented O 2
use, and/or a change to how the child receives supplemental O 2)
Reactive airway  disease, defined as a chronic lung condition associated with 
inflammation of the airway s associated with wheezing and requiring episodic 
ongoing treatment with bronchodilators and/or inhaled or s ystemic steroids
Paralyzed vocal cords, defined as impairment of the vocal cords that result in 
acute or chronic respiratory  compromise or abnormalities in the infant’s voice
Airway obstruction
Section 6.2.2.2., Neurological Conditions
Neurological conditions will include the following:
Cerebral palsy , defined as a chronic, nonprogressive neurologic disorder 
encompassing impaired motor function affecting movement, posture, balance 
muscle control, coordination, tone, or reflexes.
Seizure disorder, defined as episodic occurrence of seizure activity requiring 
ongoing anticonvulsant therap y
Hydrocephalus requiring shunt, defined as abnormal a ccumulation of 
cerebrospinal fluid in the ventricles of the brain requiring permanent shunt 
placement to prevent irreversible neurologic sequelae
ASD, defined as a neurodevelopmental disorder that impairs a child’s 
ability to communicate and interact with others
Attention deficit disorder (ADD), defined as a disorder of attention, 
organization, and impulse control, characterized by a persistent pattern of 
impulsiveness and a short attention span.
Attention deficit disorder with hyperactivity (ADHD), defined as ADD with 
the addition of hyperactive behavior
Learning difficulties, defined as a significantly reduced ability to 
understand new or complex information or to learn new skills
Behavior disorders, defined as a general term to denote behavioral 
dysfuncti on that do not fall under the category of ADD or ADHD 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
91Section 6.2.2.7. Growth Parameters
Growth parameters will be assessed only up to 24 months chronological age and will
include the following:
Section 6.2.3., Congenital Anomalies
When a congenital anomal y is reported, it will be reviewed b y an expert in teratology  
who is engaged by the RCC -PI to serve as the birth defect evaluator for this study . The 
birth defect evaluator’s responsibilities will include the review, evaluation, and 
classification of all r eports of birth defects. Additionally , he/she will provide an opinion 
regarding the possible etiologies for the development of the observed anomalies. The 
birth defect evaluator will reference medicall y confirmed reports from the infant’s child’s 
HCP in ma king the evaluation and issue targeted queries to the HCP when necessary . If 
medical data are deemed insufficient to complete the evaluation, the birth defect 
evaluator may  ask that the RCC -PI request additional medical evaluation of the infant
child. 
Section 6.2.4., Neonatal and Infant and Child Deaths
This study  will assess the proportion of neonatal and infant and child deaths that occur 
after 28 day s post EDD and up to 24 months corrected age for preterm infants and 24 
months5yearschronological age for term infants.
Section 6.2.5., Parent/Legal Guardian -Completed ASQ -3, M-CHAT-R/F,and 
CBCL/1.5–5 and Possible Referral to a Specialist
The 9-, 18-, and 24-month ASQ -3 questionnaires will be used in this study . These time 
points comply  with recommended d evelopmental screening assessment guidelines from 
the American Academ y of Pediatrics [Council on Children with Disabilities, 2006]. The 
parent/legal guardian will be asked to complete the 9-, 18 -, and 24-month ASQ -3 when 
the infant’s corrected age correspo nds to 9, 18, and 24 months, for example, parents/legal 
guardians of an infant born 3 months premature will complete the 9 -month ASQ -3 at 12 
months chronological age. To facilitate data collection, the parent/legal guardian will be 
provided with an electro nic device that will enable them to provide the protocol required 
data. They  will have the option to use alternative way s to access the same sy stem (e.g., 
their own personal devices). Further details will be provided in the SPM. The completion 
window for t he ASQ-3 is +30 day s at Month 9 and ±30 day s at Months 18 and 24; 
however, questionnaires completed outside the completion window will not be 
considered a protocol deviation. I t is essential to make age adjustments for prematurit y 
when selecting the approp riate ASQ -3. Based on results from the ASQ -3 administered at 
24 months corrected age and if no cerebral palsy diagnosis has been made to date (see 
Section 6.2.5.1) parents/legal guardians may  be asked to complete the CBCL/1.5 –5 and 
the M-CHAT-R/F to assess the risk for other behavioral problems or autism spectrum 
disorder or, alternativel y, the infant may  be referred to a qualified examiner for a formal 
assessment of cerebral palsy .
The M-CHAT-R/F will be completed for all infants at 18 and 24 months (corre cted 
age) and the CBCL/1.5– 5 will be completed for all infants at 24 months (corrected  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
92age) to assess the risk for other behavioral problems or ASD . If at any of these time 
points a child has an M -CHAT-R/F score that indicates further evaluation is 
required and/or a CBCL/1.5–5 score at or above the 97th percentile for a subset of 
prespecified questions, the child will be referred to a specialist for a formal 
assessment. An overview for the collection and review of data for the M -CHAT-R/F 
and CBCL/1.5–5 is p rovided in Figure 3.
The completion window for the CBCL/1/5- 5 and M-CHAT-R/F is +6 week at 
18months (M -CHAT-R/F) and +12 weeks at 24 months ; however, questionnaires 
completed outside the completion window will not be considered a protocol deviation.
For further details regarding the CBCL/1.5 –5 and M-CHAT-R/F, refer to the SPM.
Section 6.2.5.1., The ASQ -3 Score Interpretation and Possible Specialist Referral 
Recommendations and Completion of CBCL /1.5-5 and M-CHAT-R/F
The ASQ -3 scores for this study  will beinterpreted and recommendations will be offered 
according to the following:
The child’s development will be considered to be on schedule if the child’s 
ASQ-3 scores are in the white zone (higher than 1 SD below the mean), and no 
further action is required .
If the child’s ASQ -3 scores are in the grey  zone ( 1 SD below the mean), the 
parent/legal guardian may share the ASQ -3 test results with the child’s HCP.
If any of the child’s ASQ -3 scores are in the black zone ( 2 SD below the 
mean), then the child’s p arent/legal guardian will be asked if the child is alread y 
under the care of a developmental specialist who can or has made a formal 
assessment (e.g., using the BSID -III). If a recent ( 3 months) BSID -III was 
conducted, the BSID -III will not be repeated an d the RCC -PI will request results 
from the relevant HCP. If the child is not currently under the care of a 
developmental specialist, then the parent/legal guardian will be referred to a 
qualified assessor for developmental evaluation (e.g., using the BSID -III), and a 
neurologic examination will be conducted, if indicated. 
BSID-III retesting will be performed if the child’s ASQ- 3 scores are in the black 
zone on a subsequent ASQ 3 test following the first BSID- III referral.
If, at 24 months corrected age, th e child’s ASQ -3 nonmotor (communication, 
problem solving, and/or personal- social) domain scores are in the black zone, 
the parent/legal guardian will be asked to fill out the CBCL /1.5–5 and 
M-CHAT-R/F questionnaires. If the results of either assessment ind icate an 
increased risk for other behavioral problems or autism spectrum disorder, the 
parent/legal guardian will be referred to a developmental specialist for a more 
formal behavioral assessment.
If, at 24 months corrected age, the child’s ASQ -3 gross mot or domain score is in 
the black range and the child has not alread y been diagnosed with cerebral palsy,  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
93the parent/legal guardian will be referred to a qualified examiner for a formal 
assessment to determine if this condition is present.
Reports from all s pecialists will be included in the subject’s source documents. For 
further details regarding the ASQ -3, CBCL/1.5 –5, and M- CHAT-R/F,refer to the SPM.
An overview for the collection and review of data for the ASQ-3 is provided in Figure 3. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
94Figure 3 Ages a nd Stages Questionnaire -3ASQ-3, M-CHAT-R/F, and CBCL/1.5 –5: Flow Chart of Data Collection and Review
NOTE:  Because of the number of changes to Figure 3 and in order to provide a clear representation of the changes to this figure, the 
figure in original protocol (2014- MAY-14) and revised figure in Amendment 1 are shown below.
Original Figure:
ASQ -3 = Ages and Stages Questionnaire -3; BSID -III = Bayley Scales of Infant Development, third edition; CBCL/1.5 –5 = Child Behavior Checklist for ages 1.5 to 5; HCP = health care 
provider; M -CHAT -R/F = Modified Checklist for Autism in Toddlers -Revised with Follow -Up; RCC -PI = research coordinating center -principal investigator.
1. A neurologic examination will also be conducted, if indicated. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
95New Figure :
ASQ -3 = Ag es and Stages Questionnaire -3; BSID -III = Bayley Scales of Infant Development, third edition; CBCL/1.5 –5 = Child Behavior Checklist for ages 1.5 to 5; HCP = health care 
provider; M -CHAT -R/F = Modified Checklist for Autism in Toddlers -Revised with Follow -Up; RCC -PI = research coordinating center -principal investigator.
1. A neurologic examination will also be conducted, if indicated. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
96Section 6.2.5.2., Neurodevelopment
Neurodevelopment will be assessed b y determining the proportions of infants diagnosed 
with developmental delays listed below at 9, 18, and 24 months of age, corrected for 
prematurit y.
Proportion of infants with a BSID -III score <>2 SDs below the mean score for 
cognitive impairment (<70)
Proportion of infants with a BSID -III score <>2 SDs belo w the mean score for 
the gross motor scale (<70)
Proportion of infants with a BSID -III score <>2 SDs below the mean score for 
the fine motor scale (<70)
Proportion of infants with a BSID -III score <>2 SDs below the mean score for 
the language scale (<70)
Proportion of infants referred for an additional behavioral assessment using the 
CBCL/1.5-5 and M-CHAT-R/F
Proportion of infants with a CBCL /1.5–5 at orabove the 97th percentile for a 
subset of prespecified questions that relate to attention and hy peractivity 
problems
Proportion of infants indicated as needing further evaluation after completion of 
the M-CHAT-R/F
Proportion of infants referred for neurological evaluation to determine diagnosis 
of cerebral palsy
Section 6.2.6., Overall Measure of Neurodevel opmental Impairment
Proportion of infants with at least 1 of the following indicators of 
neurodevelopmental impairment atthe end of the :
Hearing impaired, uncorrected even with aids (at 24 months chronological 
age)
Blindness in 1 or both eyes, or sees lig ht only(at 24 months chronological age)
Cerebral palsy  (moderate defined as grade 2 or 3 and severe defined as grade 4 
or 5 using the Gross Motor Functional Classification Sy stem [GMFCS]) (at 
24months corrected age)
Cognitive impairment: BSI D-III Cogniti ve Scale Score of >2 SDs below mean 
score (<70) (at 24months corrected age)
Motor impairment: BSID -III Motor Composite Scale Score of >2 SDs below 
mean score (<70) (at 24months corrected age) 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
97Proportion of infants and children with at least 1 of the foll owing indicators of 
neurodevelopmental impairment at the end of the study :
Hearing impaired, uncorrected even with aids
Blindness in 1 or both eyes, or sees light only
Cerebral palsy (moderate and severe)
Diagnosis of ASD, ADD, or ADHD
Section 6.2.7., Adverse Events
The RCC -PI or RCC site staff will be responsible for detecting, documenting, and 
reporting events that meet the definition of an SAE. Nonserious AEs will not be tracked.
The outcomes for this study  may represent a number of potential adverse dr ug 
experiences or events that include but may  not be limited to the following:
Reports of infant childhospitalizations (see Section 6.3)
Reports of chronic health conditions in the infantchild(see Section 6.2.2)
Reports of congenital anomalies in the infantchild(see Section 6.2.3)
Reports of infant childdeath (see Section 6.2.4)
Reports of developmental delays in the infant child(see Section 6.2.5.2)
Reports of an y other SAEs in the infant childfor which there is a definite or a 
reasonable possibili ty of attribution to retosiban or comparator exposure (see Section 
6.2.7.2)
Section 6.2.8., Laboratory and Other Safety Assessment Abnormalities Reported as 
SAEs
Any nonprotocol -specified abnormal laboratory  test results (hematology , clinical 
chemistry , or urinalysis) or other safet y assessments (e.g., electrocardiograms, 
radiological scans, vital sign measurements), including those that worsen from Baseline, 
felt to be clinicall y significant in the medical and scientific judgment of the RCC -PI are 
to be recorded as SAEs. However, an y clinicall y significant safet y assessments that are 
associated with the underly ing disease, unless judged by  the RCC-PI to be more severe 
than expected for the subject’s condition, are not to be reported as SAEs.
Section 6.2.10 ., Death Events
The proportion of infantdeaths that occur redafter 28 day s post EDD and up to 24 
months corrected age (for preterm infants) or 24 months 5 yearschronological age (for 
term infants) will be collected. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
98Section 6.2.11., Time Period and Frequ ency of Detecting SAEs
The RCC -PI or RCC site staff is responsible for detecting, documenting, and reporting 
events that meet the definition of an SAE.
InfantChildSAEs will be collected from after 28 day s post EDD until 24 months 
corrected age for preterm infants and 24 months 5 yearschronological age for term 
infants. However, an y SAEs assessed as related to study  participation (e.g., protocol -
mandated procedures, invasive tests, or change in existing therapy ) or related to a GSK 
concomitant medication, will be recorded from the time a subject consents to participate 
in the study  up to the end of the study , i.e., month 24. All SAEs will be reported to 
GSK/PPDwithin 24 hours, as indicated in Section 6.2.12.
Section 6.2.13., Follow -up of SAEs
Any SAEs or AEs of special interest that were ongoing at the end of the Phase III 
treatment studies and any new SAEs reported during this study will be followed 
until resolution, until the condition stabilizes, until the event is otherwise explained, 
or until the sub ject is lost to follow -up.
Section 6.2.15.2., Ad HocMaternal Reports
It is possible that during contact with the study  staff (RCC staff or RCC -PI), the mother 
of the infant childbeing followed in this study  may report her own AEs/SAEs resultant 
from retosiban or comparator treatment from Phase III SPTL treatment studies in an ad 
hoc manner to the RCC study  staff or the RCC -PI. The RCC -PI will be responsible for 
conveying such events to the Phase III SPTL treatment study  investigator where the 
intervention was given to ensure that all safet y outcomes are captured.
Section 6.3., Health Outcomes
Resource utilization endpoints include the following:
Number of hospital admissions, proportion of infants and children with any 
hospital admission, post -birth hospit alization discharge, b y principal and 
secondary  discharge diagnosis, ty pe of hospital unit admitted to (e.g., NI CU, 
Pediatric, PICU, Nursery level 3, ICU), and length of hospital stay  per unit after 
28 days post EDD and until the end of the study .
Combined length of hospital stay  in days for all hospital admissions (for infants 
discharged from the delivery  hospitalization and for babies who were never 
discharged home post -delivery) after 28 day s post EDD and until the end of 
the study .
Number of surgical pr ocedures ( bydetails of type and whether performed on an 
inpatient basis or at an outpatient/surgical center will be collected up to 24 
months chronological age only) after 28 days post EDD and until the end of 
the study . 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
99Number of ER/UC visits and proport ion of infants with any  ER/UC visit after 
28days post EDD and up to 24 months chronological age .
Number of specialty  care or therapy  visits and proportion of infants referred for 
specialty care or therapy  by type of care/therap y after 28 days post EDD and up 
to 24 months chronological age .
Parental productivit y loss related to infant hospital admissions, ER/UC visits, or 
specialist care after 28 days post EDD and up to 24 months chronological age .
Section 6.3.1., Parent/Legal Guardian -Completed Productivi ty Questionnaire
Duringthe first 24 months of participation in the study, Iif the infant's parent/legal 
guardian reports in one of the CHI questionnaires that the child is being treated b y a 
specialist or has had emergency  department visits or hospitaliza tions, they  will be asked 
to complete the productivity  questionnaire.
Section 7.1., Data Handling Conventions
For this study , infantchilddata will be entered into GSK/PPD defined eCRFs, 
transmitted electronically to GSK/PPD, and combined with data provid ed from other 
sources e.g., data obtained directly from the parent/legal guardian via an electronic device 
provided b y the sponsor, its designated vendor, or the patient’s own devices using a 
secure and validated data sy stem. The RCC staff will enter data provided on paper into 
the specifically  designed eCRF pages.
Section 7.1.2., L oss to Follow -Up
InfantsChildren for whom follow -up information is never obtained will be considered 
lost to follow -up. These cases will be tallied in the applicable sections of the study 
reports. All other cases with some follow -up data will be anal yzed up to the length of 
infantchildfollow up.
Section 7.2., Validation Procedures
The ongoing data collection from parents/legal guardians will follow a specific script to 
elicit information from contacts with the health care s ystem. The infant’schild’sHCP 
will also be contacted to provide data on the infant’schild’shealth and resource 
utilization when triggered by  information from the parent/legal guardian. As indicated in 
the previous sections, for conditions or events that may  meet SAE criteria, medical 
confirmation and/or medical records will be obtained to provide details of the conditions. 
All study data will be captured in carefull y designed eCRFs specific to the study 
objectives. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
100Section 8.1., Hypotheses
The objective of the study is to describe the safet y and morbidity  and mortality  outcomes 
of infantschildren exposed to treatment during Phase III SPTL studies investigating 
retosiban or comparator for the treatment of SP TL. These mortality  and morbidity  
endpoints (as described in Section 6.2) will be descriptively  summarized.
Section 8.3.4., Interim Analysis
In the event of earl y stopping of the Phase III SPTL development program due to safet y 
and/or lack of efficacy , infantschildren will continue to be followed until they  have 
reached 24 months corrected age for preterm infants and 24 months 5 years
chronological age for term infants.
Section 8.3.5.1.1., Outcomes
The primary  objective of the planned analy sis will be to u se descriptive statistics to 
describe the safet y and morbidity  and mortalit y outcomes of infants children exposed to 
treatment during the Phase III SPTL studies investigating retosiban or comparator for the 
treatment of SPTL . The endpoints to be descriptiv ely summarized are those described in 
Section 6.2 . Descriptive statistics will be calculated by  treatment group and by  treatment 
group and time, where appropriate.
For binary  outcomes, all summary  tables will include the number and percentage of 
subjects w ith the response/event. The associated 95% CI  will also be reported. For those 
endpoints that occur in more than 5 infantschildren or 1% of the infants children in any 
treatment group, odds ratios and associated 95% CIs will be calculated to compare 
retosiban to placebo, atosiban, and pooled comparator treatment groups. For continuous 
variables, all summary  tables will include: n, mean, median, standard deviation, 
minimum and maximum. All summary  tables will include N for each group (i.e., the total 
numberof subjects randomized to each group within the appropriate population).
To characterize the clinical safet y in terms of neurodevelopment in infantschildren 
exposed to retosiban or comparator, the proportion of infants children with at least 1 of 
the indicators of neurodevelopmental impairment (see Section 6.2.6) at the end of the 
study will be anal yzed using a logistic regression model. The model will use a logit link 
function to estimate the log odds of percentage of infants children with indicators of 
neurodevelopmental impairment. The model will include terms for treatment group. The 
number and percentage of subjects in each treatment group, the odds ratios of response 
rates (retosiban versus placebo, retosiban versus atosiban, and retosiban versus all
comparators) and the 95% CI s for the odds ratio of response rates and p values will be 
presented. The anal ysis may be repeated for each of the individual indicators of 
neurodevelopmental impairment. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
101To further describe the infant safet y profile of retosib an, the following subgroups may  be 
explored:
Gestational age of pregnancy  at randomization
Established progesterone use (yes or no)
Magnesium sulfate use
Tocolytic use following study drug discontinuation
Maternal age
Region
For each subgroup, infant childsafety data will be summarized by treatment and 
subgroup, as previousl y described. Full details of all planned anal yses will be provided in 
the RAP.
Section 9.2.1., Release of Participant Medical Information
In order to collect data from the participant’sHCPs, medical release forms for each 
clinician who will report data to the study  must be completed and signed by  the infant’s 
child’sparent/legal guardian.
Section 9.2.2., Subject Confidentiality
Each participant’s identity will be known onl y to the thir d-party contractor, RCC -PIs, and 
relevant HCPs (e.g., pediatrician or specialist). InfantChildidentification numbers will 
be assigned and used to identify  study participants. The dataset used in the anal ysis of 
data will contain coded participant identif iers only.
Section 9.5., Study and RCC Site Closure
Recruitment in participating countries will begin with initiation of the Phase III SPTL 
treatment studies. Recruitment will continue until the Phase III SPTL treatment studies 
end recruitment. Follow -up will continue until each child enrolled completes the 5-year
24 month questionnaire at either 24 months corrected age (for preterm infants) or 
24months5 yearschronological age (for term infants) . Study close-out and final 
reporting activities will be initiated on completion of the follow -up on the last study  
participant.
Section 9.7., Provision of Study Results to RCC- PIs, Posting of Information on 
Publicly Available Clinical Trials Registers and Publication
GSK will also provide the RCC -PI with the full summary of the study  results. The 
RCC-PI is encouraged to share the summary  results with the parent/legal guardian of the 
participating infantchild, as appropriate. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
102Section 10., References
GlaxoSmithKline Document Number 2015N228508_00. Investigator’s br ochure 
supplement 1. FEB -2015.
Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Mathews TJ. Births: final data for 
2013. Natl Vital Stat Rep. 2013 5;624(91):1-8765.
Thornton S, Miller H, Valenzuela G, et al. Treatment of spontaneous preterm 
labour with retos iban: a phase 2 proof -of-concept study. Br J Clin Pharmacol. 
2015 Mar 27. DOI: 10.1111/bcp.12646. [Epub ahead of print]. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
103Protocol Amendment Number 0 2
Protocol Amendment Number 0 2is applicable to all RCC sites participating in this study . 
Protocol changes specified in Amendment Number 0 2are summarized as follows:
Reduction of study  duration from 5 y ears to 24 months due to:
‒Termination of the retosiban development program, such that there will be n o 
further in utero exposure to retosiban, and hence safet ydata from this ongoing 
study will not inform the potential risk for future use of retosiba n.
‒Low recruitment for interventional studies 200719 (NEWBORN -1) and 
200721 (ZINN) . Hence,the number of infants exposed to retosiban in utero 
and included in the cu rrent (200722) study  is small.
‒The independent d ata monitoring c ommittee (IDMC) recommendation that the 
neonatal follow -up be limited to 2 4monthsof age given no safety issues 
detected in their unblinded review of available 200722 data and also that 
statistical analy sis at a 5-year timepoint would not provide an y meaningful 
results due to the small number of enrolled subjects.
Reclassification of all resource utilization endpoints as exploratory  endpoints 
due to the reduced sample size
Correction of an err or in the mean BSID -III score for the cognitive impairment, 
fine motor and gross motor scales to <4 to reflect that these are not composite 
scores
Incorporation of other administrative changes
Justification for the Reduction of the ARIOS S tudy Duration fr om 5 Years to 
24 Months
The objective of the ARIOS long -term follow -up study was to enable the collection of 
safety data from infants exposed to retos iban in utero for preterm labor to support the 
Phase 3 data package. The design and duration of 5 y ears was agreed with the regulators, 
including theFDA, PMDA and the EMEA. The collection of data in a clinical trial 
setting would have helped to better inform potential safet y concerns prior to approval and 
treatment of an expanded population in the post -marketing setting. In May 2017, the 
corresponding treatment trials 200719 (placebo comparison) and 200721 (atosiban 
comparison) were terminated early  due to poor recruitment thatmade completion of the 
trials unfeasi ble in a reasonable timeframe. The placebo- controlled trial enrolled on ly 
23of the target 900 participants over 17 months, and the atosiban comparator trial 
enrolled 97 of the target 330 participants over 29 months. Maternal, fetal, and neonatal 
AEs were no more common with retosiban than placebo or atosiban in this small dataset. 
GSK also terminated the overall development of retosiban in May  2017, with no further 
development for this asset either in women in spontaneous pre -term labor or any  other 
indication. Thus, there will be no further in utero exposure in a clinical trial or a 
post-marketing setting for which there would be a need to inform potential risks. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
104Due to the early termination of 200719 and 200721, the sample size of ARIOS is small 
with a total of 98 babies enrolled (6 placebo treated s ubjects from NB -1, 43 atosiban 
treated subjects from ZINN and 49 retosiban treated subjects from N EWBORN -1 and 
ZINN). This represents just 8% of the planned 1230 infants that were to be enrolled in the 
study. The intent of the design of ARIOS was to compar e data from the retosiban 
exposed group in each of the treatment trials to the placebo exposed group. I n order to 
accomplish this, data from both 200719 and 200721 w ereto be pooled from all the babies 
exposed to retosiban and compared against placebo- exposed babies. As there were onl y 
6 babies exposed to placebo with the drop- out rate expected to increase as the study  
progresses, the sample size will not be sufficient to permit a meaningful comparison of 
long-term safet y between active treatment and placeb o subjects if the follow -up study 
was continued for 5 years of follow -up.
On 28 August 2018, the retosiban IDMC , composed of 1 pediatrician, 2 neonatologists , 
2maternal-fetal medicine specialists and a statistician, confirmed that there were no 
safety concerns identified following review of ZINN and NEWBORN- 1 clinical study  
reports as well as ARIOS adverse events (including congenital anomalies), 
neurodevelopment screening assessments (ASQ- 3, CBCL/1.5-5, and MCHAT -R/F), and 
neurodevelopment referrals, from an ARIOS data cut on 15 June 2018, with 34 out of a 
total of 98 babies having alread y completed 24monthsof safety follow-up. The IDMC 
also recommended that the neonatal follow -up be limited to 24 months of age given that 
thesmall number of enrolled sub jects, in particular placebo subjects for comparison, 
would not yieldmeaningfu l results. Twent y-four months, in the I DMC collective opinion, 
would allow for detection of major neonatal adverse outcomes and safet y signals and as 
such would be sufficient, e specially considering that there will be no future development 
of retosiban.
Furthermore, 24- monthoutcomes are considered by the experts in the field to be 
appropriate forsafety assessment (Marlow, 2014). Dr. Neil Marlow ,who is an IDMC 
member, in collab oration with regulatory  agencies, has developed a manuscript (in press) 
that recommends that 24-monthfollow-up is appropriate for safet y follow-upin this 
population .
Reduction of the study  duration from 5 years to 24 months will not impact the care of th e 
infant as they  will still follow neonatal and p ediatric developmental screening standard o f 
care as prescribed b y their pediatrician or health care provider following completion of 
the study. Therefore,there is no safet y risk to the neonate by reducing the study 
follow-up period from 5 y ears to24 months.
Administrative changes
Otheradministrative changes were incorporated into this amendment . The rationale for 
these changes is to ensure a clear and complete protocol for use at the RCC sites .
Specific Changes in the Text
Title Page: 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
105Authors (GSK): 
 
Authors (PPD):  
Copyright 20152018the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorized cop ying or use of this information is prohibited.
SPONSOR SIGNATORY
Kathleen J Beach, MD, MPH
Medicine Development Leader,
Maternal and Neonatal Health Unit
Alternative Discovery  and Development
Rajnish Saini, MD
Clinical Director,
Future Pipeline Discovery
Global Health R&D
SPONSOR INFORMATION PAGE
Sponsor Medical Monitors and Serious Adverse Events (SAEs) Contact Information
Issue North America 
ContractLatin America Contact Europe/Asia Contact
Safety Questions , MD
Medical Director, Medical 
Affairs and 
Pharmacovigilance
PPD
Wilmington, NC, USA
, MD, 
MPH
Associate Medical 
Director, Medical Affairs 
and Pharmacovigilance
PPD
Denver, CO, USA, MD
Medical Director, Medical 
Affairs and 
Pharmacovigilance
PPD
Buenos Aires, BrazilEurope : , MD
Associate Medical 
Director, Medical Affairs 
and Pharmacovigilance
PPD
Sofia, Bulgaria
Asia: , MD
Associate Medical 
Director, Medical Affairs 
and Pharmacovigilance
PPD
Kuala Lumpur, Malaysia
SAE Reporting 24-Hour Safety Hotline:
Safety Fax:24-Hour Safety Hotline:
 
Safety Fax: 24-Hour Safety Hotline:
Safety Fax: 2019N413355_00
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
2014N194466_02 CONFIDENTIA L
200722
106PROTOCOL SUMMARY, Rationale
The goal of this study  (ARIOS), therefore, is to assess the safet y and outcomes of infants 
and children who were exposed to retosiban (GSK221149) or comparator in utero in the 
plannedPhaseIII SPTL treatment studies and provide assurance that treatment is not 
associated with significant adverse outcomes in early  childhood.
In May 2017, the corresponding treatment trials 200719 (NEWBORN -1, placebo 
comparison) and 200721 (ZINN, atosiban comparison) were terminated early due to 
poor recruitment and the length of time needed to complete the studies. The 
placebo-controlled trial enr olled only 23 of the target 900 participants over 
17months, and the atosiban comparator trial enrolled 97 of the target 
330 participants over 29 months. Maternal, fetal, and neonatal adverse events were 
no more common with retosiban than placebo or atosib an. The development 
program was subsequently terminated with no further in utero exposure of 
retosiban planned.
PROTOCOL SUMMARY, Objectives
Primary
To characterize the clinical safet y in terms of infant and child morbidity  and 
mortality in infants and chi ldren exposed to retosiban or comparator in utero
To characterize the clinical safet y in terms of neurodevelopment in infants and 
children exposed to retosiban or comparator in utero
Exploratory
To characterize parental productivity  loss related to a sick child and infant resource 
utilization in terms of hospital admissions, length of stay , emergency  room/urgent 
care (ER/UC) visits, surgical procedures, and referral to specialt y care or therap y 
visits for infants (up to age 2 years) exposed to retosiban or comparator in utero
PROTOCOL SUMMARY, Study Design
Infants and children will be followed at prespecified intervals until they  have reached 
5years24monthschronological age.
The child’s parent/legal guardian will be asked to complete a Child Health I nventory 
(CHI) at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s chronological age and a 
modified CHI  at 3, 4, and 5 y ears of the child’s chronological age. The CHI questionnaire 
completed up to the 24 -month time point will screen for infant mortality  and morbidity  
and will capture data on resource utilization. At the 3-, 4- , and 5-year time points, the 
CHI will screen for child mortality  and morbidity , including an y indicators of 
neurodevelopmental impairment. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
107During the first 24 months of participati on in the study , if the parent/legal guardian 
indicates that the infant has been treated b y specialists or has had ER/UC visits or 
hospitalizations, he/she will be asked to complete a productivity  questionnaire to evaluate 
loss of parental productivity .
Ifat any of these time points a child has an M -CHAT-R/Fscore that indicates further 
evaluation is required and/or a CBCL /1.5–5 score at orabove the 97th percentile for a 
subset of prespecified questions, the child will be referred to a specialist for a fo rmal 
assessment.
PROTOCOL SUMMARY, Study Endpoints/Assessments
Study primary endpoints include the following and are further defined in Section 6.2.2:
Morbidity  and mortalit y endpoints:
Proportion of infants and children with newl y diagnosed (after 28 dayspost EDD) 
chronic medical conditions by  type of condition will be recorded and include the 
following:
Respiratory  conditions
Neurological conditions
Sensory conditions
Gastrointestinal conditions
Cardiovascular conditions
Renal conditions
Growth parameter s (only up to 24 months chronological age)
Proportion of infants and children with newl y diagnosed (after 28 days post EDD) 
congenital anomalies
Proportion of infant and child deaths after 28 days post EDD and until the end of the 
study24 months chronolog ical age
Neurodevelopment endpoints:
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
cognitive impairment (< 704)
Proportion of infants with BSID -III score >2 SDs below the mean score for the 
gross motor scale (< 704)
Proportion of infants with BSID -III score >2 SDs below the mean score for the 
fine motor scale (< 704) 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
108Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
language scale (<70 70)
Proportion of infants with a CBCL /1.5–5 score at orabove the 97th percentile 
for a subset of prespecified questions that relate to attention and hy peractivity  
problems 
Cognitive impairment: BSI D-III Cognitive Scale Score of >2 SDs below mean 
score (<704) (at 24 months corrected age)
Motor impairment: BSI D-III Motor Composite Scale Score of >2 SDs below 
mean score (< 7070) (at 24 months corrected age)
Proportion of infants and children with at least 1 of the following indicators of 
neurodevelopmental impairment at the end of the study :
Hearing impaired, un corrected even with aids 
Blindness in 1 or both eyes or sees light only
Cerebral palsy  (moderate and severe)
Diagnosis of ASD, attention deficit disorder (ADD), or attention deficit 
hyperactivit y disorder (ADHD)
Resource Exploratory resource utilization e ndpointsinclude:
Number of hospital admissions, proportion of infants and children with any hospital 
admission, post -birth hospitalization discharge, b y principal and secondary discharge 
diagnosis, t ype of hospital unit admitted to (e.g., neonatal intensi ve care unit
[NICU],Pediatric, pediatric intensive care unit [ PICU], Nursery level3, intensive 
care unit [ ICU)]),and length of hospital stay  per unit after 28 days post EDD and 
until the end of the study 24 months chronological age .
Combined length of h ospital stay  in days for all hospital admissions (for infants 
discharged from the delivery  hospitalization and for babies who were never 
discharged home post -delivery) after 28 days post EDD and until the end of the 
study24 months chronological age .
Number of surgical procedures (details of ty pe and whether performed on an 
inpatient basis or at an outpatient/surgical center will be collected up to 24 months 
chronological age only ) after 28 days post EDD and until the end of the study
24months chronologica l age.
Section 1.1, Background
Retosiban iswasbeing developed for the treatment of spontaneous preterm labor (SPTL ) 
in women with intact membranes. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
109Phase III SPTL treatment studies will bewereconducted to demonstrate the ability  of 
retosiban to prolon g pregnancy  and improve neonatal health, as well as to describe the 
maternal, fetal, and neonatal safet y profiles. The treatment studies were subsequently 
terminated due to limited recruitment and the development program was 
subsequently terminated with nofurther in -utero exposure planned.
Section 1.1.1, Previous Human Experience
Study OTA105256 was the first Phase II clinical study  of retosiban in preterm labor 
(n=93) [Thornton, 2015; GlaxoSmithKline Document Number CM2006/00201/ 0306].
The emerging safet yprofile for retosiban appears favorable. Results from 
protocol-specified maternal- fetal and neonatal safety  assessments were absent of any  
concerns and were similar between the retosiban and placebo groups. Furthermore, no 
clinically significant dispariti es in AEs were noted between groups [Thornton, 2015]. All 
reported AEs, whether maternal, fetal, or neonatal, were generally  consistent with those 
reported in the Investigator’s Brochure (IB) [GlaxoSmithKline Document Number 
CM2006/00201/03], IB Supplement 1 [GlaxoSmithKline Document Number 
2015N228508_00], or in the study  population.
The Phase 3 program included 2 global blinded, randomized, controlled trials 
(200721 [ZINN] and 200719 [NEWBORN-1]) and a single infant follow -up trial 
(200722 [ARIOS] ). Eligible subjects were aged 12 to 45 years with an uncomplicated 
singleton pregnancy and intact membranes in spontaneous preterm labor at 240/7to 
336/7weeks’ gestation . ZINN (N=330) aimed to show superiority of retosiban (IV) 
overatosiban on time to delivery (first subject first visi t [FSFV] was March 2015). 
NEWBORN -1 (N=900) was designed to demonstrate neonatal benefit (based on a 
composite endpoint) as well as time to delivery or time to treatment failure over 
placebo (FSFV February 2016). The intervention trials were terminated early on 
11 May 2017 because of slow recruitment and the retosiban project was 
discontinued permanently. Last subject last visit (LSLV) was 24 July2017 for 
NEWBORN -1 and 25 August2017 for ZINN. Meaningful analyses of these 
well-controlled trials could not be performed due to small numbers of completing 
participants. Mean time to delivery or treatment failure in the placebo- controlled 
trial was 18.9 days with retosiban (n=10) versus 11.1 days with placebo (n=13). Two 
neonates in the retosiban and 4in the placebo group had ≥1 component of the 
neonatal composite endpoint. The adjusted mean time to delivery in the atosiban 
comparator trial was 32.51 days with retosiban (n=50) compared with 33.71 days 
with atosiban (n=47; P>0.05). Maternal, fetal, and neonatal AE s were no more 
common with retosiban than placebo or atosiban. 
In NEWBORN -1, 1 participant in the retosiban group provided cord blood and 
breast milk samples; retosiban was found in both (cord blood, 1.9 µg/L; breast milk, 
3.6 µg/L). In ZINN, 12 women in the retosiban group provided cord blood samples, 
none of which had detectable levels of retosiban. One participant also provided a 
breast milk/colostrum sample. The retosiban concentration was 0.3 g/L. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
110Section 1.2, Rationale
The goal of this s tudy (ARIOS), therefore, is to assess the safet y and outcomes of infants 
and children who were exposed to retosiban or comparator in utero in the planned
PhaseIII SPTL treatment studies and provide assurance that treatment is not associated 
with significa nt adverse outcomes in earl y childhood.
Section 1.3, Benefit:Risk Assessment
Summaries of findings from both clinical and nonclinical studies conducted with 
GSK221149 can be found in the IB and the Phase III SPTL treatment clinicalstudy 
protocols reports. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
111Section 1.3.1, Risk Assessment
Potential Risk of 
Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
Fetal exposure 
through placental 
transferPreclinical data indicate very minimal, if 
any, maternal central ne rvous system 
(CNS) penetration or placental transfer 
of retosiban as supported by the 
following: 
In pregnant monkeys there was no 
detectable retosiban in the cord 
blood when mothers were dosed up 
to 100 mg/kg (approximately 
7times the human exposure). 
However, approximately 4% of 
circulating drug was detected in the 
cord blood when mothers were 
dosed at 300 mg/kg (approximately 
24-fold the human exposure).
Retosiban is a substrate of 
P-glycoprotein and breast cancer 
resistant protein transporters, which 
are thought to play a role in keeping 
xenobiotics out of the CNS and out 
of the fetal blood, thereby limiting 
fetal exposure to retosiban.
In reproductive toxicology studies in 
pregnant monkeys, there were no 
adverse mother and infant 
behavioral or locomoto r effects 
observed that were suggestive of 
CNS toxicity. 
In rodent neurobehavioral safety 
studies, there were no adverse 
clinical signs observed at doses up 
to 1000 mg/kg.Analysis of maternal blood and cord 
blood samples will be was performed to 
test fo r levels of retosiban in women 
who deliver delivered at an 
investigative center within 12 hours of 
the completion of study treatment 
infusion as part of the Phase III SPTL 
treatment studies.
Surveillance for signals indicating 
adverse fetal or neonatal eff ects with 
inutero exposure to retosiban will be 
performed throughout this study.
Infants exposed to retosiban in utero 
will be followed for up to 5 years
24months in this study to assess 
safety and neurodevelopmental 
outcomes. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
112Potential Risk of 
Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
For both N EWBORN -1 and ZI NN, 
cord blood samples were requested 
from subjects who delivered at the 
investigative center within 12 hours 
after discontinuation of study drug. 
Samples were only analyzed for 
subjects randomized to retosiban. A 
total of 4 cord samples were 
collected wit hin NEWBORN -1 
(3placebo: 1 retosiban) and 27 
within ZINN (12 retosiban: 15 
atosiban). Within both studies, only 
1cord blood sample tested positive 
for retosiban at a concentration of 
1.9 µg/L. The 1.9 µg/L is 
approximately 0.006x to 0.01x the 
cord blood concentrations that were 
observed in the pregnant monkey 
toxicity studies (cord blood 
concentrations = 159 to 313 µg/L). 
There were no adverse effects 
observed in the offspring in monkey 
studies, where growth and 
development included a full 
assessment of reflexive behaviors, 
infant ECG and blood chemistry were 
analyzed. Furthermore, a rat post -
natal study starting in juvenile rats 
that were 1 day old did not show any 
adverse effects on growth and 
development, including 
neurobehavior and reproductive 
assessments at exposure levels that 
were approximately 800 -fold of what 
was observed in the cord blood 
(gender averaged C max =1535 µg/L). 
Day 1 old rats were used in this 
study as they were developmentally 
similar to late third -term human 
fetuses. The overall a nimal data 
indicate that potential risk for a fetus 
exposed gestationally to retosiban is 
negligible. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
113Potential Risk of 
Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
Neonatal exposure 
via breast milkWhile there are no clinical data on the 
degree of retosiban transfer into breast 
milk, the available data based on 
physiochemical properties suggest 
retosiban will be excreted into breast 
milk if dosed close to or during the time 
of milk production. Given the rapid 
clearance of retosiban, the risk for 
neonatal drug exposure via breast milk 
appears low but could occur in t he 
situation where the infant is fed breast 
milk/colostrum produced within 
12hours of treatment. Since 
lactogenesis is typically delayed 30 to 
48 hours postpartum in mothers going 
to term (and is further delayed in 
mothers who deliver preterm), it seems 
unlikely that any drug would be in the 
plasma postpartum to transfer into the 
milk.Breast milk/colostrum samples will be
were collected for measurement of 
retosiban when delivery occurs
occurred and lactation hashadstarted 
within 12 hours of receiving st udy 
treatment infusion as part of the Phase 
III SPTL treatment studies.
Infants exposed to retosiban via breast 
milk will be followed for up to 5 years
24months in this study to assess 
safety and neurodevelopmental 
outcomes. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
114Potential Risk of 
Clinical 
SignificanceData/Rationale for Risk Mitigation Strategy
Retosiban [e.g., GSK221149]
Positive breast milk samples were 
detected within 1maternal subject in 
NEWBORN -1 and 1 subject in ZINN, 
with the highest concentration being 
0.36 µg/L. Assuming a standardized 
milk consumption of 0.150 L/kg/day 
(the mean milk intake of a fully 
breast -fed 2 -month old infant [Begg, 
1999; Bennett, 1988; Hagg, 2000; 
Kristensen, 1999]), the worst- case 
dose of retosiban that a breast- fed 
child would be exposed to is 0.54 
µg/kg/day (3.6 µg/L x 0.15 L/kg/day). 
This is approximately 0.5% of the 
human dose. This is the worst- case 
scenario beca use the mother is not 
being administered retosiban post -
partum during the lactation period, 
and retosiban is cleared rapidly ,
which would rapidly diminish the 
amount retosiban present circulation 
and in the milk. Furthermore, based 
on body surface area ,this potential 
infant dose is greater than 8000 -fold,
the dose where no adverse effects 
were seen in growth and 
development in the rat post -natal 
development study (rat post -natal 
develo pment study NOAEL = 
30mg/kg/day; human equivalent 
dose = 4800 µg/kg/day ). The 
potential lactational dose of 
retosiban that would therefore pose 
any significant risk to a newborn is 
negligible.
ECG = electrocardiogram; NOAEL = no-observed -adverse -effect -level; SPTL = spontaneous preterm labor.
Section 1.3.2, Benefit Assessment
Given the inverse relationship between the risks for prematurit y complications and 
gestational age at birth, the development of a treatment that significantl y prolongs 
pregnancy  in women with SPTL  would be invaluable if associated with improved 
perinatal outcomes. Results from the Phase II study  OTA105256 offer hope that retosiban 
may prolong pregnancy  to such a degree that perinatal outcomes could be favorabl y 
affected [ Thornton, 2015].There are currentl y no safet y findings that would preclude  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
115further development of retosiban for an indication for the treatment of SPTL in 
conjunction with standard of care treatments in women with an uncomplicated, singleton 
pregnancy However, the results from the Phase III interventional studies did not 
provide compel ling evidence that retosiban could prolong time to delivery of 
retosiban relative to placebo or atosiban, but because of the low enrollment 
numbers and inadequate statistical power, results should be interpreted with 
caution.
The benefit to infants and chi ldren participating in this study  is the focus on following 
morbidity  and neurodevelopment for up to 5years24monthsfollowing exposure to 
retosiban or comparator medication.
Section 1.3.3, Overall Benefit:Risk Conclusion
For detailed information on the identified risks and benefit:risk assessment of retosiban, 
refer to the Investigator’s Brochure ( IB)and IB Supplement 1 [GlaxoSmithKline 
Document Number CM2006/00201/ 0306; GlaxoSmithKline Document Number 
2015N228508_00]. Although, experience in pregnant w omen is limited, no clinical or 
preclinical safet y issues have been identified that preclude further development. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
116Table 1, Summary of Study Objectives and Corresponding Endpoints
Objective Endpoints
Primary 
To characterize the clinical safety in terms of infant 
and child morbidity and mortality in infants and 
children exposed to retosiban or comparator in 
utero Proportion of infants and children with newly diagnosed 
(after 28 days post EDD) chronic medical conditions by type 
of condition will be recorde d and include the following:
 Respiratory conditions
o Chronic lung disease
o Reactive airway disease
o Vocal cord paralysis
o Airway obstruction 
 Neurological conditions
o Cerebral palsy
o Seizure disorder
o Hydrocephalus requiring shunt
 Sensory conditions
o Vision
o Vision impairment
o Blindness in 1 or both eyes, or sees light 
only
o Hearing 
o Hearing impairment
o Deafness in 1 or both ears
o Hearing impaired, uncorrected even with 
aids
 Gastrointestinal conditions
o GERD (moderate to severe)
o Tube/parenteral feeding 
o Short bowel syndr ome
 Cardiovascular conditions
o Pulmonary hypertension
o Hypertension
 Renal conditions
o Renal impairment requiring dialysis
 Growth parameters (only up to 24 months 
chronological age)
o Poor weight gain
o Reduced length
o Reduced head circumference
o Failure to thrive
 Proportion of infants and children with newly diagnosed 
(after 28 days post EDD) congenital anomalies
 Proportion of infant and child deaths that occur after 
28days post EDD and until the end of the study 24 months 
chronological age 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
117Objective Endpoints
To characterize the cl inical safety in terms of 
neurodevelopment in infants and children exposed 
to retosiban or comparator in utero Neurodevelopment endpoints assessed at ages 9, 18, and 
24 months, corrected for prematurity:
 Proportion of infants with an ASQ -3 score in the bla ck 
zone in any domain
 Proportion of infants with an ASQ -3 score in the black 
zone for gross motor skills
 Proportion of infants with an ASQ -3 score in the black 
zone for fine motor skills
 Proportion of infants with an ASQ -3 score in the black 
zone for commu nication
 Proportion of infants with an ASQ -3 score in the black 
zone for problem -solving
 Proportion of infants with an ASQ -3 score in the black 
zone for personal -social skills
 Proportion of infants referred for developmental 
evaluation (using BSID -III)
 Proportion of infants with a BSID- III score > 2SDs 
below the mean score for the cognitive scale (< 704)
 Proportion of infants with BSID- III score > 2SDs below 
the mean score for the gross motor scale (< 704)
 Proportion of infants with BSID- III score > 2SDs be low 
the mean score for the fine motor scale (< 704)
 Proportion of infants with a BSID -III score > 2SDs 
below the mean score for the language scale (< 7070)
 Proportion of infants with a CBCL/1.5 -5 score at or 
above the 97th percentile for a subset of prespe cified 
questions that relate to attention and hyperactivity 
problems
 Proportion of infants indicated as needing further 
evaluation after completion of the M -CHAT -R/F
 Proportion of infants referred for neurological 
evaluation to determine diagnosis of cereb ral palsy
 Proportion of infants with at least 1 of the following 
indicators of neurodevelopmental impairment:
 Hearing impaired, uncorrected even with aids (at 
24months chronological age)
 Blindness in 1 or both eyes, or sees light only (at 
24months chrono logical age)
 Cerebral palsy (moderate and severe) (at 24 months 
corrected age)
 Cognitive impairment: BSID -III Cognitive Scale Score 
of >2SDs below mean score (< 704) (at 24 months 
corrected age)
 Motor impairment: BSID- III Motor Composite Scale 
Score of >2SDs below mean score (< 7070) (at 
24months corrected age)
 Proportion of infants and children with at least 1 of the 
following indicators of neurodevelopmental impairment at 
the end of the study:
 Hearing impaired, uncorrected even with aids 
 Blindness in 1 or both eyes, or sees light only
 Cerebral palsy (moderate and severe)
 Diagnosis of ASD, ADD, or ADHD 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
118Objective Endpoints
Exploratory
To characterize parental productivity loss related 
to a sick child and infant resource utilization in 
terms of hospital admissions, length of stay, 
ER/UC visits, surgical procedures, and referral to 
specialty care or therapy visits for infants (up to 
age 2 years) exposed to retosiban or comparator 
in utero Number of hospital admissions, proportion of infants and 
children with any hospital ad mission, post -birth 
hospitalization discharge, by principal and secondary 
discharge diagnosis, type of hospital unit admitted to (e.g., 
NICU, Pediatric, PICU, Nursery level 3, ICU), and length of 
hospital stay per unit after 28 days post EDD and until the 
end of the study 24 months chronological age
 Combined length of hospital stay in days for all hospital 
admissions (for infants discharged from the delivery 
hospitalization and for babies who were never discharged 
home post- delivery) after 28 days post EDD and until the 
end of the study 24 months chronological age
 Number of surgical procedures (details of type and whether 
performed on an inpatient basis or at an outpatient/surgical 
center will be collected up to 24 months chronological age 
only) after 28 days post EDD and until the end of the study
24 months chronological age
 Number of ER/UC visits and proportion of infants with any 
ER/UC visit after 28 days post EDD and up to 24 months 
chronological age
 Number of specialty care or therapy visits and proport ion of 
infants referred for specialty care or therapy by type of 
care/therapy after 28 days post EDD and up to 24 months 
chronological age
 Parental productivity loss related to infant hospital 
admissions, ER/UC visits, or specialist care after 28 days 
post EDD and up to 24 months chronological age
ADD = attention deficit disorder; ADHD = attention deficit hyperactivity disorder; ASD = autism spectrum disorder; 
ASQ -3 = Ages and Stages Questionnaire -3; BSID -III = Bayley Scales of Infant Development, third ed ition; 
CBCL/1.5 -5= Child Behavior Checklist for Ages 1.5 to 5; EDD = estimated date of delivery; ER/UC = emergency 
room/urgent care; GERD = gastroesophageal reflux disease; ICU = intensive care unit; M -CHAT -R/F = Modified 
Checklist for Autism in Toddlers -Revised with Follow -Up; NICU = neonatal intensive care unit; PICU = pediatric 
intensive care unit.
Section 3.1, Study Design
Infants and children will be followed at prespecified intervals until they  reach 5 years
24monthschronological age (see Table 2 ). 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
119Figure 1, Study Design
Original Figure :
Updated Figure :
The child’s parent/legal guardian will be asked to complete the CHI at 2, 6, 9, 12, 15, 18, 
21, and 24 months of the child’s chronological age and a modified CHI at 3, 4, and 
5years of the chi ld’s chronological age . The CHI questionnaire completed up to the 
24-month time point will screen for infant mortality  and morbidity  and will capture data  2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
120on resource utilization. At the 3-, 4-, and 5-year time points, the CHI  will screen for child 
mortality and morbidity , including an y indicators of neurodevelopmental impairment.
If protocol -specific evaluations are in progress at the end of the child’s protocol -defined 
participation in this study  (5years24monthschronological age) and results have not yet 
been received or reported, the time period may  be extended to collect those reports.
During the first 24 months of participation in the study , if the parent/legal guardian 
indicates that the infant has been treated b y specialists or has had ER/UC visit s or 
hospitalizations, he/she will be asked to complete a productivity  questionnaire to evaluate 
loss of parental productivity .
The M-CHAT-R/F will be completed for all infants at 18 and 24 months (corrected age) 
and the CBCL/1.5 –5 will be completed for all infants at 24 months (corrected age) to 
assess the risk for other behavioral problems or autism spectrum disorder (ASD). If at 
any of these time points a child has an M- CHAT-R/Fscore that indicates further 
evaluation is required and/or a CBCL /1.5–5 score at orabove the 97th percentile for a 
subset of prespecified questions, the child will be referred to a specialist for a formal 
assessment.
Protocol Amendment 2 has updated the total study duration to 24 months. Babies or 
infants that have passed the 24-monthassessments after the amendment 
implementation are not required to continue further within the study, nor do they 
need to complete any subsequent study related assessments. Following completion of 
the study, the neonates will continue their normal pe diatric standard of care with 
their primary care pediatrician or health care provider.
The 24-monthdata will form the final s tudy endpoint assessment timing; however,if 
data has been collected from a baby/infant after they have passed the 24-month
endpoint, then this data will be included as a data listing within the clinical report.
Section 4.2, Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent information on the GSK investigational produ ct or other stud y treatment that 
may impact subject eligibility  is provided in the IB and IB Supplement 1 
[GlaxoSmithKline Document Number CM2006/00201/ 0306; GlaxoSmithKline 
Document Number 2015N228508_00] .
Section 6, Study Assessments and Procedures
The infants and children will be followed beginning from after 28 days post EDD and 
until 5years24monthschronological age.
The timing of the first questionnaire is scheduled to begin at 2 months chronological age 
and end at 5 years24monthschronological a ge. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
121The EPDS should ideally be completed at 6 weeks (±-2 weeks/+6 weeks) post -delivery 
but may be completed as earl y as 14weekspost-delivery or as late as 12 weeks post-
delivery. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
122Table 2, Time and Events Table
Event 28Days Post 
EDDMonths Years1
2 6 9 12 15 18 21 24 3 4 5
Written informed consent2
Baseline characteristics and demographic data X3
RCC confirms and updates contact information from 
the parent/legal guardianX
Parent/legal guardian completes CHI4 X X X X X X X X X4 X4 X4
RCC -PI follows up with HCP and reviews medical or 
other records to confirm parent -reported outcomes
RCC -PI reviews CHI results and refers to birth -defect 
evaluator based on results
Parent/legal guardian completes produ ctivity 
questionnaire5
Parent/legal guardian completes ASQ -36 X6 X6 X6
RCC -PI reviews ASQ -3 results and refers for 
developmental evaluation based on results7
Parent/legal guardian completes M -CHAT -R/F8 X X
Parent/legal guardian completes CBCL/1.5 –58 X
RCC -PI refers child to specialist for cerebral palsy 
assessment (if required)9X 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
123ASQ -3 = Ages and Stages Questionnaire -3; CBCL/1.5 –5 = Child Behavior Checklist for ages 1.5 to 5; CHI = Child Health I nventory; EDD =estimated date of delivery; HCP =health 
care provider; M -CHAT -R/F = Modified Checklist for Autism in Toddlers -Revised with Follow -Up; RCC = research coordinating center; RCC- PI = research coordinating center -
principal investigator.
Note:  All specified completion windows for applicable questionnaires (CHI, ASQ -3, CBCL/1.5 –5, M-CHAT -R/F, and productivity) are provided to help standardize the data and avoid 
overlap. Information captured outside of these windows will be collected and analyzed separately, and questionnaires completed outside the completion window will not be 
considered protocol deviations.
1. Assessments performed at years 3, 4, and 5 are based on the child’s chronological age.
1.2.Collected at the start of the Phase III spon taneous preterm labor (SPTL) treatment studies until the later date of either the date of discharge from the birth hospitaliz ation or up to 
9months corrected age (to allow for the infant’s 9 -month CHI and ASQ- 3 data collection).
2.3.Captured in Phase III SPTL treatment studies and combined with child follow -up data for analyses.
3.4.A positive response by the parent/legal guardian may trigger follow -up with the relevant HCP and/or medical record review for confirmation or more details on the condition or 
hospitalization. A modified CHI will be completed at 3, 4, and 5 years of the child’s chronological age. At each time point, the completion window of the CHI is +6 weeks.
4.5.Completed if infant has been treated by a specialist or has had an emergency room/urgent care or hospital visit. The completion window for the productivity questionnaire is +2 
weeks from the date of completion of the relevant CHI.
5.6.Based on infant’s corrected age. The completion window for the ASQ -3 is +30 days at Month 9 and ±30 days at Months 18 and 24.
6.7.If the parent/legal guardian receives a referral, then a qualified specialist will complete required assessments.
7.8.The CBCL/1.5 –5 and M -CHAT -R/F questionnaires will be completed for all infants. The completion wind ow for the CBCL/1.5 –5 and M -CHAT -R/F is +6 weeks at 18 months 
(M-CHAT -R/F only) and +12 weeks at 24 months. 
8.9.Referral will be made for infants who score in the black zone for the gross motor skills domain on the 24 -month corrected age ASQ -3 and do not have an existing diagnosis of 
cerebral palsy. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
124Section 6.2.1
The morbidity  endpoints will be assessed at 2, 6, 9, 12, 15, 18, 21, and 24 months and 3, 
4, and 5yearsof the child’s chronological age.
Section 6.2.1.1, Parent/Legal Guardian -Completed Chil d Health Inventory
The child’s parent/legal guardian will be asked to complete the CHI at 2, 6, 9, 12, 15, 18, 
21, and 24 months of the child’s chronological age and a modified CHI at 3, 4, and 
5years of the child’s chronological age . At each time poi nt, the completion window is 
+6weeks; however, CHI questionnaires completed outside the completion window will 
not be considered a protocol deviation.
The CHI administered at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s 
chronological age will screen for infant mortalit y and morbidity  and capture data on 
resource utilization. At 3, 4, and 5 years of the child’s chronological age, the CHI will 
screen for child mortalit y and morbidity , including any  indicators of neurodevelopmental 
impairment. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
125Figure 2, Child Health Inventory: Flow Chart of Data Collection and Review
Original Figure:
CHI = Child Health Inventory; HCP = health care provider; RCC -PI = research coordinating center -principal investigator.
1. The CHI completed at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s chronological age will screen for infant mortality and morbidity and capture data on resource uti lization. 
At 3, 4, and 5 years of the child’s chronological age, the CHI will screen for child mortality and morbidity, including a ny indicators of neurodevelopmental impairment. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
126Updated Figure:
CHI = Child Health Inventory; HCP = health care provider; RCC -PI = research coordinating center -principal investigator.
1. The CHI completed at 2, 6, 9, 12, 15, 18, 21, and 24 months of the child’s chronological age will screen for infant mortality and morbidity and capture data on resource utilization. 
At 3, 4, and 5 years of the child’s chronological age, the CHI will screen for child mortality and morbidity, including any i ndicators of neu rodevelopmental impairment. 
 
 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
127Section 6.2.2.7, Growth Parameters
Growth parameters will be assessed onl y up to 24 months chronological age and will
include the following:
Section 6.2.4, Infant and Child Deaths
This study  will assess the proportion of infant and child deaths that occur after 28 days 
post EDD and up to 5years24monthschronological age.
Section 6.2.5, Parent/Legal Guardian- Completed ASQ -3, M CHAT R/F, and 
CBCL/1.5–5 and Possible Referral to a Specialist
If at any of these time points a child has an M-CHAT-R/Fscore that indicates further 
evaluation is required and/or a CBCL /1.5–5 score at orabove the 97th percentile for a 
subset of prespecified questions, the child will be referred to a specialist for a formal 
assessment.
In this stud y, infants with test scores at or above the 97th percentile for a subset of 
prespecified questions that relate to attention or hyperactivit y problems s yndrome or the 
American Ps ychiatric Association's Diagnostic and Statistical Manual (DSM) -oriented 
attention-deficit/hyperactivity  disorder scale will be considered to have a behavior 
problem, which will trigger a referral to a developmental spec ialist for a formal 
assessment.
The completion window for the CBCL/1/5- 5 and M-CHAT-R/F is +6 weeks at 
18months (M -CHAT-R/Fonly) and +12 weeks at 24 months; however, questionnaires 
completed outside the completion window will not be considered a protocol deviation.
Section 6.2.5.2, Neurodevelopment
Proportion of infants with a BSID -III score >2 SDs below the mean score for 
cognitive impairment (< 704)
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
gross motor scale (< 704)
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
fine motor scale (< 704)
Proportion of infants with a BSID -III score >2 SDs below the mean score for the 
language scale (<70 70)
Proportion of infants with a CBCL /1.5–5 at orabove the 97th percentile for a 
subset of prespecified questions that relate to attention and hy peractivit y 
problems
Section 6.2.6, Overall Measure of Neurodevelopmental Impairment
Cognitive impairment: BSI D-III Cognitive Scale Score of >2 SDs below mean 
score (<704) (at 24months corrected age) 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
128Motor impairment: BSID -III Motor Composite Scale Score of >2 SDs below 
mean scor e (<7070)(at 24months corrected age)
Proportion of infants and children with at least 1 of the following indicators of 
neurodevelopmental impairment at the end of the study :
Hearing impaired, uncorrected even with aids 
Blindness in 1 or both eyes, or sees light only
Cerebral palsy  (moderate and severe)
Diagnosis of ASD, ADD, or ADHD
Section 6.2.10, Death Events
The proportion of deaths that occur after 28 day s post EDD and up to 5 years24months
chronological age will be collected.
Section 6.2.11, Tim e Period and Frequency of Detecting SAEs
Child SAEs will be collected from after 28 day s post EDD until 5 years24 months
chronological age. All SAEs will be reported to GSK/PPD within 24 hours, as indicated 
in Section 6.2.12.
Section 6.2.14, Prompt Report ing of SAEs and Other Events to GSK/PPD
The contact information for reporting SAEs is as follows:
Issue North America 
ContractLatin America Contact Europe/Asia Contact
Serious Adverse 
Event Reporting24-Hour Safety Hotline:
Safety Fax:24-Hour Safety Hotline:
Safety Fax :24-Hour Safety Hotline:
Safety Fax:
Section 6.3, Health Outcomes
Resource utilization exploratory endpoints include the foll owing: 
Number of hospital admissions, proportion of infants and children with any 
hospital admission, post -birth hospitalization discharge, b y principal and 
secondary  discharge diagnosis, ty pe of hospital unit admitted to (e.g., NI CU, 
Pediatric, PI CU, Nursery level 3, ICU), and length of hospital stay  per unit after 
28days post EDD and until the end of the study up to 24 months chronological 
age. 2019N413355_00
PPD
PPD
PPD
PPD
PPD
PPD
2014N194466_02 CONFIDENTIA L
200722
129Combined length of hospital stay  in days for all hospital admissions (for infants 
discharged from the delivery hospitalization and for babies who were never 
discharged home post -delivery) after 28 day s post EDD and until the end of the 
studyup to 24 months chronological age .
Number of surgical procedures (details of ty pe and whether performed on an 
inpatient basi s or at an outpatient/surgical center will be collected up to 
24months chronological age onl y) after 28 days post EDD and until the end of 
the study up to 24 months chronological age .
Section 6.3.1, Parent/Legal Guardian -Completed Productivity Questionna ire
During the first 24 months of participation in the study , if the infant's parent/legal 
guardian reports in one of the CHI questionnaires that the child is being treated b y a 
specialist or has had emergency  department visits or hospitalizations, they  will be asked 
to complete the productivity  questionnaire.
Section 8.1, Hypotheses
If deemed appropriate, point estimates and associated 95% confidence intervals (CIs) 
may be calculated for the comparison of retosiban to placebo and retosiban to atosiban 
for some safet y endpoints. No type I error adjustments are planned.
Section 8.2.1, Sample Size Assumptions
The sample size for this study  will depend on the total number of subjects enrolled in the 
Phase III SPTL treatment studies. AtIn May 2017 , thetime of protocol publishing , 
2 Phase III SPTL treatment studies are planned that will enroll at total of approximately  
1100 mothers. However, were terminated early due to the number feasibility of studies 
and/or size of recruiting the studies may change depending on in a timely manner, 
meaning that theoutcome of the first planned Phase III SPTL treatment study , such that 
the total number of mothers enrolled could be size of these studies was lower or higher
than currently  planned. originally planned. This has resu lted in a greatly reduced 
sample size for this study.
Section 8.3.1, Analysis Populations
The primary  population for safet y assessment will be all infants whose mothers have 
been randomized and received retosiban or comparator in any of the Phase III 
treatment trials. Of these mothers, the infant safety population includes the 
mother/infant pairs who enrolled into the study with at least 1 observation , the 
mother/infant pairs who decline to consent to the study, and the mother/infant pairs 
whose fetus/neona tes/infants died prior to the enrollment of the study . Subjects will 
be analyzed according to their actual treatment in case this differs from their randomized 
treatment. All analyses will be based on the primary  population dataset. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
130Section 8.3.4, Interim Analysis
In the event of earl y stopping of the Phase III SPTL development program due to safet y 
and/or lack of efficacy , children will continue to be followed until they  have reached 
5years24monthschronological age. 
For any subject for which the CHIquestionnaire at 3, 4, and 5 years of the child’s 
chronological age was completed prior to Amendment 2, data will be reported.
Section 8.3.5.1.1, Outcomes
For binary  outcomes, all summary  tables will include the number and percentage of 
subjects with the response/event . The associated 95% CI  will also be reported. For those 
endpoints that occur in more than 5 children or 1% of the children in an y treatment 
group, odds ratios and associated 95% CIs will be calculated to compare retosiban to 
placebo, atosiban, and pooled comparator treatment groups. For continuous variables, all 
summary tables will include: n, mean, median, standard deviation, minimum and 
maximum. All summary  tables will include N for each group (i.e., the total number of 
subjects randomized t o each group within the appropriate population).
To characterize the clinical safet y in terms of neurodevelopment in children exposed to 
retosiban or comparator, the proportion of children with at least 1 of the indicators of 
neurodevelopmental impairment (see Section 6.2.6) at the end of the study  will be 
analyzed using a logistic regression model. The model will use a logit link function to 
estimate the log odds of percentage of children with indicators of neurodevelopmental 
impairment. The model will inc lude terms for treatment group. The number and 
percentage of subjects in each treatment group, the odds ratios of response rates 
(retosiban versus placebo, retosiban versus atosiban, and retosiban versus all 
comparators) and the 95% CI s for the odds ratio of response rates and p values will be 
presented. The anal ysis may be repeated for each of the individual indicators of 
neurodevelopmental impairment.
To further describe the infant safet y profile of retosiban, the following subgroups may  be 
explored:
Gestational age of pregnancy  at randomization
Established progesterone use (y es or no)
Magnesium sulfate use
Tocolytic use following study  drug discontinuation
Maternal age
Region
For each subgroup, child safet y data will be summarized by treatment and subgrou p, as 
previously  described. Full details of all planned analy ses will be provided in the RAP. 2019N413355_00
2014N194466_02 CONFIDENTIA L
200722
131Section 8.3.5.2, Health Outcomes Analyses
The primaryobjective of the exploratory planned anal ysis will be to use descriptive 
statisticsisto characterize reso urce utilization in infants exposed to retosiban or 
comparator in the Phase III SPTL treatment studies. The Exploratory endpoints to be 
descriptivel y summarized are those described in Section 6.3 . Descriptive statistics will
maybe calculated by  treatment group and by treatment group and time, where 
appropriate. Additional analy ses and modeling may  be conducted to further characterize 
the resource utilization of infants exposed to retosiban, placebo, and atosiban. Full details 
of the planned exploratory analyses will be provided in the RAP.
Section 9.2, Regulatory and Ethical Considerations, Including the Informed 
Consent Process
The study  will be conducted in accordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles th at are outlined in the current version of the
Declaration of Helsinki 2008, including, but not limited to:
Section 9.5, Study and RCC Site Closure
Follow-up will continue until each child enrolled completes the 5-year questionnaire at 
5years chronological age.24-month questionnaire at 24 monthschronological age. 
For any subject that was enrolled prior to Amendment 2, those subjects who have 
completed the 24 months assessments will not be required to complete the CHI 
questionnaire at 3, 4, and 5 years of the child’s chronological age.
Section 10, References
Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human m ilk, Br J Clin 
Pharmacol . 1999;48 (2):142-7.
Bennett PN (ed ), 1988, Drugs and human l actation, Amsterdam: Elsevier.
GlaxoSmithKline Document Number 2015N228508_00. CM2006/00201/06 . Retosiban 
Investigator's Brochure Version 3 Supplement 1. FEB -20156. JUN_2018 .
GlaxoSmithKline Document Number CM2006/00201/03. Retosiban I nvestigator's 
Brochure Version 3. APR -2014.
Hagg S,SpigsetO.Anticonvulsan t use during l actation, Drug Saf . 2000;22 (6):425-
40.
Kristensen JH, Ilett KF, Hackett LP , et al. Distribution and xxcretion of fluoxetine 
and norfluoxetine in human m ilk.Br J Clin Pharmacol . 48(4):521-7.
Marlow N. Is survival and neurodevelopmental impair ment at 2 years of age the 
gold standard outcome for neonatal studies? Arch Dis Child Fetal Neonatal Ed .
2015;100(1):F82 -4. 2019N413355_00